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Abstract	
Background.		The	male	genital	tract	is	a	major	site	of	HIV	acquisition	and	transmission.		It	is	an	
obvious	site	for	inducing	immune	responses	to	candidate	HIV	vaccines,	to	prevent	infection	or	
halt	the	spread	of	the	virus.		There	are	relatively	few	published	studies	characterising	T	cells	in	
the	male	 genital	 tract.	 	 A	 challenge	 that	 hampers	 studies	 at	 this	mucosal	 surface	 is	 obtaining	
samples	with	sufficient	immune	cells.		Therefore,	the	first	aim	of	this	study	was	to	establish	an	
optimised	method	to	 isolate	 immune	cells	 from	the	male	genital	 tract.	 	Cellular	activation	and	
inflammation	 in	 the	 genital	 tract	 have	 important	 implications	 for	 both	 transmission	 and	
acquisition	 of	HIV,	 since	 they	 provide	 target	 cells	 for	 viral	 replication.	 	 Thus,	 the	 second	 and	
third	aim	of	this	study	was	to	investigate	mucosal	T	cell	activation	and	inflammatory	cytokine	
profiles	 in	semen	 in	HIV‐infected	and	uninfected	men,	and	compare	the	 immune	milieu	of	 the	
genital	tract	with	the	systemic	compartment.	
		
Methods.	 	 For	 the	 optimisation	 of	 immune	 cell	 isolation	 from	 the	male	 genital	 tract,	 semen	
samples	 from	199	men	were	used	 to	enumerate	T	cell	yields	after	 the	use	of	combinations	of	
pronase	digestion,	cell	strainers,	ficoll	isolation	and	magnetic	bead	capture.		Using	the	optimised	
method,	 the	 viability	 and	 function	 of	 T	 cells	 were	 ev luated	 by	 flow	 cytometry.	 	 Additional	
leukocyte	subsets,	namely	B	cells,	monocytes,	neutrophils,	Langerhans	cells	and	NK	cells	were	
enumerated	 in	 semen	 using	 flow	 cytometry.	 	 For	measuring	 T	 cell	 activation,	 frequencies	 of	
CCR5‐expressing	and	activated	(CD38+)	T	cells	 in	semen	and	blood	of	42	HIV‐uninfected	men	
were	 compared	 with	 those	 in	 26	 HIV‐infected,	 ARV‐naïve	 and	 12	 HIV‐infected,	 ARV‐treated	
men.	 Seminal	 and	 plasma	 viral	 loads	 were	 quantified	 and	 correlated	 with	 frequencies	 of	
activated	 T	 cell	 subsets.	 	 Cytokine	 multiplex	 assays	 were	 used	 to	 quantify	 cytokine	 and	
chemokine	 concentrations	 in	 the	 seminal	 and	 blood	 plasma	 of	 28	 HIV‐uninfected,	 26	 HIV‐
infected,	 ARV‐naïve	 and	 12	 HIV‐infected,	 treated	men.	 	 Univariate	 and	multivariate	 analyses	
were	 performed	 on	 associations	 between	 cytokine	 concentrations	 and	 viral	 loads,	 as	well	 as	
activated	T	cell	subsets	in	both	the	genital	and	systemic	compartments.	
	
Results.	 This	 study	 found	 that	 pronase	 digestion	 and	 the	 use	 of	 cell	 strainers	 resulted	 in	
improved	 CD3+	 T	 cell	 yields	 compared	 to	 gradient	 separation,	 whilst	 selection	 of	 CD3+	 cells	
using	 magnetic	 beads	 resulted	 in	 improving	 seminal	 lymphocyte	 differentiation	 by	 flow	
cytometry.	 	 This	method	 allowed	 for	 the	 subsequent	 functional	 analysis	 of	 CD4+	 and	 CD8+	 T	
cells,	and	found	abundant	NK	and	DC‐SIGN‐expressing	cell	populations	in	semen.		In	the	second	
part	of	the	study,	HIV	replication,	activation	and	inflammation	were	investigated.		There	was	a	
positive	 correlation	 between	 viral	 loads	 in	 semen	 and	 blood.	 	 ARVs	 successfully	 suppressed	
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viral	replication	 in	the	male	genital	 tract	 in	the	majority	of	 infected	men	on	treatment.	 	There	
was	 substantially	 greater	 immune	 activation	 in	 semen	 compared	 to	 blood,	 regardless	 of	 HIV	
infection	or	suppressive	ARV	treatment.		The	highest	levels	of	immune	activation	in	semen	were	
found	in	untreated	HIV‐infected	men,	and	this	was	mirrored	in	blood.	 	Notably,	although	ARV‐
treatment	reduced	the	numbers	of	activated	T	cells	in	semen,	frequencies	were	not	restored	to	
those	 observed	 in	 HIV‐uninfected	 men.	 	 Although	 frequencies	 of	 activated	 CD8+	 T	 cells	
correlated	 between	 compartments	 in	 HIV‐infected	men,	 there	 were	 no	 associations	 between	
immune	 activation	 and	 viral	 loads.	 	 HIV‐uninfected	 men	 in	 partnerships	 with	 HIV‐infected	
women	had	elevated	 frequencies	of	CD8+CCR5+	T	cells	 in	 their	blood,	but	no	differences	were	
seen	 in	 the	genital	 tract.	 	Semen	and	blood	differed	substantially	with	respect	 to	 the	cytokine	
milieu,	with	the	majority	of	cytokines	and	chemokines	found	at	higher	concentrations	in	semen	
than	blood,	both	 in	HIV‐infected	and	uninfected	men.	 	HIV‐infection	caused	a	dysregulation	of	
the	 network	 of	 cytokine/chemokine	 associations	 in	 semen.	 	 While	 there	 were	 no	 significant	
associations	found	between	levels	of	cytokines	and	seminal	viral	load,	higher	levels	of	G‐CSF	in	
semen	of	HIV‐infected	men	were	associated	with	higher	levels	of	CCR5+CD8+	T	cells	in	semen.	
Conclusions.	This	study	described	an	optimised	method	for	the	isolation	of	CD3+	T	cells	 from	
semen,	 that	can	be	used	 in	 immune	assays	 to	 investig te	 the	phenotype	and	 function	of	 these	
cells.	 	 The	 methods	 developed	 in	 this	 study	 could	 be	 applied	 to	 assess	 vaccine‐induced	
immunity	 in	HIV	 vaccine	 trials.	 	 In	 addition,	 this	 study	 characterised	 a	 range	 of	 immune	 cell	
types	found	 in	semen,	suggesting	 further	avenues	of	study	 in	 terms	of	characterising	humoral	
and	innate	responses	in	the	male	genital	tract.		Furthermore,	this	study	showed	a	high	degree	of	
immune	activation	in	semen,	regardless	of	HIV	infection.		HIV	target	cells	were	abundant	in	HIV‐
uninfected	men,	while	75%	of	HIV‐infected	men	were	shedding	virus,	which	has	implications	for	
both	HIV	acquisition	and	transmission.	 	No	direct	relationship	between	T	cell	activation	in	the	
genital	tract	of	HIV‐infected	men	and	viral	replication	was	observed,	and	together	with	the	high	
degree	 of	 T	 cell	 activation	 in	 the	 semen	 of	 HIV‐uninfected	 men,	 implies	 that	 there	 may	 be	
ongoing	inflammation	due	to	other	causes,	resulting	in	immune	activation.		Although	there	were	
substantial	differences	in	the	immune	milieu	of	blood	compared	to	the	genital	tract,	there	were	
no	 differences	 in	 the	 levels	 of	 cytokines	 and	 chemokines	 in	 the	 semen	 of	 HIV‐infected	 and	
uninfected	men,	or	HIV‐infected	men	on	suppressive	ARV	treatment.		Thus,	even	in	the	absence	
of	HIV	infection,	the	male	genital	tract	appears	to	maintain	a	state	of	inflammation,	which	may	
be	as	 a	 result	of	undetected	and	untreated	co‐infections	 that	may	also	mask	 the	effect	of	HIV	
replication.	 	 Lastly,	 this	 study	 showed	 no	 obvious	 link	 between	 inflammation	 and	 viral	 load,	
emphasizing	 that	 the	 relationship	 between	 inflammation,	 cellular	 activation	 and	 viral	
replication	is	likely	to	be	complex.	
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This thesis focuses on immunity in the male genital tract in the context of HIV 
infection.  The male genital tract plays a central role in sexual transmission of HIV.  
HIV transmission occurs predominantly through sexual contact with semen as the 
carrier (Krieger et al., 1995, Vernazza 2005).  The importance of the male genital 
tract in HIV transmission has been highlighted by several key discoveries in the last 
few years.  A considerable reduction in female-to-male HIV transmission was shown 
in three randomised controlled trials of circumcision.  In South Africa, Kenya and 
Uganda, female-to-male HIV transmission was reduced by 60%, 53% and 48% 
respectively, following male circumcision (Auvert et al., 2005, Bailey et al., 2007, 
Gray et al., 2007).  Recently, sexual transmission of HIV from males to females was 
shown to be enhanced by amyloid fibrils in semen (Munch et al., 2007).  These 
fibrils, termed semen-derived enhancer of virus infection (SEVI), were shown in vitro 
to trap HIV virions in a network of fibrils, thereby potentially extending vaginal 
exposure to HIV acquisition.  HSV-2 is the most prevalent co-infection with HIV, and 
can cause genital ulcers (Weiss 2004).  HSV-2 not only elevates levels of genital pro-
inflammatory cytokines (Rebbapragada et al., 2007), but even asymptomatic 
reactivation of HSV-2 elevates HIV levels in the genital tract (Mbopi-Keou et al., 
2000).  Although antiviral treatment of HSV-2 lowered HIV levels at the rectum and 
in the genital tract (Zuckerman et al., 2007, Baeten et al., 2008, Dunne et al., 2008), a 
recent randomised trial showed no reduction in HIV-1 transmission upon treatment 
for HSV-2 with acyclovir, despite a decrease in plasma HIV viral load (Celum et al., 
2010). 
 
This introduction will review the anatomy of the male genital tract, potential target 
cells for HIV infection within the genital tract, factors that may enhance HIV 
replication and transmission, including immune activation and inflammation, the male 
genital tract as a potential HIV reservoir and HIV-specific immunity in the genital 
tract. 
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1.1  The HIV pandemic 
 
In an attempt to combat the HIV pandemic, there have been successes and failures.  
By the end of 2009 the number of people receiving antiretroviral (ARV) treatment 
increased 13-fold, however an estimated 10 million people still need therapy globally.  
In the 10 years between 1999 and 2009, there has been a 27% increase (26.2 million – 
33.3 million) in the estimated number of people living with HIV (UNAIDS, 2010).  
Overall there has been a global drop in the number of new infections in the past few 
years, with 22 countries in sub-Saharan Africa showing a decrease in the occurrence 
of HIV infection by more than 25%.  Despite this decrease, there were still 1.8 million 
new infections in sub-Saharan Africa in 2009 (Avert, 2011) [Table 1.1].  World-wide 
in 2009, a third of all AIDS-related deaths, new infections and people living with HIV 
lived in 10 southern African countries (UNAIDS, 2010).  Furthermore, approximately 
40% of all HIV-infected adult women live in southern Africa (UNAIDS, 2010). 
 
 
Table 1.1  Regional statistics for HIV and AIDS, end of 2009 
Region 
Peoplea 
living with 
HIV/AIDS 
Peoplea  
newly 
infected 
Adult 
prevalenceb 
 
AIDS-related 
deaths  
 
Sub-Saharan Africa 22.5 million 1.8 million 5.0% 1.3 million 
North Africa & Middle 
East 460,000 75,000 0.2% 24,000 
South and South-East 
Asia 4.1 million 270,000 0.3% 260,000 
East Asia 770,000 82,000 <0.1% 36,000 
Oceania 57,000 4,500 0.3% 1,400 
Central & South America 1.4 million 92,000 0.5% 58,000 
Caribbean 240,000 17,000 1.0% 12,000 
Eastern Europe & 
Central Asia 1.4 million 130,000 0.8% 76,000 
North America 1.5 million 70,000 0.5% 26,000 
Western & Central 
Europe 820,000 31,000 0.2% 8,500 
Global Total 33.3 million 2.6 million 0.8% 1.8 million 
aAdults and children 
b Proportion of adults aged 15-49 who are living with HIV/AIDS 
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1.1.1 The HIV burden in sub-Saharan Africa 
Despite a decrease in the number of new HIV infections in sub-Saharan Africa, the 
total number of people living with HIV have steadily increased, reaching 22.5 million, 
which constituted 68% of the global total in 2009 (UNAIDS, 2010).  Southern Africa 
is still the most severely affected region, with an estimated 11.3 million people living 
with HIV, which constituted an increase of nearly one third from estimates a decade 
earlier (UNAIDS, 2010).  In sub-Saharan Africa, the majority of newly infected HIV 
cases occurred during unprotected heterosexual intercourse, transmission to newborns 
and breastfeeding.  The greatest risk factor for HIV infection in this region continues 
to be unprotected sex with multiple partners (UNAIDS, 2010).  South Africa remains 
one of the only countries in the world where, since the 1990s, child and maternal 
mortality has increased (UNAIDS, 2010) [Figure 1.1].   
 
Figure 1.1  HIV prevalence in sub-Saharan Africa.  Sub-Saharan Africa’s disease burden has 
increased progressively since 1990 (taken from UNAIDS, 2010).   
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In fact, in South Africa, 35% of deaths in children under five as well as the largest 
cause of maternal mortality is due to AIDS (UNAIDS, 2010).  The availability of 
ART has increased dramatically in sub-Saharan Africa, from 2 – 37%, while AIDS-
related deaths have decreased by 18% in southern Africa alone (UNAIDS, 2010).  
 
1.1.2 Preventing new HIV infections: HIV vaccines and other biomedical 
prevention tools 
Despite the success of highly active antiretroviral therapies (HAART) in suppressing 
HIV replication, the development of an HIV vaccine to avert new infections remains a 
priority. There are several major challenges in developing a prophylactic HIV 
vaccine.  These include the degree of genetic diversity of the virus, which results in a 
variety of subtypes and recombinant forms circulating in different geographical areas.  
This presents the challenge of whether a vaccine based on one subtype would 
potentially protect against all subtypes equally well (McBurney et al., 2008).  Due to 
its high rate of mutation, HIV has the ability to evade the host immune response 
(Korber et al., 2009), which may imply that vaccines might have to target regions of 
the virus that cannot mutate without a fitness cost.  Furthermore, the correlates of 
immune protection against HIV infection are largely unknown, and although the 
macaque SIV model of infection has given us many answers, it is limited in predicting 
the efficacy of candidate HIV vaccines (Kim et al., 2010).  The focus of vaccine 
design has been on inducing cell-mediated immune responses capable of reducing 
viral load (Kim et al., 2010), or neutralising antibodies that would be capable of 
providing sterilising immunity (Walker & Burton, 2008).  Variability in the 
frequency, magnitude, breadth and functional nature of cellular immune responses to 
viral vectors carrying HIV genes has emphasized the need for further research (Harari 
et al., 2008; Priddy et al., 2008; Catanzaro et al., 2007).  New adenovirus vectors 
show promise as vaccine vectors (as reviewed in Barouch 2010), and recent data on 
persistent replicating CMV vectors show that sterilising immunity may be possible 
with T cell-generating vaccines (Hansen et al., 2011).  The recent discovery of more 
broadly cross neutralising antibodies against HIV in infected individuals also raises 
hopes of developing a vaccine capable of generating such antibodies (as reviewed in  
Stamatatos et al., 2009). 
 
Two recent clinical trials of candidate HIV vaccines have illustrated the challenges in 
HIV vaccine development.  In the Phase IIb Step trial, designed to test the ‘T cell 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 6
vaccine’ concept, a recombinant adenovirus vector (rAd5) containing HIV-1 gag, pol 
and nef genes from HIV-1 subtype B did not protect participants from HIV 
acquisition or achieve lower viral load in those who became infected (Buchbinder et 
al., 2008; Sekaly 2008).  A parallel trial, Phambili, conducted in South Africa was as 
a result halted early and also did not show any efficacy (Gray et al., 2011).  In the 
Step trial, those volunteers that received the vaccine exhibited higher rates of HIV 
infection compared to the placebo group.  Researchers have hypothesized that pre-
existing antibodies to Ad5 in participants elevated the risk of HIV infection after 
vaccination with the rAd5 vector (Perreau et al., 2008), and a recent study found a 
link between Ad5-specific CD4+ T cells and an elevated risk of HIV-1 acquisition 
during the Step trial (Hutnick et al., 2009).  However, vaccine recipients in the 
Phambili trial did not show enhanced acquisition (Gray et al., 2011).  The RV144 
Phase III efficacy trial in Thailand tested a modified canarypox vaccine carrying 
gp120, gag and protease (ALVAC) as a prime, boosted with a bivalent gp120 subunit 
vaccine (AIDSVAX B/E) (Rerks-Ngarm et al., 2009).  Although the vaccine showed 
31.2% efficacy in modified intent-to-treat analysis of participants, there were no 
decreases in viral load in those that became infected.  Although this represents a 
moderate degree of protection, this is the first HIV vaccine trial to show any effect in 
reducing HIV infections; follow up trials are planned, as well as in-depth studies to 
identify the correlates of protection from HIV infection. 
 
Although a prophylactic vaccine for HIV has not yet been developed, additional 
biomedical measures to prevent HIV transmissions that have been developed in 
parallel have recently shown a great deal of promise.  These involve using 
antiretroviral therapy to prevent new infections.  In the recent CAPRISA 004 trial, the 
antiretroviral tenofovir formulated in a vaginal gel decreased HIV acquisition by 54% 
in women using the gel > 80% of the time (Abdool Karim et al., 2010).  The use of 
oral pre-exposure prophylaxis (PrEP), in the form of emtricitabine combined with 
tenofovir (Truvada), in men who have sex with men in the iPrEx trial, showed a 44% 
reduction in incidence of HIV infection among participants receiving PrEP compared 
to those not receiving PrEP (Grant et al., 2010).  A similar study (FEM-PrEP) 
investigated the same protection in women, but was stopped due to the ineffectiveness 
of Truvada in preventing HIV infection (http://www.fhi.org).  Extremely promising 
findings from the HPTN052 study showed a 96% reduction in the risk of HIV-1 
transmission from HIV-infected individuals to their partners through oral prophylaxis 
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at high CD4 counts (http://www.hptn.org).  These trials herald a new era in HIV 
prevention using antiretrovirals. 
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1.2  HIV is a disease of the mucosal immune system 
 
Transmission of HIV occurs mainly across mucosal surfaces and the ability of the 
virus to cross this normally effective barrier takes place by means of disruption of 
epithelial integrity, transcytosis, infection through M-cells and infection and/or 
transference by mucosal dendritic cells (Shattock & Moore 2003, Mestecky 2006).  
However, regardless of the site of viral entry into the body, HIV (and SIV), 
particularly during acute and early productive infection, replicates in the mucosal 
tissues of the genital tract and gastrointestinal tract where it is responsible for the 
destruction of a majority of the CD4+ T cells in the body (Veazey et al., 1998, 
Brenchley et al., 2004, Li et al., 2005, Mattapallil et al., 2005).  CD4 and the co-
receptor CCR5 are used by HIV for cell entry, and in mucosal effector sites, the 
majority of effector memory T cells express CCR5 (Poles et al., 2001, Mehandru et 
al., 2004, Veazey et al, 2003), leading to a massive depletion in CD4+CCR5+ T cells 
from mucosal sites (Brenchley et al., 2004, Mehandru et al., 2004, Shacklett et al., 
2003). 
 
1.2.1 Structure and function of mucosal immune system 
The mucosa-associated lymphoid tissue (MALT) is the term that describes lymphoid 
tissue found in association with mucosal surfaces (Lydyard & Grossi 2006). MALT 
consists of organised and non-organised secondary lymphoid tissues, like the tonsils, 
the bronchus-associated lymphoid tissue (BALT) in the lungs, the gut-associated 
lymphoid tissue (GALT) and the urogenital lymphoid tissues (Lydyard & Grossi 
2006) [Figure 1.2].  The MALT exhibits varying degrees of organised lymphoid 
tissue.  For example, the main organised lymphoid tissue in the GALT are found in 
structures called Peyer’s patches that contain M cells, rich in T and B cells as well as 
dendritic cells and macrophages (MacDonald & Monteleone 2005), all ideal targets 
for HIV infection.  In contrast, the genital tract has no organised lymphoid structures, 
and in the female genital tract of macaques and humans potential HIV target cells, 
like CD4 T cells, are evenly distributed below the epithelium (Ma et al., 2001, Pudney 
et al, 2005) and sometimes cluster in small founder foci (Zhang et al., 2004).  From 
studying SIV infection in macaques, subsequent to a productive infection in the 
genital tract, HIV reaches the draining iliac lymph nodes where concentrated 
populations of T cells are infected and may then spread throughout the body (Miller et 
al., 2005).  
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Figure 1.2  Major lymphoid organs and tissues.  Tonsils, Peyer’s patches and other 
mucosa-associated lymphoid tissues (MALT) [blue boxes] react to antigens entering mucosal barriers 
(taken from Lydyard & Grossi, 2006). 
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1.2.2 Organisation of the male genital tract 
The male genital tract (MGT) consists of the testes, the excurrent duct system (rete 
testis, efferent ducts, epididymis and vas deferens), accessory glands (seminal 
vesicles, prostate and bulbourethral glands) and the penis (Cao & Hendrix 2008) 
[Figure 1.3].  The epithelia of the male genital tract consist mainly of two types, 
simple and stratified epithelia.  A single layer of simple columnar, cuboidal or 
pseudostratified epithelia are found in accessory organs, rete testis, epididymis, vas 
deferens and penile urethra, while stratified squamous epithelia can be found at the 
meatus (distal end of penile urethra), fossa navicularis (opening) and foreskin 
(Anderson & Pudney 2005).  Both the foreskin and meatus exhibit differential levels 
of keratinisation (McCoombe & Short 2006).  The outer foreskin is highly keratinized 
while the inner foreskin has a lower degree of keratinisation (Patterson et al., 2002). 
Mucus glands found in most simple epithelia in the MGT protect against pathogens 
through secretion of large amounts of mucus, for example the mucin, MUC6, secreted 
by the seminal vesicles.  Conversely, stratified epithelium is glandless with numerous 
layers physically hindering pathogen invasion (Anderson & Pudney 2005).   
 
Testis and excurrent duct system 
The tissue within the testis consists f a germinal compartment connected by 
interstitial tissue.  Sertoli cells, the “nurse-maid” cells that assist in spermatogenesis, 
immature germ cells and spermatozoa are the main cells inside the seminiferous 
tubules (germinal compartment), whereas the interstitial tissue contain blood vessels, 
lymphatics, mast cells, macrophages and Leydig cells (Anderson & Pudney 2005). 
The testis provides an immunologically advantaged location protecting germ and 
sperm cells against the body’s autoimmune reaction (Tung 1995).  Protection of these 
germ cells from the immune immune system is achieved by tight junctions between 
neighbouring Sertoli cells forming the blood-testis barrier (Dym & Fawcett 1970, 
Johnson & Setchell 1968, Shehu-Xhilaga et al., 2005).  Entry of macromolecules such 
as immunoglobulins and complement into the seminiferous tubules is also restricted 
(Anderson & Pudney 2005).  
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Figure 1.3  Anatomy of the male genital tract.  (Taken from Cao & Hendrix, 2008) 
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The rete testis, efferent ducts, epididymis and vas deferens all form part of the 
excurrent duct system (Shehu-Xhilaga et al., 2005).  From the seminiferous tubules 
immature sperm cells move through the rete testis which connects the mediastinum to 
the tightly wound up epididymis through a series of efferent ducts (Anderson & 
Pudney 2005).  Within the epididimys, sperm cells attain maturity by forming of the 
sperm tails and achieving fertilising capacity, while the muscular duct (vas deferens) is 
responsible for expelling the mature spermatozoa into the urethra (Anderson & 
Pudney 2005). 
 
Accessory glands 
The seminal vesicles, prostate and bulbourethral glands make up the accessory glands 
of the male genital tract.  The seminal vesicles are a pair of large glands on either side 
of the vas deferens, extending to the base of the prostate (Anderson & Pudney 2005, 
Shehu-Xhilaga et al., 2005).  Nearly 30% of seminal fluid, consisting of mucus and 
nutrients, is secreted by the seminal vesicles.  The urethra originates from the urinary 
bladder and it is here where the prostate surrounds the urethra (Anderson & Pudney 
2005).  Regulated by male hormones, the remaining 60% of seminal fluid, mainly 
proteins and other nutrients essential for sperm function, is contributed by the largest 
male accessory organ, the prostate (Shehu-Xhilaga et al., 2005).  The bulbourethral 
glands or Cowper’s glands, are small glands located on either side of the urethral bulb.  
The function of the bulbourethral glands is to secrete lubricant (mostly glycoproteins) 
to facilitate the ejaculation of sperm (Chughtai et al., 2005). 
 
The penis, foreskin and penile urethra  
The penis consists of three cylindrical hollow bodies, the corpora cavernosa, the 
corpus spongiosum surrounding the urethra, and the urethra that broadens into the 
glans penis.  The loose connective tissue that moves freely over the glans penis is 
called the foreskin (Shehu-Xhilaga et al., 2005).  As part of the ejaculatory duct 
system of the genital tract, the penile urethra transports spermatozoa at the time of 
ejaculation.  Directly before ejaculation, numerous glands in the penile urethra 
produce a highly viscous secretion that is released, called pre-ejaculatory fluid 
(Anderson & Pudney 2005).   
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1.2.3 Semen 
Semen consists of seminal plasma and seminal cells.  The testis, epididymis, seminal 
vesicles, bulbourethral glands, prostate and periurethral glands contribute secretions to 
make up seminal plasma (Coombs et al, 2003).  Seminal cells in semen consist of 
spermatozoa, immature germ cells, macrophages, T cells and polymorphonuclear cells 
(Anderson et al., 1991, Quayle et al., 1998).  In the semen of HIV-infected men, the 
virus is found as free viral particles and present in infected T cells or macrophages (Le 
Tortorec & Dejucq-Rainsford 2010).  Leukocytes in semen are derived from organ 
epithelia and different ducts of the male genital tract (Aitken, & Baker 1995). 
 
1.2.4 Immune cell targets for HIV infection 
Although the male genital tract contains immune cells that can support HIV replication 
in the epithelium and interstitial tissue of the semen-producing organs (el-Demiry et 
al., 1985), it is not known precisely where in the MGT HIV replicates.  Immune cells 
are found in all tissues comprising the male genital tract (Anderson & Pudney 
2005)[Figure 1.4].  Langerhans cells and CD4+ CCR5+ cells were found in the foreskin 
and other epithelial layers of the penis (McCoombe & Short 2006).  Although CD8+ T 
cells dominate in the penile urethra, the presence of CD4+ T cells has also been shown 
(Anderson & Pudney 2005).  Within the testis, the most likely targets for HIV-1 
infection are tissue-specific macrophages and CD4+ T cells (Hedger 2002).  Of all the 
organs of the male genital tract, the testis has been implicated as being the most 
important as a possible viral sanctuary, which is defined as any part of the body (organ 
or tissue) where ARVs are less effective in penetrating allowing HIV-1 to persist. 
 
Macrophages are found in the mucosa of the rete testis, the efferent ducts, the 
epididymis and the vas deferens, while T cells are compartmentalised between the 
epithelium and lamina propria (Anderson & Pudney 2005).  The lamina propria is a 
thin layer of connective tissue directly below the epithelium that together with the 
epithelium forms the mucosal layer.  It is rich in capillaries and mucus-producing 
glands (Young et al., 2006).  CD8+ T cells are restricted to primarily the epithelium 
lining, whereas CD4+ T cells are found mainly in the lamina propria (Ritchie et al., 
1984, el-Demiry et al., 1984)  As with the epididymis, the accessory glands consist of 
an epithelial layer and lamina propria.  In the seminal vesicles, the epithelia have a 
secretory function, whereas the lamina propria is made up of connective tissue  
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consisting of mast cells and macrophages (Shehu-Xhilaga et al., 2005).  T cells have 
also been shown to reside in both the epithelium and the lamina propria of the mucosa 
of the seminal vesicles (Anderson & Pudney 2005).  In both the epithelium and lamina 
propria of the prostate, macrophages and lymphocytes may be found (Anderson & 
Pudney 2005).  When the prostate becomes inflamed, due to, for example, bacterial 
infection, a significant number of CD4+ T cells traffic there (McClinton et al, 1990; 
Moser et al., 2002).  Prostatitis is common, occuring with a prevalence of 40% in 
healthy, HIV-uninfected men (Blumenfeld et al, 1992).  Macrophages along with both 
CD4+ and CD8+ T cells are present in the urethra (Anderson & Pudney 2005), although 
the majority of cells have been reported as CD8+ T cells.  Antigen-presenting cells are 
abundant along the whole penile urethra, while Langerhans cells are in the majority in 
the meatus, fossa novicularis and the foreskin (Anderson & Pudney 2005).  The 
foreskin also contains activated memory CD4+ T cells expressing both CCR5 and 
CXCR4 receptors ideal for HIV infection (Patterson et al., 2002, Hussain & Lehner 
1995).  DC-SIGN is expressed on both dendritic cells and macrophages in the foreskin 
(Soilleux & Coleman 2004).  The concentration of target cells for HIV infection in the 
foreskin illustrates why circumcision may be so effective at reducing HIV infection. 
 
To investigate which organs of the male genital tract may be involved in recurrent viral 
shedding into semen, SIV RNA was quantified in a range of genital tract organs of 
SIV-infected macaques (Le Tortorec et al., 2008).  The seminal vesicles and prostate 
had the highest levels of SIV RNA and since these organs together contribute nearly 
90% of seminal fluid (Wolff & Anderson 1988), it is likely that these organs are the 
source of most viral particles (Le Tortorec et al., 2008).  Contrasting results from a 
study quantifying HIV RNA in several genital fluids sampled in different sites within 
the human male genital tract, found that the prostate was not the major source of 
seminal HIV, but rather the urethra, seminal vesicles, periurethral and bulbourethral 
glands (Coombs et al., 2006).  Regardless of what the major sources of HIV replication 
are, these studies emphasise that almost all parts of the male genital tract may shed 
either SIV/HIV at differential levels in semen (Le Tortorec et al., 2008, Coombs et al., 
2006). 
 
Whether or not spermatozoa can transmit HIV remains a controversy.  Despite reports 
from several groups that provide evidence that sperm cells may bind HIV virions 
through mannose, glycolipid receptors or even CCR5 receptors (Dussaix et al., 1993, 
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Bandivdekar et al, 2003, Brogi et al., 1998, Fanibunda et al., 2008, Gadella et al., 
1998), other groups have not found evidence of HIV infection of viable spermatozoa 
(Quayle et al., 1998, Pudney et al., 1998).  So whether HIV can enter sperm cells or 
merely “hitch” a ride still has to be conclusively proven. 
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Figure 1.4  Schematic representation of the male genital tract.  Distribution and abundance of T lymphocytes, macrophages and 
Langerhans cells (Taken from Mestecky et al.,, 2006). 
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1.3  HIV acquisition and transmission in the male genital tract 
 
The majority of HIV infection occurs through heterosexual penile-vaginal or vaginal-
penile transmission.  The rate of sexual transmission in serodiscordant, heterosexual 
couples was found to be 0.0012 per coital act; strikingly, during the first 3 months after 
seroconversion, this risk increased 12-fold (Wawer et al., 2005), emphasizing that the 
risk of HIV transmission is at its highest shortly after seroconversion, when the 
infected person may not be aware of their status and viral loads are high (Baeten & 
Overbaugh 2003, Brenner et al., 2007).  The risk of acquisition for uncircumsised men 
compared to circumcised men was increased two-fold per sexual encounter (Baeten et 
al., 2005).  Several studies estimate that male-to-female transmission within 
heterosexual encounters is more efficient than female-to-male transmission (Nicolosi et 
al., 1994, Padian et al., 1997, Carpenter et al., 1999).  However, this is not evident in 
all studies (Quinn et al., 2000, Guthrie et al, 2007) and in fact, it has been suggested 
that at the level of a single sex act, there is no difference in the direction of 
transmission favouring either male or female infection (Powers et al., 2008).  
 
Powers et al., provide evidence that the ubiquitous estimation of 0.001 (1 in 1000 
contacts) for the rate of heterosexual HIV transmission (Royce et al., 1997) may be an 
underestimation.  In a meta-analysis, Powers et al., suggest that factors such as STIs, 
genital viral load, additional sex partners, age of participants, stage of infection, design 
of studies and circumcision of male partners may all play a role as confounders of HIV 
infectivity (Powers et al., 2008).  Transmission of HIV from an infected male to an 
uninfected female partner may be affected by seminal viral load.  In semen, viral loads 
may vary from exceedingly high to disproportionately low, when compared to plasma 
viral loads (Sheth et al., 2006).  An empiric study by Chakraborty et al., proposed that 
at 100 000 copies of HIV RNA per ejaculate, the probability of HIV transmission rises 
to 1 in 100 acts of sexual intercourse compared to when there are 1000 HIV RNA 
copies per ejaculate, where the probability of transmission is reduced to 3 in 10 000 
acts of intercourse (Chakraborty et al., 2001). 
 
It is known that circumcision protects men from HIV-1 acquisition (Auvert et al., 
2005, Bailey et al., 2007, Gray et al., 2007).  Many studies have investigated a 
proposed mechanism for HIV acquisition and transmission in the female genital tract, 
however very few have investigated the same in the male genital tract.  A recent study 
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compared the transmissibility of CCR5 and CXCR4-utilising viruses in different 
explant tissues of the the male genital tract (Fischetti et al., 2009).  They found that due 
to a preponderance of HIV target cells in the foreskin, glans, meatus and urethra of the 
penis, CCR5 HIV infection was successful, whereas CXCR4-tropic strains could not 
be productively disseminated (Fischetti et al., 2009). 
 
1.3.1 How does HIV cross the genital mucosal barrier? 
The first studies investigating a productive HIV infection in the genital tract were 
performed in the female genital tract.  The inherent properties of the mucosal barrier 
can be a natural deterrent to HIV transmission.  The genital tract produces a host of 
mucins that are responsible for protection against pathogens and lubrication of this 
surface (Russo et al., 2006).  Further protection is provided by an intact genital 
mucosal barrier, and the presence of genital innate immune factors and the low 
numbers of HIV-infected CD4+ T cells may explain lower HIV levels in genital 
secretions compared to blood (Kaul et al., 2008).  HIV binds to DC-SIGN on dendritic 
cells with subsequent infection of CD4+ T cells locally or in lymph nodes, or direct 
infection of CD4+CCR5+ lymphocytes, to establish a productive infection in the female 
genital tract (Belyakov & Berzofsky 2004).  Transcytosis involves the fusion of an 
HIV-infected cell and an epithelial cell t  form a viral synapse, where viral budding at 
the synapse leads to internalisation of the virions by epithelial cells and release at the 
basal side of the epithelial layer (Bomsel 1997, Bobardt et al., 2007).  In stratified 
epithelia, such as the vagina, exocervix and anus, HIV-infection via Langerhans cells 
(LCs) is proposed to be the means by which HIV crosses the mucosal barrier.  
Sampling or capturing of HIV virions by Langerhans cells across the mucosal epithelia 
leads to transfer to T cells, either locally or in the lymph nodes (Hladik & McElrath 
2008, de Witte et al., 2008). 
 
There are few studies investigating HIV transmission across the epithelia of the male 
genital tract.  The presence of HIV target cells in the penile urethra (Pudney & 
Anderson 1995), the epithelia of the remainder of the penis (McCoombe & Short 
2006), and especially the preponderance of target cells in the foreskin enhances the risk 
of HIV acquisition and productive infection (Figure 1.5).  As in the female genital 
tract, both Langerhans and DC-SIGN+ cells are present in the foreskin, and other non-
keratinized epithelia of the human penis may play an important role in binding, 
internalisation and spread of HIV to draining genital lymph nodes (McCoombe &  
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Figure 1.5  Potential areas of HIV-1 entrance.  (a) Flaccid uncircumcised penis. (b) 
Erect uncircumcised penis with foreskin retracted showing likely sites of HIV-1 entry. 
(Taken from McCoombe & Short, 2006) 
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Short 2006).  A recent study described the development of an ex vivo foreskin explant 
model to investigate the early events after HIV exposure of foreskin (Ganor et al., 
2010).  This study found abundant LCs and T cells in the inner foreskin. HIV entry 
through the inner foreskin occurred more effectively than the outer, suggesting that the 
keratinized outer foreskin provides protection that may only enable HIV entry and 
infection of LCs subsequent to skin abrasions, supporting earlier findings (Kawamura 
et al., 2008).  Importantly, Ganor et al., showed that HIV infection in this model was 
more effective with HIV-infected cells, rather than cell-free virus.  They observed the 
formation of LC-T cell conjugates in the inner foreskin, as well as viral synapses 
between HIV-infected cells and apical foreskin keratinocytes.  The LC-T cell 
conjugates occurred at high concentrations of virus, confirming a previous study that 
showed that at low viral concentrations, LCs protected from HIV infection (de Witte et 
al., 2007) [Figure 1.6]. 
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Figure 1.6  Initial events during HIV-1 transmission across the foreskin.  (Left) Inner 
foreskin, synapses form, leading to particle budding (1). Low virion concentrations:  Langerhans cells 
(LCs) remain within the epidermis; virions are destroyed by LCs (2). In contrast, high concentrations of 
virions: (3) LCs move to mucosal surface; virions are captured (4) LCs migrate back to the epidermal – 
dermal interface; conjugates with T cells allow virion transfer to T cells (5). Conjugates or single 
infected T cells disseminate the infection (6). (Right) Outer foreskin, synapse formation also occurs (7). 
However, newly budded virions may remain trapped within the thick layer of keratin (8). Thus, virus 
entry into the epidermis is limited, and infection cannot spread (9) [Taken from Ganor et al., 2010]. 
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1.3.2 Factors that enhance local replication and transmission of HIV 
STIs can lead to enhanced HIV shedding in the genital tract and increased transmission 
of HIV, as well as increased suseptibility in uninfected persons (Corbett et al., 2002, 
Kaul et al, 2000).  Herpes simplex virus (HSV)-2 is one such STI.  People with both 
infections may transmit HIV more efficiently than people infected with HIV alone, and 
people that are infected with HSV-2 can acquire HIV more readily (Schacker 2001).  
HSV-2 causes genital ulcer disease, but HSV-2 shedding in the genital tract can also be 
asymptomatic (Corey et al., 2004, Wald & Corey 2003, Chen et al., 2000).  A three-
fold risk of HIV acquisition in both men and women has been associated in several 
studies with pre-existing HSV-2 infection (Freeman et al., 2006), whereas a six-fold 
increase in HIV acquisition was shown in highly exposed sex workers infected with 
HSV-2 (Kaul et al., 2004).  Even in the absence of HSV-2 shedding or ulceration, 
HSV-2 was associated with elevated levels of CD4+CCR5+ T cells and DC-SIGN+ 
dendritic cells (Rebbapragada et al., 2007) and in fact, HIV genital shedding has been 
associated with local HSV-2 replication (Kaul et al., 2008, Baeten et al., 2004, 
McClelland et al., 2002) [Figure1.7].  Since symptomatic HSV-2 may cause lesions in 
the genital tract, HIV-1 transmission is more likely, although in asymptomatic patients, 
re-activation is sub-clinical and shows similar microscopic damage as well as elevated 
levels of lymphocytes as clinical disease (Corey et al., 2004).  
 
Non-ulcerative STIs such as gonorrhoea and chlamydia have been found to increase 
HIV shedding in the genital tract by recruiting target cells for possible infection 
(Fleming & Wasserheit 1999).  Gonococcal urethritis has been shown to elevate 
seminal viral loads in HIV-infected men (Winter et al., 1999, Sadiq et al., 2005b, 
Taylor et al., 2003).  Chlamydia infections, that are often asymptomatic, have been 
associated with increased inflammation in the male genital tract (Kokab et al., 2010) 
and in vitro, this has been shown to increase HIV replication (Ho et al., 1995).  In 
HIV-infected men, non-specific urethritis causes up to eight times higher shedding of 
HIV-1 than in healthy men (Dyer et al., 1998), and even non-STI conditions such as 
prostatitis can elevate inflammation in the MGT (Motrich et al., 2005), potentially 
increasing the risk of HIV acquisition by recruiting target cells for HIV.   
  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 23
 
 
Figure 1.7  Model showing synergy between HIV-1 and HSV-2.  (taken from Kaul et 
al., 2007) 
 
 
Other STIs that may cause genital ulcers are the bacterial infections syphilis and 
chancroid.  During primary and secondary syphilis, mucosal lesions may allow viral 
entry in co-infected people, and HIV may also be transmitted from these lesions 
(Fleming & Wasserheit 1999).  One study reported a significant increase in plasma 
HIV viral load and a reduction in CD4+ T cells in men with primary and secondary 
syphilis (Buchacz et al., 2004), whereas no association was found between syphilis and 
either HIV seminal or plasma viral loads in a subsequent study (Sadiq et al., 2005a).  
Chancroid infections in men are associated with an influx of CD4+ T cells into the 
genital tract (Magro et al., 1996, Van Laer et al., 1995). Symptomatic chancroid-
infected men are up to five times more likely to acquire HIV from female partners than 
asymptomatic men (Cameron et al., 1989). 
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1.3.3 Factors associated with protection from HIV infection in the genital tract 
There are several innate immune factors in the genital tract that have demonstrated 
anti-HIV activity in vitro.  These include MIP-3α, RANTES, lactoferrin, SLPI and α/β-
defensins (Iqbal et al., 2005).  A recent study showed that the genital innate immune 
factor, elafin/trappin-2 is associated with HIV-1 protection in women (Iqbal et al., 
2009).  Although these molecules may contribute to antiviral defence, some, such as 
MIP-3α, RANTES and α-defensin, may also facilitate transmission of HIV through 
increased recruitment of target cells to the sites of infection (Kaul et al., 2008); 
(Vendrame et al., 2009, Levinson et al., 2009, Li et al., 2009).  Most studies have 
investigated the presence of these innate immune factors in the female genital tract.  In 
semen and urethral lavages of men, SLPI and lactoferrin were detected (Sheth et al., 
2005, Anderson et al, 2011), and lactoferrin was shown to be significantly positively 
associated with HIV-1 RNA levels (Sheth et al., 2005).  RANTES levels have also 
been quantified in the semen of both healthy and HIV-infected men (Politch et al., 
2007, Anderson et al., 2010).  In the semen of healthy men, RANTES levels were 
detected at moderate levels, whereas in HIV-infected men, low levels were detected.  It 
remains to be seen whether these factors in the male genital tract protect or enhance 
HIV-1 transmission. 
 
Circumcision has been shown to be highly effective at protecting men against 
acquisition of HIV-1 (Auvert et al., 2005, Bailey et al., 2007, Gray et al., 2007).  The 
outer surface of the foreskin is more keratinized than the inner part (McCoombe & 
Short 2006, Patterson et al., 2002, Hussain & Lehner 1995), and studies have linked 
keratinization to protection against HIV-1 acquisition (Patterson et al., 2002; Pask et 
al., 2008).  In contrast, the inner foreskin is less keratinized and also has a higher 
density of target cells for HIV infection (McCoombe & Short 2006, Donoval et al., 
2006).  As mentioned previously, a recent study has proposed that HIV-1 uses 
dendritic cells and keratinocytes in the foreskin to increase transmission (Ganor et al., 
2010).  Thus, excision of the foreskin results in removal of potential HIV-1 target cells 
and can aid in protection from HIV infection. 
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As discussed, co-infection with STIs can lead to increased shedding of HIV (Galvin & 
Cohen 2004).  Previous studies have shown that treatment of urethritis with antibiotics 
can reduce HIV shedding in semen by as much as two-thirds (Moss et al., 1995, Cohen 
et al., 1997).  Four randomized trials in women showed that HIV levels can be reduced 
in plasma and the genital tract by treating HSV-2 (Baeten et al., 2008, Dunne et al., 
2008, Nagot et al., 2007, Delany et al., 2009).  In men, a randomised trial showed the 
same result in plasma and rectum (Zuckerman et al., 2007), while a recent study 
showed a 44% reduction in levels of seminal HIV after treatment of HSV-2 
(Zuckerman et al., 2009).  Despite successes in reducing the genital HIV burden 
through treating STIs, clinical trials aimed at decreasing HIV acquisition and 
transmission have largely failed.  Thus far only one trial in Tanzania showed a 
significant decrease of 38% in HIV incidence after treatment of non-viral STIs such as 
chancroid, syphilis, gonorrhoea, chlamydia and trichomoniasis (Grosskurth et al., 
1995, Grosskurth et al., 2000), whereas HSV-2 suppressive treatment trials have all 
failed to show a decrease in HIV infection (Celum et al., 2010, Watson-Jones et al., 
2008). 
 
1.3.4 Semen as an inhibitor or enhancer in HIV transmission 
In male to female transmission of HIV, there are a number of seminal factors that have 
been implicated in providing either an inhibitory or enhancing effect to transmission of 
HIV (Figure 1.8).  Seminal plasma contains 52 cationic polypeptides that have been 
shown to enhance endogenous anti-HIV activity in vitro in two cell lines (Martellini et 
al., 2009).  Semen can also act as an enhancer of HIV transmission within the female 
recipient by more non-specific means.  The pH of semen varies from 7.0 – 8.4 (WHO, 
2010).  The natural antiviral acidic environment of the vagina is temporarily 
neutralised by semen (Wolters-Everhardt et al., 1986), which may facilitate HIV 
survival and subsequent transmission. 
 
Amyloid aggregates in semen have been shown to dramatically enhance HIV infection 
in vitro through the trapping of HIV virions, which promotes target cell attachment in 
vitro (Munch et al., 2007).  These amyloid fibrils have been termed ‘semen-derived 
enhancer of virus infection’ (SEVI), and are formed through the action of the enzyme 
prostatic acidic phosphatase (PAP).  The same group found that SEVI fibrils are highly  
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cationic, enhancing HIV attachment and subsequent infection of target cells (Roan et 
al., 2009), and that a compound, aminoquinoline surfen, inhibits SEVI-mediated 
enhancement of HIV infection (Roan et al., 2010).  Another mechanism of semen 
enhancement that has been highlighted recently involves interactions between 
spermatozoa and HIV virions.  Heparin sulphate expressed on the surface of 
spermatozoa can bind to HIV, and may transmit virus directly to DC-SIGN on 
dendritic cells in the female genital tract (Ceballos et al., 2009). 
 
Semen can also enhance infection by leading to localised vaginal inflammation.  Up-
regulation of expression of inflammatory genes in vaginal epithelial cells has been 
demonstrated in response to semen exposure (Sharkey et al., 2007).  Semen contains 
high concentrations of transforming growth factor (TGF)-β and prostaglandins, both of 
which have been shown to have pro-inflammatory effects and attract immune cells in 
the vagina (Robertson et al., 2002, Templeton et al., 1978).  Paradoxically, TGF-β also 
suppresses macrophage activation serving as the main constituent in seminal plasma 
responsible for immune tolerance within the female genital tract (Robertson et al., 
2002, Ashcroft 1999).  Seminal plasma can also induce the expression of MIP-3α, a 
soluble factor responsible for the recruitment and maturation of Langerhans and 
dendritic cells (Berlier et al., 2006b).  MIP-3α recently been shown to attract these 
cells to the endocervix in SIV infected macaques, in turn recruiting CD4+ T cells, 
thereby facilitating early establishment of foci of infection and dissemination 
systemically (Li et al., 2009, Haase 2010).  
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Figure 1.8  Factors in semen that may enhance or inhibit male-to-female transmission. (Taken from Doncel et al., 2010) 
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1.4 Immune activation and inflammation in HIV transmission and 
pathogenesis 
 
Disease progression in HIV infection occurs as the result of destruction and loss of 
CD4+ T cells, and dysfunction of a range of immune cells.  Massive depletion of 
activated CD4+ T cells that express CCR5 takes place in mucosal tissues at all stages of 
HIV infection (Brenchley et al., 2004).  Not only are the majority of CD4+ T cells lost 
by direct infection, but also as bystanders, and there is substantial evidence pointing to 
hyperactivation of the immune system and activation-induced cell death as a major 
mechanism driving HIV disease progression (Hunt 2007, Douek et al, 2009, Appay & 
Sauce 2008) [Figure 1.9]. 
 
1.4.1 HIV elevates immune activation and immune exhaustion 
HIV infection is characterised by widespread T cell activation that is not always 
antigen-specific (Papagno et al., 2004, Doisne et al., 2004).  Besides increased levels 
of non-specifically activated T cells during HIV infection, B cells are also polyclonally 
activated, and increased levels of pro-inflammatory cytokines and chemokines are 
evident (Douek et al, 2009). 
 
Chronic immune activation has been found to be detrimental in HIV infection.  The 
levels of activated CD8+ T cells in chronic infection are more predictive of clinical 
progression to AIDS and death than plasma CD4+ T cell counts or HIV RNA 
concentration (Giorgi et al., 1993, Liu et al., 1998, Giorgi et al., 1999).  Furthermore, 
in people at risk of HIV acquisition, higher levels of T cell activation prior to infection 
may be associated with faster HIV progression subsequent to HIV infection 
(Hazenberg et al., 2003).  Further evidence that immune activation may be involved in 
HIV disease progression is provided by studies of non-pathogenic SIV infection of 
primates.  In SIV-infected sooty mangabeys and African green monkeys, despite high 
viral loads, T cell hyperactivation is not found and these animals do not develop AIDS 
(Silvestri et al., 2003).  In contrast, in SIV-infected macaques and HIV-infected 
humans, elevated T cell activation accompanies CD4+ T cell loss and progression to 
AIDS (Silvestri et al., 2003). 
 
Immune activation increases the potential for T cells and macrophages to be infected,  
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by up-regulation of surface expression of CCR5 (Wu et al., 1997, Bleul et al., 1997).  
Furthermore, trafficking of T cells to lymphoid tissues is increased by activation-
induced up-regulation of adhesion molecules, further enhancing HIV replication and 
potential systemic spread of the virus (Shattock et al., 1996).  Transcription of 
integrated virus is noticeably sped up in activated T cells, promoting expression of 
HIV from latently-infected cells (Calman et al., 1988, Kawakami et al, 1988).  In 
addition, T cell homeostasis may be disrupted by the high turnover of CD4 and CD8 T 
cells (Kovacs et al., 2001).  Continued immune activation causes damage to lymphoid 
tissues, such as the thymus and lymph nodes, impairing the regenerative capacity of the 
immune system.  The ability of the thymus to generate mature, functionally competent 
naive T cells is reduced in HIV-infected individuals (Douek et al., 1998).  Persistent 
immune activation has also been linked to progressive collagen deposition and 
destruction of lymph node architecture (Schacker et al., 2002b).  This damage may 
further decrease the half-life of resting naïve and memory T cells, restricting cells from 
entering or leaving lymph nodes, as well as reducing the ability of APCs to effectively 
prime naïve T cells, thereby affecting the HIV-specific T cell immunity (Hellerstein & 
McCune 1997). 
 
HIV infection can lead to immune activation by direct or indirect means.  HIV 
antigenic stimulation directly activates T cells, inducing HIV-specific CD4+ and CD8+ 
T cells (Betts et al., 2001).  Up-regulation of pro-inflammatory mediators along with 
increased activation of both lymphocytes and macrophages have been suggested to be 
the directly induced by HIV gene products.  For example, gp120 and Nef can activate 
macrophages and lymphocytes (Merrill, Koyanagi & Chen 1989, Rieckmann et al., 
1991, Lee et al., 2003, Swingler et al., 1999, Wang et al., 2000, Simmons et al, 2001).  
Immune activation may be exacerbated by re-activation of co-infections, such as CMV 
and EBV (Doisne et al., 2004).  In addition, HIV depletes CD4+ T cells in the gastro-
intestinal tract mucosa, leading to enteropathy, a condition characterized by damage to 
the epithelium of the gut, increased intestinal permeability as well as malabsorption 
(Sharpstone et al., 1999, Smale et al, 2000). 
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Figure 1.9  A proposed model for HIV pathogenesis.  Possible causes for immune 
activation are in yellow, while the effects are in red.  (Taken from Appay & Sauce, 2008) 
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Because of this increased permeability in the gut, significantly increased levels of 
bacterial products, such as bacterial DNA, lipopolysaccharides (LPS) and other 
bacterial components from gut microbial flora can ‘leak’ into plasma, and this 
‘microbial translocation’ has been linked to systemic immune activation  (Brenchley et 
al., 2006, Jiang et al., 2009).  
 
1.4.2 Inflammation in HIV transmission and pathogenesis 
During acute HIV infection, an HIV-induced “cytokine storm” has been described, 
where high levels of pro-inflammatory cytokines are found in plasma, which peak in 
conjunction with viral load (Stacey et al., 2009).  It appears that cytokines that are 
normally produced to control HIV replication by orchestrating innate and adaptive 
immunity may well contribute to disease progression, due to their sustained and high 
level production. Pro-inflammatory cytokines can promote the activation of CD4+ T 
cells (Decrion et al., 2005), continually providing new targets for viral infection. 
 
A recent study by Li et al., investigated the earliest steps in of SIV infection after 
cervicovaginal inoculation of macaques.  They found an aggregation of plasmacytoid 
dendritic cells (pDCs) producing IFNα and β as well as MIP-1α and MIP-1β.  These 
chemokines were found to attract CD4+CCR5+ T cells that may serve as SIV target 
cells (Li et al., 2009).  In the female genital tract pro-inflammatory cytokines are 
associated with ulceration and increased HIV shedding (Lawn et al., 2000).  Persistent 
shedding of HIV in semen has been reported (Coombs et al., 1998, Gupta et al., 2000, 
Bujan et al., 2004) which may in turn elevate inflammation in the male genital tract 
sustaining viral replication.  Microbial translocation together with concomitant 
systemic activation can be worsened by reduction of transepithelial resistance 
(monolayer integrity) in gut mucosal tissues through increased levels of IL-1β and 
TNFα (Stockmann et al., 2000, Nazli et al., 2010); in the same way, pre-existing 
inflammation may enhance transmission of HIV by thinning and disruption of the 
vaginal epithelium (Haase 2010). 
 
Sustained local inflammation in the genital tract results in the influx of target cells for 
HIV, which has implications for susceptibility, or HIV-infected cells and thus local 
replication of HIV, which has implications for transmission.  In the female genital 
tract, increased levels of pro-inflammatory cytokines, such as TNFα, IL-1β, IL-6 and 
IL-8, were significantly associated with HIV shedding (Gumbi et al., 2008).  In the 
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semen of HIV-infected men, several pro-inflammatory cytokines (IL-6, IL-8, IL-12 
and IFNγ) were associated with increased HIV shedding (Sheth et al., 2006).  Seminal 
plasma levels of RANTES and IL-1β have also been shown to positively correlate with 
seminal viral load (Storey et al., 1999, Berlier et al., 2006a).  Pro-inflammatory 
mediators identified to be up-regulated in HIV-infection differ from study to study, 
depending on the panel of cytokines and chemokines investigated.  A recent study 
investigating cytokine levels in HIV-infected male genital tissue explants of the 
foreskin, glans and urethra showed high levels of IL-6, IL-8, MIP-1α, MIB-1β, G-CSF, 
MCP-1 and IP-10 (Fischetti et al., 2009).  A comprehensive investigation of cytokines 
and chemokines present in seminal plasma of HIV-infected men revealed significant 
up-regulation of IL-1β, IL-4, IL-6, IL-7, IL-8, GM-CSF and MCP-1 (Anderson et al., 
2010) compared to uninfected men, although adjustment for multiple comparisons was 
not performed.  Since the genital tract is an effector site, exposed to multiple insults 
up-regulation of levels of cellular activation and inflammation is to be expected.  From 
these studies above, IL-1β, IL-6 and IL-8 were the inflammatory mediators that were 
most often identified in the genital tract.  The majority of the studies above controlled 
for the presence of other STIs, and despite the variation of pro-inflammatory mediators 
in different studies, there appears to be evidence that inflammation in the genital tract 
is linked to HIV replication. 
 
 
1.5 HIV replication in the genital tract: distinct viral reservoirs 
 
The genital tract poses a challenge for effective viral suppression.  Despite ART 
reducing seminal viral loads to undetectable levels in most patients (Bujan et al., 2004, 
Ghosn et al., 2008, Chan et al., 2008a), certain antiretroviral drugs have been measured 
at sub-optimal concentrations in the genital tract (Kashuba et al., 1999, Lafeuillade et 
al., 2002, Ghosn et al., 2004a, Chan et al., 2008b).  Differential penetration of 
antiretroviral drugs into genital organs and tissues can lead to sustained viral 
replication there, as well as the emergence of drug-resistant strains (Taylor et al., 2003, 
Ghosn et al., 2004a, Eyre et al, 2000, Ghosn et al., 2004b, Taylor, Pereira 2001, Eron 
et al., 1998), which may be spread by means of sexual transmission (Grant et al., 2002, 
Little et al., 2002, Markowitz et al., 2005). 
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1.5.1 Antiviral drug resistance in the male genital tract 
Antiretroviral therapy may adequately suppress viral loads in blood, without achieving 
suppression in the genital tract (Lorello et al., 2009; Haggerty et al, 2006) [Figure 
1.10].  In fact, several studies have shown genetically divergent strains between blood 
and semen (Eyre et al, 2000, Ghosn et al., 2004b, Smith et al., 2007, Kroodsma et al., 
1994) for men on antiretroviral therapy.  The lack of successful suppression of seminal 
viral replication may be due to a disparity in penetration of different antiretrovirals in 
semen compared to blood (Chan 2005, Pereira et al., 2002, Taylor & Davies 2010, 
Lowe et al., 2006, Lafeuillade et al., 2003).  Lorello et al., found that 2/13 men on 
efavirenz had detectable seminal viral loads (Lorello et al., 2009), whereas Sheth et al., 
found no association between seminal HIV shedding and any specific antiretroviral 
agents or classes (Sheth et al., 2009).  A recent meta-analysis investigating antiviral 
drug concentrations in the genital tract showed a 0 – 48% seminal viral shedding 
depending on the ARV regime and the length of time on treatment (Taylor & Davies 
2010). 
 
1.5.2 The male genital tract as a potential viral reservoir 
Several studies have shown that the male genital tract gives rise to distinct viral 
populations from blood (Coombs et al., 1998, Gupta et al., 2000, Eyre, Zheng & 
Kiessling 2000, Ghosn et al., 2004b, Zhu et al., 1996, Vernazza et al., 1994, Byrn et 
al., 1997, Kiessling et al., 1998, Ping et al., 2000, Pillai et al., 2005, Diem et al., 
2008), suggesting that the unique tissue-specific environment in the male genital tract 
results in the evolution of distinct HIV strains. 
 
A recent study investigating genetic differences between viral strains in semen and 
blood of acutely SIV-infected macaques showed that at the time of peak viral 
replication, there were no significant differences between compartments, with distinct 
seminal viral differences only developing after 16 weeks of infection in 4 out of 7 
animals (Whitney et al., 2011).  The authors suggest that during peak viremia there is 
likely more trafficking of virus between the male genital tract and blood and that 
compartmentalization only occurs after a decrease in viral load (Whitney et al., 2011).  
In humans, a recent study proposed a model that demonstrated that not only does 
compartmentalization result in viral shedding in semen, but that there may be direct 
transfer of virus from blood to the genital tract.  Furthermore, the authors postulate that 
uninfected target cells may be infected by infected CD4+ T cells or virions that  
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Figure 1.10  HAART does not guarantee low-level viraemia.  Anti-retroviral therapy may 
reduce HIV-1 RNA below the detection level of most clinical assays (50 copies/ml).  More 
sensitive methods detecting HIV-1 RNA < 50 copies/ml may represent continuing rounds of 
replication (top) or release of HIV-1 from stable reservoirs (bottom).  (Taken from Haggerty et al., 
2006) 
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infiltrate the seminal tract, establishing local areas of infection within the male genital 
tract (Anderson et al., 2010).  In the case of compartmentalization, the question 
remains, what part of the male genital tract is responsible for contributing to shedding 
of virus in semen?  Due to the blood-testis barrier, antiretroviral entrance into the testes 
are constrained (Choo et al., 2000, Livni et al., 2004), and therefore it has been 
postulated that the testis is the most probable site of a viral sanctuary in the male 
genital tract (Shehu-Xhilaga et al., 2005). 
 
 
1.6 HIV-specific immunity in the genital tract 
 
A range of studies have identified HIV-specific T cell responses i  the cervix and 
semen of HIV-infected individuals (Quayle et al., 1998, Sheth et al., 2005, Musey et 
al., 1997, Musey et al., 2003b, Shacklett et al., 2000, Kaul et al., 2000, Kaul et al., 
2003).  HIV-specific responses have been shown to be shared between the blood and 
mucosa of HIV-infected individuals (Musey et al., 2003a, Ibarrondo et al., 2005).  An 
important question is whether these responses play a role in the control of local HIV 
replication, either in the context of natural infection or if induced prior to exposure in 
the context of vaccination. 
 
1.6.1 The female and male genital tracts 
Important insights into adaptive immunity to HIV in the genital have been gained from 
studying vaginal transmission in the SIV-macaque model, demonstrating that even 
robust SIV-specific T cell responses in the female genital tract and gut did not prevent 
or contain SIV infection (Reynolds et al., 2005).  Reynolds et al., suggested that a 
contributing factor for the massive depletion of CD4+ T cells early in infection is the 
delay in the development of SIV-specific CD8+ T cell responses, which takes up to two 
weeks.  This results in the establishment of a productive SIV infection that cannot be 
controlled by subsequent T cell responses (Reynolds et al., 2005), what these authors 
termed “too little, too late”.  Similar studies of early HIV infection in the male genital 
tract have not been undertaken.  In humans, clonality of HIV-specific CD8+ T cells was 
compared between the blood, semen and cervix, and it was shown that the majority of 
clones were shared between blood and the mucosal sites investigated (Musey et al., 
2003a), implying a trafficking of responses from blood to the genital tract.  Similar 
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HIV-specific responses by CD8+ T cells between blood and the GALT have also been 
demonstrated (Ibarrondo et al., 2005). 
 
An important question is whether HIV-specific T cells at these sites have any effect on 
controlling local viral replication.  A study by Gumbi et al., found that there was no 
association between the magnitude of HIV Gag-specific CD8+ T cell responses and 
viral shedding in the female genital tract (Gumbi et al., 2008), suggesting that T cell 
responses in the genital tract may not be as a result of local HIV viral replication alone; 
and that these cells may not be involved in effective viral control.  A similar study of 
semen of HIV-infected men found that HIV-specific CD8+ T cells correlated positively 
with the levels of HIV in semen (Sheth et al., 2005), mirroring the situation often 
described in blood, where it appears that antigen load drives the magnitude of T cell 
responses, and there is no obvious relationship between T cell frequency and viral 
control.  This may be due to non-optimal functioning, as has been shown for mucosal 
HIV-specific responses (Ferre et al., 2009), where individuals controlling HIV had 
CD8+ responses in the rectal mucosa with greater functionality than non-controllers. 
 
1.6.2 Does an HIV vaccine need to induce mucosal immunity? 
As discussed, the majority of HIV transmission occurs via mucosal surfaces, and the 
lymphoid tissue of the gut is an earl  target for HIV replication.  Therefore, immunity 
at mucosal surfaces, especially the genital tract and the gut, is paramount for vaccine-
mediated protection.  Thus, vaccination that can induce effective mucosal responses, 
whether they are T cell or antibody responses, is needed. 
 
Several studies in macaques using different vectors and vaccination regimes showed 
that SIV-specific T cells and antibodies can be induced at various mucosal surfaces 
(Bertley et al., 2004, Fuller et al., 2002, Nilsson et al., 1998, Tenner-Racz et al., 2004).  
A study in mice and macaques showed that effective mucosal T cell responses elicited 
by an intramuscular recombinant adenovirus (rAd) vaccine were found in the spleen, 
lymph nodes, gut and vaginal surfaces of mice, whereas in macaques robust, 
longlasting responses were shown in lymph nodes, the gut bronchoalveolar lavages 
(BAL) and the vaginal tract (Kaufman et al., 2008). 
 
In humans, Musey et al., demonstrated HIV-1-specific CD8+ T cell responses detected 
in rectal mucosa following intramuscular vaccination with a live recombinant 
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canarypox ALVAC-HIV vaccine containing HIV-1 genes encoding for env, gag and 
parts of the pol gene (Musey et al., 2003b).  This demonstrated that even systemic 
vaccination may induce mucosal immunity, likely due to the trafficking of these 
responses from blood.  Also in a macaque model of SIV infection, a recent study 
showed a reduction of SIV levels in the semen of macaques after vaccination with a 
DNA-rAd5 candidate vaccine expressing Gag and Pol (Whitney et al., 2009).  Sixteen 
weeks after vaccination, macaques were infected intravenously with SIV.  A 
comparison between vaccinated animals and the unvaccinated control group showed a 
significant reduction of more than one log in seminal viral load at peak viremia 
between vaccinated and unvaccinated animals.  Furthermore, seminal viral loads in the 
vaccinated animals decreased to undetectable levels by day 42 after challenge, and 
remained so for the remaining 10 weeks of the study. The data in this study implies 
that vaccination can not only lower seminal viral loads, but significantly impact on 
lowering the risk of sexual transmission. 
 
A vastly understudied area is humoral immunity to HIV in the male genital tract, with  
a single study to date characterising HIV-specific antibody responses in semen 
(Mestecky et al., 2009).  Further studies on the presence of neutralising antibodies in 
both natural infection and in vaccine trial volunteers are warranted.  It seems clear that 
an effective HIV vaccine will need to elicit not only effective systemic immunity, but 
most importantly provide protection where infection occurs, namely the genital 
mucosa. 
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1.7 Aims and objectives 
 
Overall aim of the thesis 
The aim of this thesis was to develop methodologies for the isolation and 
characterization of T cells from semen, as a representation of local immunity in the 
male genital tract.  These methodologies were then applied to characterizing cellular 
activation and inflammation in the male genital tract in a cohort of HIV-infected and 
uninfected men, in order to gain insights into the acquisition and transmission of HIV. 
 
Rationale for developing methodologies for the isolation of T cells from semen 
Studies of mucosal immunity in the genital tract are significantly hampered by inherent 
difficulties associated with mucosal sampling and the resultant low yields of mucosal 
cells obtainable from clinical specimens (Gumbi et al., 2008, Nkwanyana et al., 2009).  
There is a need for the development of optimized protocols for isolating and evaluating 
sufficient numbers of viable lymphocytes from the male genital tract, as no 
standardized protocols currently exist.  Such methods would aid in improving our 
understanding of both local immunity and the assessment of responses to candidate 
HIV vaccines.   
 
Rationale for investigating immune activation and inflammation in the male genital 
tract 
Semen is the main vector for HIV transmission.  Inflammation in the male genital tract 
may therefore have important implications for onward transmission of HIV. Local 
inflammation may increase local viral replication (Mitchell et al., 2011), and higher 
viral loads in semen would likely increase the probability of successful transmission 
(Pilcher et al., 2004, Wilson et al., 2008).  Inflammation may also influence HIV 
acquisition, leading to target cell activation and infiltration into the genital tract 
(Nkwanyana et al., 2009), increasing the susceptibility of uninfected individuals to 
productive HIV infection.  No studies to date have specifically investigated the impact 
of local T cell activation and virus levels in semen, and a few studies have evaluated a 
limited range of inflammatory cytokines in semen and their relationship with viral 
shedding. Extending these studies may improve our understanding of the local 
microenvironment of the genital tract and how genital tract  
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T cell activation, inflammation and local viral replication relate to each other and 
influence HIV transmission and acquisition.  
 
Specific objective 1 
To develop methods for the optimal isolation of CD3+ T cells from semen, as well as to 
characterize the types of immune cells present in semen (Chapter 2).   
 
Specific objective 2 
Using methods developed in Chapter 2, the objective was to characterize and compare 
levels of T cell activation in the semen and blood of HIV-infected and HIV-uninfected 
men, and to evaluate the impact of local viral replication on immune activation in the 
genital tract (Chapter 3). 
 
Hypothesis 
Levels of T cell activation will be higher in semen from HIV-infected men compared 
to HIV-uninfected men, and there is a direct correlation between T cell activation in 
semen and seminal HIV viral load. 
 
Specific objective 3 
The objective of this part of the thesis was to investigate inflammation in the male 
genital tract during HIV infection, by characterizing the presence and levels of a range 
of cytokines and chemokines in seminal plasma.  The association between the levels of 
inflammatory cytokines and T cell activation, as well as local viral replication, was 
investigated (Chapter 4). 
 
Hypothesis 
HIV-infected men maintain higher levels of inflammation in the genital tract than 
uninfected men, and that this is associated with higher levels of T cell activation and 
HIV shedding in semen. 
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CHAPTER 2 
 
Isolation and characterisation of leukocytes from semen 
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2.1 Introduction 
 
HIV-1 is predominantly a disease of the mucosa. Infection, transmission and much of 
the pathogenesis of the disease occurs at the mucosal surfaces of the genital tract and 
the gastrointestinal tract (Haase 2010).  In the context of developing strategies for 
preventing HIV infection by vaccination, inducing immune responses in the genital 
tract is paramount.  However, few HIV vaccine studies in humans to date have 
measured the ability of candidate vaccines to induce mucosal immunity (Musey et al., 
2003b).  This is likely due to the difficulty in sampling genital tract sites, and the fact 
that there are few well-established methods for processing the cells obtained.  A good 
understanding of the immune milieu of genital tract sites, including the types of cells 
and their abundance, as well as soluble factors present, is lacking.  This chapter focuses 
on methodologies for obtaining and studying T cells from the male genital tract, as 
well as the characterisation of immune cells present in this compartment. 
 
T cells play a central role in immune control of HIV-1 infection (Koup et al., 1994, 
Schmitz et al., 1999, Allen et al., 2005).  Many current HIV vaccine strategies are 
aimed at eliciting cellular responses against HIV (as reviewed in Gamble & Matthews 
2010).  In natural HIV infection, the presence of HIV-specific CD8+ T cells has been 
demonstrated both in the female genital tract (in the cervix), as well as in the male 
genital tract, using semen (Quayle et al., 1998, Shacklett et al., 2000).  Recently it was 
demonstrated that a significant decrease in viral load in the semen of SIV-infected 
macaques is possible through vaccine-induced cellular immune responses, which, 
although only measured in blood, may have been present in the genital tract (Whitney 
et al., 2009).  In addition to cellular immune responses, an effective HIV-1 vaccine 
would very likely need to elicit humoral responses at mucosal surfaces, capable of 
combating HIV-1 by means of neutralising antibodies (Shacklett et al., 2009). 
 
Isolation of functional T cells from the genital tract, and especially semen, can be 
challenging, as the genital tract harbours fewer immune cells than blood or other 
mucosal surfaces such as the gastrointestinal tract where an abundance of T cells can 
be found in organised lymphoid tissue (Anderson et al., 1998).  Low numbers of 
immune cells from the genital tract limits the ability to characterise the cells and  
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perform functional assays to detect immune responses, which is an important aspect for 
example of assessing candidate HIV vaccines for further development.  Further 
challenges include the effective treatment of viscous samples and removal of highly 
autofluorescent sperm and germ cells from semen samples.  
 
A need exists for the establishment of standardised methodologies for the isolation and 
characterisation of T cells from the male genital tract. Standardised methods are 
important for provision of consistent and reliable data during clinical trials that are 
likely to be conducted at multiple sites in areas of high HIV prevalence.  The aim of 
this study was to investigate immune cells in semen, as a representative sample of the 
male genital tract. Different factors influencing T cell yields from semen, including the 
optimal storage temperature and time to processing of ejaculates, as well as various 
methods for isolation of T cells from semen, were investigated.  In addition, 
characterisation of the immune composition of semen was performed.  A simple, 
optimised method of leukocyte isolation from semen that maximizes recovery of 
functional T cells while minimising interfering fluorescence from residual sperm and 
germ cells for flow cytometric analysis is described.  This standardised method may be 
applied to clinical trials of candidate HIV vaccines, where it may be important to 
establish whether cellular responses are generated not only in the peripheral blood 
compartment, but also in the genital tract. 
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2.2 Materials and Methods 
 
2.2.1 Participant recruitment and sample collection 
One hundred and ninety nine men of unknown HIV status were recruited from the 
Embryology and Andrology Laboratory at Groote Schuur Hospital, Cape Town.  The 
study was approved by the Faculty of Health Sciences Human Research Ethics 
Committee (HREC REF 045/2007), University of Cape Town, and written informed 
consent was obtained from all volunteers.  Ejaculates were collected in sterile 
specimen jars following voluntary self masturbation.  Days of sexual abstinence prior 
to ejaculation were self-reported.  Sample volume, sperm count, pH and viscosity were 
noted.   
2.2.2 T cell isolation from semen 
At the clinic, semen samples were immediately diluted with 6 ml of transport medium 
[RPMI-1640 medium supplemented with 5 mM L-glutamine, 50 U/ml penicillin, 50 
µg/ml streptomycin (GIBCO Invitrogen, Carlsbad, CA, USA), 2 mg/ml fungin 
(Invivogen, San Diego, CA, USA)].  All samples were processed 2 – 4 h after 
donation, apart from during the time course experiments.  To investigate the impact of 
transport temperature and time to processing on CD3+ T cell yields, samples from 34 
men were incubated at either 4 °C (n=12), room temperature (n=10) or 37 °C (n=12) 
prior to processing.  Samples were divided into three equal volumes and CD3+ T cells 
extracted at 4, 12 and 24 h post ejaculation.  Seminal mononuclear cells (SMCs) were 
isolated using Ficoll-Histopaque (Sigma-Aldrich, Egham, Runnymede, UK) density 
gradient centrifugation.  Alternatively, samples were centrifuged at 1000×g for 10 min 
and seminal supernatant was removed.  The pelleted fraction from semen was then 
digested with 0.4 mg/ml Pronase (Roche, Mannheim, Germany) for 15 min at 37 °C, 
followed by addition of cold PBS (GIBCO, Invitrogen).  Samples were then filtered 
though 40 µM cell strainers (BD Biosciences, Plymouth, UK) and filtrates were 
centrifuged at 380×g for 10 min. Resuspended cell pellets were subjected to either 
CD3+ or CD45+ T cell selection using anti-CD3 or anti-CD45 beads according to the 
manufacturer’s specifications (Miltenyi Biotec Inc, Auburn, CA, USA).  CD3+ cell 
counts were performed on a Guava cell counter using anti-CD3 PE monoclonal 
antibody (Guava Technologies, Hayward, CA, USA).  In order to account for 
interference from autofluorescence as a result from residual sperm cells, an unstained 
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sample was used to measure sample autofluorescence and subtracted to obtain the 
number of CD3+ cells in the sample. 
 
2.2.3 Flow-cytometric analysis of seminal leukocytes 
Functional T cells were assessed intracellularly by applying a monoclonal antibody 
panel: anti-CD3 APC, anti-CD4 FITC, anti-CD8 PerCP-Cy5.5, anti-IFN-γ PE (all BD 
Biosciences, San Diego, CA, USA).  All antibodies were pre-titered to determine 
optimal staining amounts.  To investigate the ability of seminal T cells to produce IFN-
γ, cells were stimulated by the addition of 0.025 µg/ml PMA and 1 µg/ml ionomycin 
(Sigma Aldrich, St. Louis, MO, USA) for 4 h at 37 °C. Brefeldin A (10 µg/ml; Sigma 
Aldrich, St. Louis, MO, USA) was added to both PMA/ionomycin stimulated and 
unstimulated controls.  Surface and intracellular staining of cells was performed for 20 
min at room temperature.  For intracellular staining, cells were permeabilized using 
CytoFix/CytoPerm (BD Biosciences, San Diego, CA, USA).  Cells were fixed in Cell 
Fix (BD Biosciences, San Diego, CA, USA) and samples acquired on a FACSCalibur 
(BD Biosciences, San Jose, CA, USA).  Data were analysed using FlowJo software 
v8.5.3 (Tree Star Inc, Ashland, OR, USA).  To ssess viability of T cells in semen, 
cells were stained with a green reactive amine dye (‘GrVid’, Invitrogen Molecular 
Probes, Eugene, OR, USA) for 20 min at room temperature followed by surface 
staining for 20 min at room temperature with anti-CD3 APC, anti-CD4 PE and anti-
CD8 PerCP-Cy5.5 monoclonal antibodies (all BD Biosciences, San Diego, CA, USA). 
 
Further phenotypic assessment of leukocytes was performed by splitting samples into 
four fractions and applying the following monoclonal antibody panels: 1. anti-CD19 
PerCP-Cy5.5 (B cell marker) and anti-CD24 PE (neutrophil marker); 2. anti-CD16 
PerCP-Cy5.5 and anti-CD56 PE (NK cell markers); 3. anti-CD207 PE (Langerhans cell 
marker) and anti-CD209 PerCP-Cy5.5 (DC-SIGN-expressing cells); 4. anti-CD14 PE 
(monocytes/macrophages) and anti-CD209 PerCP-Cy5.5 (all BD Biosciences, San 
Diego, CA, USA).  All four panels also contained anti-CD3 APC and a seminal 
marker, anti-hAP FITC (human intra-acrosomal protein) to exclude residual sperm 
cells.  Surface and intracellular staining of cells was performed for 20 min at room 
temperature. For intracellular staining of hAP, cells were permeabilized using 
CytoFix/CytoPerm (BD Biosciences).  Cells were fixed in Cell Fix (BD Biosciences) 
and samples acquired on a FACSCalibur (BD Biosciences, San Jose, CA, USA).  Data 
were analysed using FlowJo software v8.5.3 (Tree Star Inc, Ashland, OR, USA). 
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2.2.4 Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 5.0 (GraphPad 
Software, San Diego, CA, USA).  The Mann–Whitney U test was applied for 
independent non-parametric sample comparisons, the Wilcoxon rank test was used for 
matched non-parametric comparisons and Spearman ranks correlation was applied for 
assessing non-parametric associations.  All tests were two-tailed and p-values ≤ 0.05 
were considered significant.   
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2.3 Results 
 
2.3.1 Comparison of methods to isolate T cells from semen 
To optimise T cell recovery from semen samples, CD3+ T cell yields using different 
processing and isolation procedures were investigated (Fig 2.1).  Four methods were 
compared, namely Ficoll-Histopaque gradient separation, pronase digestion, pronase 
digestion followed by cell straining, and pronase digestion followed by cell straining 
and subsequent CD3 magnetic bead isolation.  CD3+ T cell numbers in samples prior to 
any leukocyte isolation or enrichment technique were determined using a Guava cell 
counter and an anti-CD3 PE stain, as described in the Methods.  Purification of 
mononuclear cells using Ficoll-Hypaque density gradient centrifugation resulted in a 
median of 20 600 CD3+ T cells (IQR 13 120 – 79 600), which represented a five-fold 
significant decrease of CD3+ T cells from a median count of 190 000 prior to Ficoll 
isolation (Figure 2.1A).  When semen samples were subjected to proteolytic enzyme 
digestion with pronase to release mononuclear cells from seminal mucus, median 
CD3+ T cell recovery increased significantly from a median of 158 000 (IQR 86 000 – 
212 000) pre-pronase treatment to 302 000 (IQR 123 000 – 394 000) post-pronase 
treatment (Figure 2.1B).  When a cell strainer was used to filter the sample,  median 
CD3+ T cell yields increased significantly from 146 250 (IQR 62 900 – 312 750) to 
196 000 (IQR 178 500 – 491 000; Figure 2.1C). 
 
Since T cells isolated from semen were going to be analysed by flow cytometry, it was 
important to remove residual sperm and germ cells, since these non-immune cells 
autofluoresce during flow cytometry and interfere with detection by target-specific 
antibodies (Hulspas et al.,, 2009).  To address the issue of autofluorescence during 
flow cytometric analysis, positive magnetic bead selection of CD3+ T cells was used.  
First incorporating the steps of pronase digestion and filtration, followed by magnetic 
bead isolation of CD3+ T cells, resulted in a T cell population of 71% purity (IQR 56-
98%; data no shown).  Using bead separation resulted in three-fold lower yield 
compared to pre-bead separation (Figure 2.1D).  Nevertheless, this significantly 
improved CD3+ T cell yield nearly four-fold  to a median of 75 740 (IQR 59 410 – 91 
425) compared to Ficoll isolation alone (p=0.013; Figure 2.1D).  Furthermore, when 
applying anti-CD3 magnetic bead selection, the seminal lymphocyte population 
became clearly distinguishable by flow cytometry (Figure 2.5A). 
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Thus, by combining three methods, namely pronase digestion, the use of cell strainers 
and CD3 magnetic bead isolation (as outlined in Figure 2.2), CD3+ T cell yield was 
improved over using density gradient separation alone.  Furthermore, by using 
magnetic bead selection, the seminal lymphocyte population could be distinguished by 
flow cytometric analysis. 
 
 
 
 
Figure 2.1  Isolation strategies for maximising CD3+ T cell yields from semen.  
Semen samples were subjected to (A) Ficoll-Hypaque gradients (n=15), (B) pronase digestion (n=13) 
and (C) filtration through cell strainers (n=12) and (D) a comparison between Ficoll-Histopaque gradient 
(n=18) and anti-CD3+ magnetic bead separation (n=16).  Box-and-whisker plots indicate the median, 
25th and 75th percentile.  Wilcoxon matched pairs test was performed to compare matched groups and the 
Mann-Whitney U test was applied to compare unmatched groups.  p-values < 0.05 were considered 
significant. 
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Figure 2.2  Schematic representation of seminal CD3+ T cell isolation method.  Samples were processed within 4 h of ejaculation by 
incubation at 37 °C with pronase.  Subsequent filtration though cell strainers was followed by magnetic bead capture of CD3+ T cells. 
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2.3.2 The influence of semen parameters on T cell yield 
A range of characteristics were recorded for each semen sample collected (Table 2.1).  
From the 199 ejaculates collected in this study, ejaculate volumes ranged from 0.8 ml 
to 7.5 ml (median 3 ml, IQR 2-4 ml), and the median time from last ejaculation was 4 
days (IQR 3-5 days).  CD3+ T cell yields were determined after pronase digestion and 
cell straining but prior to semen ejaculates being subjected to magnetic bead isolation.  
CD3+ cell yields were weakly but significantly positively correlated with ejaculate 
volume (p=0.0004, r=0.25; Figure 2.3A).  Furthermore, the number of days of 
abstinence prior to ejaculation had a profound influence on CD3+ T cell yield, with a 
54% higher cell yield in men who had abstained from ejaculation for ≥4 days 
compared to those that had abstained for only 2 days (p=0.043; Figure 2.3B).  
Consistent with this, there was a weak but significant positive correlation between days 
of abstinence and ejaculate volume (p=0.02, r=0.16; data not shown).  Sperm count 
showed a significant association with CD3+ T cell yield (Figure 2.3C; p=0.0002, 
r=0.26), however there was no direct association between sample volume and sperm 
count (Figure 2.3D).  Samples were stratified according to raised versus normal 
viscosity by recording observed mucus in samples.  Raised viscosity in samples 
resulted in a significantly lower CD3+ T cell yield compared to samples with none to 
little (classified as normal) mucus present (p=0.0021; Figure 2.4A).  The pH of 
samples had no significant influence on CD3+ T cells yields (Figure 2.4B). 
  
Thus, CD3+ T cell yields can be improved if participants abstain from ejaculation for at 
least four days.  Sample volume and sperm count may be used as an indicator of CD3+ 
T cell yields. 
 
Table 2.1  Characteristics of semen samples 
Semen parameter (n=199) Median (IQR) 
Sample volume (ml) 3 (2 – 4) 
Days abstinence 4 (3 – 5) 
pH 7.5 (7.2 – 7.5) 
Sperm counta 60 (30 – 84) 
aMillion viable spermatozoa/ml 
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Figure 2.3  The relationship between CD3+ T cell yields and clinical parameters. Shown are (A) a correlation 
between sample volume and CD3+ T cell yields (n=199), (B) comparison between CD3+ T cell yields after 2 days (n=12), 3 days (n=81) 
and longer than 4 days of abstinence (n=104), (C) correlation between sperm count and CD3+ T cell yields (n=199) and (D) correlation 
between sperm count and sample volume (n=199).  Box-and-whisker plots represent the median, 25th and 75th percentiles.  p-values ≤ 
0.05 were considered significant.  Spearman correlations were performed, and the Mann-Whitney U test was applied to compare groups. 
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Figure 2.4  Viscosity and pH of semen samples.  Shown are (A) the differences in CD3+ T 
cell yields between semen samples with observed viscosity (raised) and those without (normal) and (B) 
A comparison of CD3+ T cell yields at different sample pH levels.  Box-and-whisker plots represent the 
median, 25th and 75th percentiles.  p-values ≤ 0.05 were considered significant. 
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2.3.3 Functional capacity and viability of CD4+ and CD8+ T cells isolated from 
semen 
Seminal CD4+ and CD8+ T cells, isolated by CD3+ magnetic bead separation, were 
investigated for their ability to produce IFNγ following stimulation with the mitogen 
PMA/ionomycin, using intracellular cytokine staining and flow cytometry.  
Representative plots are shown in Figure 2.5B and C.  Of the 61 semen samples 
analysed, 35/61 (58%) samples produced IFNγ, while 26/61 (42%) failed to respond to 
PMA/ ionomycin stimulation.  Of the semen samples that responded to 
PMA/ionomycin stimulation, CD4+ T cells produced a median frequency of 8.7% 
IFNγ, whilst CD8+ T cells produced a higher median of 30.4% IFNγ (Table 2.2; Figure 
2.5C). 
 
The viability of T cells isolated from semen was tested in 18 samples using an amine 
reactive fluorescent dye (‘GrVid’) followed by flow cytometric analysis.  As shown in 
Table 2.3, median viabilities for CD4+ T cells were 64% (IQR 47.6-78%), and 71% for 
CD8+ T cells (IQR 45.2-84.9%).    
 
In summary, using the technique described to isolate T cells from semen, viable and 
functional cells able to produce cytokine in response to mitogen were obtained.  The 
low to moderate viability obtained may influence the functional ability of the cells.    
 
Table 2.2  IFNγ production from stimulated CD4+ and CD8+ T cells 
Cell subset IFNγ production
a (IQR) Fold increase over 
background Background PMA/Ionomycin 
CD4 0  (0 – 0.44) 8.66  (3.28 - 20) 8.66 
CD8 0  (0 – 1.02) 30.4  (10 – 48.4) 30.4 
aMedian IFNγ percentage with interquartile range 
 
 
 
 
Table 2.3  Viability of T cell subsets 
Cell subset Percentage viablea (IQR) 
CD4 64.2 (47.6 – 78) 
CD8 71.3 (45.2 – 84.9) 
aMedian of frequencies with interquartile range (IQR) 
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Figure 2.5  The impact of anti-CD3+ isolation on flow cytometric visualisation of T cells and characterization of functional T cells.  Shown are flow 
cytometry plots before and after anti-CD3 magnetic bead capture (A), gating strategy for seminal lymphocytes, CD3+, CD4+ and CD8+ T cells (B) and IFNγ production by 
unstimulated versus PMA/ionomycin-stimulated CD4+ and CD8+ T cells (C). 
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2.3.4 Influence of semen processing time and temperature on T cell yields 
In order to determine whether T cell yields from semen are affected by procedures 
prior to cell isolation, the influence of the time between ejaculation and processing of 
samples, as well as the impact of processing temperature on CD3+ T cell yields, was 
investigated.  Each sample was divided into equal fractions and each fraction was 
either processed at 4, 12 or 24 hours post ejaculation, or at 4 oC, room temperature or 
37 oC for the varying time points.  As before, CD3+ T cell yields were calculated using 
a Guava cell counter.  
 
To investigate the influence of processing time, 34 samples were processed at 4 h, 12 h 
and 24 h post ejaculation (Table 2.4 and Figure 2.6).  Regardless of the processing 
temperature, there was a steady decrease in the CD3+ T cell yield with longer 
processing times.  At a processing time of 4 h post ejaculation, the median CD3+ T cell 
yield was 274 960 (IQR 147 050 – 426 000).  At 12 h post ejaculation, the CD3+ T cell 
yield decreased by approximately 100 000 to 175 500 (IQR 55 470 – 258 650).  By 24 
h post ejaculation, the median CD3+ T cell yield had decreased significantly from the 4 
h processing time to 62 700 (IQR 31 030 – 162 100; p<0.0001).  
  
To investigate storage temperature on CD3+ cell yield, 10 samples were processed after 
incubation at room temperature (RT), while 12 samples each were processed after 
incubation at either 4 °C or at 37 °C (Table 2.4).  When processing the samples within 
4 h of ejaculation, the storage temperature did not affect the median CD3+ yields, and 
the same was true when comparing the 12 h time point for the different storage 
temperatures.  In contrast, for longer storage times (24 h), greater cell loss was 
prevented if the sample was stored at 37 °C, with a median CD3+ T cell yield of 153 
860 (40 050 – 184 550), compared 38 390 (IQR 7905 – 107 850) CD3+ T cells 
remaining at 4 °C.  This represented a 75% loss and was significantly less than the 
CD3+ T cell yield at 37 °C (p=0.046; Figure 2.6).   
 
Thus, it appears that optimal T cell yields from semen require processing within 4 h of 
ejaculation, regardless of the storage temperature investigated here.  When it becomes 
necessary to store samples for longer periods of time before they are processed, storage 
at 37 °C results in a significantly greater yield of CD3+ T cells from semen. 
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Table 2.4  Comparison of CD3+ T cell yields at three different time points and storage temperatures after ejaculation 
Temperature 
Yielda (IQR) 
p valueb 
4 h 12 h 24 h 
4°C (n = 12) 274 960 (145 950 – 424 200) 173 900 (49 950 – 253 450) 38 390 (7905 – 107 850) 0.0005 
RTc  (n = 10) 229 600 (69 055 – 381 850) 142 860 (50 115 – 260 200) 67 300 (43 140 – 144 250) 0.002 
37°C (n = 12) 265 000 (173 310 – 473 500) 180 100 (106 200 – 307 250) 153 860 (40 050 – 184 550) 0.0005 
Total (n = 34) 274 960 (147 050 – 426 000) 175 500 (55 470 – 258 650) 62 700 (31 030 – 162 100) <0.0001 
aMedian CD3+ T cell count with interquartile range (IQR) 
bWilcoxon matched pair analysis between 4 h and 24 h timepoints 
cRT = Room Temperature 
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Figure 2.6  The impact of processing time and temperature on CD3+ T cell yields.  
CD3+ T cell yields were compared after incubation of samples at either 4 °C (n=12), room temperature 
(RT; n=10) or 37 °C (n=12) for either 4 h, 12 h or 24 h post ejaculation.  Bars represent median values.  
p-values < 0.05 were considered significant and the Mann Whitney U test was applied to compare 
groups. 
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2.3.5 Characterisation of immune subsets in semen 
In order to characterise the range of immune subsets in semen beyond T cells, sixteen 
semen samples were processed as described earlier and isolated with CD45-specific 
magnetic beads, followed by staining with phenotypic markers for T cells, B cells, 
monocytes, neutrophils, Langerhans cells, dendritic cells and NK cells (Figure 2.7).   
 
The most prominent immune cells in semen were DC-SIGN+ leukocytes, with a 
median number of 447 931 (IQR 274 758 – 676 459) per semen sample. (Table 2.5 and 
Figure 2.8).  This was followed by neutrophils, with a median number of 42 308 (IQR 
6 038 – 99 824).  Next, B cells were enumerated at a median of 28 878 B cells (IQR 1 
882 – 62 621) per semen sample, and monocytes at a median of 3 558 (IQR 1 110 – 9 
147).  The relative median number of T cells was 18-190 fold less than either 
neutrophils or DC-SIGN+ cells, at 2 393 (IQR 1 275 – 4 758), indicating that these are 
a relatively minor immune cell population in semen, approximately equivalent to the 
number of monocytes, at 3 558 (IQR 1 110 – 9 147).  Langerhans cells made up the 
second smallest subset tested, at a median of 1514 (563 – 4 925) cells per sample. The 
smallest subset was NK cells at a median of 1054 cells per sample, although their 
numbers were highly variable between samples (10 – 8 154).  
 
In summary, DC-SIGN+ leukocytes represent the major immune cell type found in 
semen, and large numbers of neutrophils and B cells are present.  T cells represent a 
relatively minor population in semen. 
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Figure 2.7  Gating strategy for immune cell subsets in semen.  Cells were first gated on (A) spermatozoa-negative 
population (using human acrosomal protein), followed by either (B) lymphocytes and (C) B cells, or (D) CD3-negative population, followed 
by either (E) monocytes, (F) neutrophils, (G) NK cells, (H) DC SIGN+ cells or (I) Langerhans cells. 
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Table 2.5  Immune cell subsets in semen 
Specificity Subset Yielda (IQR) 
NK cells CD56+, CD16+CD56+  1054 (10 – 8 154) 
Langerhans cells Langerin+/CD207+ 1 514 (563 – 4 925) 
T cells CD3+ 2 393 (1 275 – 4 758) 
Monocytes CD14+ 3 558  (1 110 – 9 147) 
B cells CD19+ 28 878 (1 882 – 62 621) 
Neutrophils CD24+ 42 308 (6 038 – 99 824) 
DC SIGN+ cells CD209+ 447 931 (274 758 – 676 459) 
aMedians with interquartile range (IQR) 
 
 
 
 
Figure 2.8  Immune cell subsets in semen. Shown are flow cytometric cell counts for DC 
SIGN+ cells, neutrophils, B cells, monocytes, T cells, Langerhans cells and NK cell subsets in n=16 
semen samples. Box-and-whisker plots represent the median, 25th and 75th percentiles.  p-values ≤ 0.05 
were considered significant. 
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2.4 Discussion 
 
Optimised, standardised protocols for isolating and evaluating viable lymphocytes 
from the male genital tract are needed, in order to improve our understanding of HIV 
pathogenesis, and to assess HIV vaccine responses at the male genital mucosa.  The 
aim of this study was to optimise a method for the isolation of CD3+ T cells from 
semen to maximise functional CD3+ T cell recovery while simultaneously minimising 
interfering fluorescence from residual sperm and germ cells during flow cytometric 
analysis.  Various methodologies were compared to isolate T cells from semen, namely 
gradient separation, enzymatic digestion, sample filtering and magnetic bead isolation.  
It was found that pronase digestion (to dissolve leukocyte-trapping endogenous 
seminal proteins) and the use of cell strainers (to filter resulting debris) resulted in 
improved CD3+ T cell yields compared to gradient separation, whilst selection of CD3+ 
cells using magnetic beads resulted in improving seminal lymphocyte differentiation 
by flow cytometry.  This method allowed for the subsequent functional analysis of 
CD4+ and CD8+ T cells. 
 
To date, no studies have compared methods for optimising leukocyte isolation from 
semen.  Ficoll-Histopaque density gradient centrifugation is commonly used for PBMC 
isolation from peripheral blood.  However, this technique resulted in the loss of up to 
90% of CD3+ T cells.  This finding was consistent with a previous study by Focacci et 
al., who showed that almost 80% of leukocytes were lost subsequent to Ficoll 
separation (Focacci et al., 1997).  Upon ejaculation, semen coagulates form a dense 
network of fibres that can trap sperm and other cells.  The principle proteins 
responsible for semen coagulates are semenogelin I and II (de Lamirande 2007).  In the 
present study, the use of pronase to liberate trapped lymphocytes in semen resulted in 
significantly higher CD3+ T cell yields.  Use of cell strainers subsequent to pronase 
treatment was effective in filtering the digested protein fragments and improving T cell 
yields.  After cell straining, residual sperm and germ cells in samples often obfuscated 
seminal lymphocyte populations during flow cytometry.  Therefore magnetic beads 
were applied to positively select for CD3+ T cells or CD45+ leukocytes. 
 
For robust assessment of immunity, for example in an HIV vaccine trial, isolation of 
functional cells is important.  In response to mitogen stimulation, approximately 60% 
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of semen samples produced IFN-γ, and the frequency of responsive cells was between 
30-35-fold above background.  Although this study did not investigate the presence of 
antigen-specific immunity, the presence of HIV-specific T cells in semen from HIV-
infected men has been shown previously (Quayle et al., 1998, Sheth et al., 2005).  This 
finding, coupled with studies showing that HIV-specific T cells are capable of 
trafficking between blood and mucosal surfaces, including the male genital tract 
(Musey et al., 2003a, Huang et al., 2006), supports the possibility that candidate HIV 
vaccines (even those applied systemically) may be capable of eliciting T cell immunity 
in the male genital tract.  Methods such as that described in this Chapter may be 
applied in clinical trials to assess such responses. 
 
Semen sample volume and increased time of abstinence from ejaculation were found to 
significantly predict CD3+ T cell yield.  Because clinical trial sites may not be 
physically associated with laboratories capable of processing biological specimens, the 
impact of time to processing on yield and viability of lymphocytes from mucosal 
samples such as semen is crucial.  In the present study, a shorter time to processing and 
a sample storage temperature of 37 °C prior to processing were identified to be critical 
for preserving CD3+ T cells in semen.  Although sample processing within 4 h was 
optimal, when samples were stored for a period of 24 h prior to processing, cell loss 
was greatly reduced by incubation at 37 °C, compared to at 4 °C or room temperature.  
A study performed in our laboratory on comparison of incubation of cervical cytobrush 
samples at 4°C, 37 °C or room temperature, found that detection of 
Cytomegalovirus/Epstein Barr virus/Influenza virus (CEF)-specific functional 
responses from T cells were highly significantly increased after 24 h at 37°C compared 
to the other two temperatures (Liebenberg et al., 2011). 
 
A shortcoming of the present study was that the maximum CD3+ T cell yields and 
viability obtained were relatively low, at a median of approximately 250 000 cells after 
isolation, 75 000 following T cell enrichment with magnetic beads, and 2 400 T cells 
per semen sample subsequent to flow cytometric analysis. A previous studies using 
flow cytometry reported similar CD3+ T cell counts (2 862 CD3+ T cells) as the present 
study (Sheth et al., 2005).  Whilst our CD3+ T cell yield obtained was the result of 
optimised procedures in terms of storage time, temperature and isolation method 
tested, it still limits subsequent analysis of immune function to just a few assays with a 
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few stimulations, making detailed functional analysis difficult.  Additional techniques 
for measuring antigen-specific responses other than by flow cytometry, such as the 
IFN-γ ELISPOT assay, could be used prior to the T cell enrichment bead step, as the 
interfering fluorescence would not pose a problem.  To address the low cell numbers, 
future studies could also explore short-term polyclonal expansion methods to increase 
T cell numbers, as performed previously with T cells isolated from genital tract 
samples (Huang et al., 2006, Quayle et al., 1997, Bere et al., 2010a, Bere et al., 
2010b). 
 
A further aim of this study was to characterise the immune milieu of the male genital 
tract by enumerating a range of immune cells subsets in semen.  Previous studies have 
shown the presence of leukocyte populations other than T cells in semen and that the 
most prevalent of these are granulocytes and monocytes/macrophages (Wolff & 
Anderson 1988, Ball et al., 1999, Politch, Mayer & Anderson 2009).  In the present 
study, neutrophils and monocytes made up a substantial portion of the leukocyte 
population assayed.  This is to be expected as neutrophils migrate to sites of recurring 
inflammation (Furze & Rankin 2008) like the mucosal surfaces.  The present study 
shows that B cells are also abundant in semen, whereas previously they have been 
shown in semen at low to non-detectable levels (Ball et al., 1999).  The presence of B 
cells in semen suggests that the male genital tract may have the capacity to produce 
humoral responses to pathogens, and it remains to be seen whether HIV-specific 
antibodies, including neutralising antibodies, are present locally.  The importance of 
Langerhans and DC-SIGN+-DCs have been demonstrated in the transmission of HIV-1 
(reviewed in de Witte et al., 2007).  Although the presence of Langerhans and DC-
SIGN+ cells has not conclusively been shown in semen, they are present in the foreskin 
and the epithelial layer of the urethral meatus of the penis (McCoombe & Short 2006), 
implying that these cells can be deposited in semen.  In the present study, the largest 
population of leukocytes were found to be DC-SIGN+.  In addition to dendritic cells, 
DC-SIGN is expressed on neutrophils and a subset of macrophages.  Regardless, this 
high prevalence of DC-SIGN+ leukocytes in semen has serious implications for 
potential HIV-1 acquisition in the male genital tract.  It may indicate that the 
susceptibility of the male genital tract to HIV is substantially higher than previously 
thought.  NK cells are normally not abundant in tissues of the MGT or semen (Pudney 
& Anderson 1995), and few NK cells were found in the present study. 
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In summary, this Chapter describes an optimised method for the isolation of CD3+ T 
cells from semen that can be used in immune assays to investigate the function of these 
cells in response to stimulation.  The data presented here may be useful in the 
establishment of standardised protocols for testing the ability of candidate vaccines to 
elicit mucosal cellular immunity in the male genital tract, or other studies seeking to 
characterise aspects of immune cells in the male genital tract, as discussed in the 
following Chapter.  
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CHAPTER 3 
 
T-cell activation in the male genital tract 
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3.1 Introduction 
 
Sexual transmission of HIV-1 is the major route of infection and the mucosal surfaces 
of the male and female genital tracts therefore play an important role (Royce et al., 
1997, Simon et al., 2006).  Semen serves as the main vector for HIV transmission from 
men to their partners during sexual transmission, via cell-free or cell associated virus 
(Krieger et al., 1995, Vernazza 2005). 
 
HIV transmission is influenced by the concentration of virus in semen.  When semen 
contains 100 000 HIV-1 RNA copies, the probability of transmission increases to 1 in 
100 acts of intercourse, from 3 in 10 000 acts when semen contains 1000 HIV-1 RNA 
copies (Chakraborty et al., 2001).  The concentration of HIV-1 RNA in semen is 
influenced by the stage of HIV infection.  In fact, it has been sho n that seminal viral 
load peaks at 30 days post infection (Pilcher et al., 2007), which elevates the risk of 
HIV-1 acquisition by a partner to maximum levels during acute infection.  Although it 
has been shown that antiretroviral therapy reduces the concentration of HIV-1 in 
semen (Coombs et al, 2003), differential penetration of antiretroviral drugs into the 
male genital tract (MGT) can result in the establishment of HIV viral reservoirs (Zhang 
et al., 1998; Ghosn et al., 2004b, Smith et al., 2007, Craigo et al., 2004).  Persistent 
viral replication due to local reservoirs of HIV-1 infection can lead to intermittent viral 
shedding in semen of infected men (Krieger et al., 1995; Eyre et al, 2000, Bujan et al., 
2002), which in turn may lead to transmission of HIV-1. 
 
Other factors may enhance HIV-1 transmission to a partner by elevating levels of viral 
replication in the MGT and subsequent viral shedding in semen.  Primary among these 
are sexually transmitted infections (STIs), such as HSV-2 and gonorrhoea.  
Gonococcal infection elevates seminal viral loads (Sadiq et al., 2005b, Taylor et al., 
2003), while HIV genital shedding has been shown to associate with HSV-2 replication 
(Baeten et al., 2004, Mole et al., 1997, Schacker et al., 2002a, Serwadda et al., 2003).  
Apart from enhancement of infection with higher viral shedding, increased risk of 
infection may also take place by other means.  A seminal study by Munch et al., found 
that amyloid fibrils present in semen may form complexes called SEVI (semen-derived 
enhancer of virus infection) that may trap HIV-1 virions and potentially enhance 
transmission (Munch et al., 2007).  The availability of infectable target cells within the 
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MGT can influence HIV acquisition via the penile route.  The foreskin provides ideal 
target cells for enhanced acquisition of HIV-1 in the MGT (Ganor et al., 2010).  
Circumcision has been shown in a number of randomized trials to have a protective 
benefit against HIV infection (Auvert et al., 2005, Bailey et al., 2007, Gray et al., 
2007).  In addition, target cells in other parts of the MGT may facilitate transmission 
and spread of HIV subsequent to viral entry. 
 
Immune activation is one of the main contributors to the pathogenesis of HIV disease. 
This is manifested in various ways, from increased T cell proliferation to increased 
expression of surface activation markers such as HLA-DR and CD38 (Ho et al., 1993, 
Kestens et al., 1994).  Elevated CD38 expression in the context of HIV-1 infection was 
first described on CD8+ T cells (Giorgi & Detels 1989).  Since then, numerous studies 
in blood have shown that CD8+CD38+ can be used to predict the rate of HIV disease 
progression independent of plasma viral load and CD4+ T cell counts (Giorgi et al., 
1993, Liu et al., 1997, Bofill et al., 1996).  CD38 expressing CD4+ T cells have also 
been shown to be elevated in HIV-infection (Carbone et al., 2000, Hunt et al., 2003).  
Two-thirds of gut mucosal CD4+ T cells express CD38 during acute and early HIV-1 
infection (Mehandru et al., 2007) and in semen of HIV-infected men, frequencies of 
CD8+CD38+ memory T cells were significantly higher compared to healthy men (Lo 
Caputo et al., 2003).  The chemokine receptor CCR5 is the major co-receptor for HIV-
1 (Alkhatib et al., 1996, Zhu et al., 1993, Roos et al., 1992), and thus the availability of 
CCR5+ T cells in the genital tract has specific importance for acquisition of HIV-1 
through sexual contact.  The levels of CCR5+ T cells in the genital tract of healthy 
women are substantially higher compared to blood (Hladik et al., 1999), as would be 
predicted for an effector site such as the genital tract, where CD4+ CCR5+ cells have 
been found in the foreskin and other epithelial layers of the penis (McCoombe & Short 
2006). 
 
Thus the genital tract of healthy sexually active adults seems to be the ideal target for 
HIV-1 acquisition and transmission, with elevated levels of CCR5-expressing CD4+ T 
cells.  In fact, not only are CCR5 levels elevated, a recent study found both CD4+ and 
CD8+ T cells expressing either the activation marker CD69 alone or together with 
CCR5, were significantly increased in the genital tract of HIV-uninfected Kenyan 
women (Cohen et al., 2010) compared to genital activation levels in their counterparts 
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in the United States.  The authors postulate that despite controlling for confounders 
such as genital co-infections, sexual behaviour and menstrual phase, it may be that 
genital immune activation is the result of differences in host genetics or systemic 
infections.  Higher levels of systemic immune activation have also been reported in 
HIV-seronegative Africans (Kassu et al., 2001, Clerici et al., 2000, Eggena et al., 
2005).  Investigating the status and impact of immune activation in the male genital 
tract of healthy and HIV-infected African men is an important unaddressed issue. 
 
The aim of this chapter was to investigate T cell activation in the male genital tract, to 
understand more about the role it may play in both acquisition of HIV infection in 
uninfected men, and onward transmission of HIV in those already infected. T cell 
activation was examined in semen using the marker CD38, and CCR5 expression was 
used to identify CD4+ target cells. T cells from HIV-infected, HIV-uninfected and 
ARV-treated men were examined, and genital tract activation levels were compared to 
those in blood.  The impact of seminal and plasma viral loads on T cell activation was 
examined.  Lastly, since a portion of participants formed part of an HIV-discordant 
couples cohort, T cell activation was examined in the semen and blood of HIV exposed 
but sero-negative men.	
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3.2 Materials and Methods 
 
3.2.1 Study participants 
Twenty-six ARV naïve and 12 ARV-treated HIV-infected men, along with 42 HIV-
uninfected men were enrolled from the Empilisweni Clinic in Athlone, Cape Town, 
South Africa.  All men gave written informed consent, and the Research Ethics 
Committee of the University of Cape Town approved all aspects of the study (HREC 
REF: 258/2006).  Seventy-one of the 80 participants were part of 602 couples that were 
enrolled in a study investigating Human Papillomavirus (HPV) infection in HIV-
discordant and concordant couples. Of the 38 HIV-infected men enrolled in the present 
study, 20 belonged to HIV-concordant couples and 16 were part of HIV-discordant 
couples.  There were 14 HIV-uninfected men with HIV-uninfected partners and 21 
HIV-uninfected men had HIV-infected partners.  For 9 men, the HIV-status of the 
partner was unknown. 
 
CD4 counts were performed by FlowCARE PLG kits (Beckman Coulter, Inc., Brea, 
CA) according to the manufacturer’s protocol.  CD4 counts were available for 21 of 
the 38 HIV-infected men within 2 months of sampling.  For the HIV-infected men, the 
time of infection was not known.  For ARV-treated men, neither the time on treatment 
nor the antiretroviral regimen was known.  
 
3.2.2 Sample collection and processing 
Ejaculates were collected in sterile specimen jars containing 6 ml of transport media 
[RPMI-1640 medium supplemented with 5 mM L-glutamine, 50 U/ml penicillin, 50 
µg/ml streptomycin (GIBCO®, Invitrogen™, Carlsbad, CA, USA), 2 mg/ml fungin® 
(Invivogen, San Diego, CA, USA)] following voluntary self masturbation.  Semen 
samples were processed by optimal methods as established and described in Chapter 2 
(Section 2.2.2).  Whole blood was collected in ACD Vacutainer tubes (BD 
Biosciences, Plymouth, UK) by venipuncture.  Peripheral blood mononuclear cells 
(PBMCs) were isolated from whole blood by density gradient centrifugation using 
Ficoll-Histopaque (Sigma-Aldrich, Egham, Runnymede, UK) and LeucoSep centrifuge 
tubes (Greiner Bio-one; Frickenhausen, Germany).  Briefly, whole blood was layered 
on Ficoll and subsequent to 15 min of centrifugation at 1000 x g, the resulting plasma 
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and buffy layers containing PBMCs were harvested.  Blood and seminal plasma was 
stored at -80°C for viral load determination as well as cytokine measurements (Chapter 
4).  CD3+ cell counts were performed on a Guava cell counter using anti-CD3 PE 
monoclonal antibody (Guava Technologies, Hayward, CA, USA).  
3.2.3 Flow-cytometric analysis 
Both seminal mononuclear cells (SMCs) and PBMCs (2 million cells/sample) were 
split into two fractions and stained with the following two monoclonal antibody panels: 
1. anti-CD3 PE, anti-CD4 FITC, anti-CD8 PerCP-Cy5.5 and anti-CCR5 APC or 2. 
anti-CD3 PE, anti-CD4 FITC, anti-CD8 PerCP-Cy5.5 and anti-CD38 APC (all BD 
Biosciences, San Diego, CA, USA).  All antibodies were pre-titered to determine 
optimal staining dilutions.  Surface staining of cells was performed for 20 min at room 
temperature.  Cells were fixed in Cell Fix (BD Biosciences, San Jose, CA, USA) and 
samples acquired on a FACSCalibur.  All events were collected for semen, whereas 
500 000 events were collected for stained PBMC.  Data were analysed using FlowJo 
software v8.5.3 (Tree Star Inc, Ashland, OR, USA).  The gating strategy used to detect 
CD8+ and CD4+ T cells expressing CD38 and CCR5 started by applying a lymphocyte 
gate based on forward and side scatter, CD3+ T cells were then gated on, followed by 
CD4+ and CD8+ gates.  Each T cell subset was then examined for expression of CD38 
or CCR5, depending on the panel used to stain with.  To set gates for CD38 and CCR5, 
fluorescence minus one (FMO) controls were used.  Subsequent to analysis, samples 
with CD38+ and CCR5+ event counts of 10 or less were excluded from the study. 
3.2.4 Quantification of HIV RNA in semen and blood 
Plasma and seminal HIV-1 RNA concentrations (copies/ml) were quantified using 
NucliSENS EasyQ® HIV-1 (version 2.0) [bioMérieux SA, Lyon, France] according to 
the manufacturer’s protocol.  The assay had a lower limit of detection of 70 copies of 
HIV-1 RNA/ml and a linear range of detection up to 10 x 106 copies of HIV-1 
RNA/ml.  For semen viral loads, values were adjusted according to the dilution factor 
according to the transport medium and the volume of the semen sample, and expressed 
as RNA copies/ml of semen. 
3.2.5 Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 5.0® (GraphPad 
Software, San Diego, CA, USA).  The Mann–Whitney U test was applied for 
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independent non-parametric sample comparisons, the Wilcoxon rank test was used for 
matched non-parametric comparisons and Spearman ranks correlation was applied for 
assessing non-parametric associations.  Kruskal-Wallis test with Dunn’s post test was 
used for non-parametric sample comparisons of three unmatched groups or more.  All 
tests were two-tailed and p-values ≤ 0.05 were considered significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
71 
 
3.3 Results  
 
3.3.1 Clinical characteristics of study participants 
Forty-two HIV-uninfected men and 38 HIV-infected men were recruited into this study 
(Table 3.1).  Twelve of the HIV-infected men were receiving anti-retroviral treatment.  
The median age of the men was 42 years (range 23 – 58), and this did not differ 
significantly between the groups.  Only 22 out of the 38 HIV-infected men had recent 
CD4 counts available.  The median absolute CD4 count for ARV-naïve men was 356 
cells/mm3 (IQR 257 – 650 cells/mm3).  Although the median CD4 counts were lower in 
ARV-treated men, at 264 cells/mm3, this was not significant (IQR 208 – 585 
cells/mm3). 
 
The majority of men were enrolled from a larger study, and specific STI data were not 
available for the group of men studied in this chapter.  However, within the larger 
cohort from which they were recruited, 23% of male participants reported having 
penile discharge and 11% reported the occurrence of genital ulcers within 6 months of 
enrolment.  HPV prevalence among men in the larger cohort was found to be 58% 
(49% in HIV-uninfected and 77% in HIV-infected men) [Mbulawa et al., 2010].  At 
enrolment, male participants reported that they were with their partners for an average 
of 6 years and were having an average of 8 sex acts per month.  Sixty-four percent of 
men reported using condoms with their partners and 93% of men were circumcised. 
 
3.3.2 T cell yields and ratios in semen of HIV-infected and uninfected men 
A recent study (Politch et al, 2009) provided immunohistological evidence that CD4+ 
T cells are depleted in semen, implying that CD4+ T cell depletion described in 
mucosal sites such as the gastrointestinal tract may also be occuring in the male genital 
tract.  Here, flow cytometry was used to enumerate CD4+ and CD8+ T cells in blood 
and semen of all participants.  The median CD3+ T cell yields were lower in the semen 
of HIV-infected and ARV-treated compared to HIV-uninfected men, although this was 
not significant.  Median CD4+ T cell yields in semen were higher in HIV-uninfected 
compared to infected men and significantly so compared to ARV-treated men 
(p=0.039; Table 3.2).  In contrast, median CD8+ T cell yields were higher in the semen 
of HIV-infected and ARV-treated men compared to HIV-uninfected men.  CD4/CD8 
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ratios were significantly lower in HIV-infected and ARV-treated than uninfected men 
(p=0.0011; Table 3.2). 
 
3.3.3 Viral loads in semen and plasma 
Viral loads were measured in matched plasma and seminal fluid of HIV-infected 
participants (Table 3.1 and Figure 3.1).  Among the 26 untreated HIV-infected men, 25 
had a detectable plasma viral load, whilst 19 had a detectable seminal viral load.  ARV 
treatment successfully suppressed viral replication in both semen and blood to below 
detectable levels in the majority (10/12) men (Figure 3.1).  Interestingly, two out of 12 
ARV-treated men had detectable plasma viral load despite suppression of seminal virus 
replication, and a further two men had detectable virus in semen, despite plasma viral 
suppression.  In one of these cases, the viral load was amongst the highest measured in 
semen, at 60 200 copies/ml.   
 
As shown in Figure 3.2A, the median plasma viral load in HIV-infected men was 
11000 RNA copies/ml (IQR undetectable – 300 000 RNA copies/ml), which was 
significantly higher than the median seminal viral load, at 1389 RNA copies/ml (IQR 
undetectable – 135 000 RNA copies/ml; p=0.039).  A weak but significant positive 
correlation was found between viral loads in semen and blood (p=0.04, r=0.4; Figure 
3.2B). 
 
The relationship between CD4 counts in blood and seminal viral loads was 
investigated in untreated HIV-infected men. Although CD4 counts were available for 
just 13 men, there was a strong and highly significant inverse correlation between 
blood CD4 counts and seminal viral loads (p=0.0046, r=-0.75; Figure 3.3A).  In blood, 
no such association was evident (data not shown).  As shown in Figure 3.3B, the 
median seminal log viral load of 3.3 (IQR 2.4 – 4.0) for men with CD4 cell count > 
350/mm3 was lower than the median of 4.4 (IQR 3.4 – 5.4) for men with CD4 cell 
count ≤ 350.  The median log plasma viral load of 1.8 (IQR 1.8 – 2.7) for men with 
CD4 cell count > 350/mm3 was significantly lower than the median of 4.3 (IQR 2.8 – 
4.5) for men with CD4 cell count ≤ 350 (p=0.011; Figure 3.3B).   
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Table 3.1  Clinical characteristics of participants 
Characteristic HIV+ ARV-naïve HIV+ ARV-treated HIV-uninfected 
N 26 12 42 
Age [years; median (IQR)] 39 (34-44) 43 (39-46) 44 (37-51) 
CD4 count [cells/mm3; median (IQR)] 356 (257-650)a 264 (208-585)b - 
Plasma viral load [RNA copies/ml; median (IQR)] 10200 (2250-40000) LDLc - 
Number of men with detectable HIV RNA in plasma [N/Total (%)] 25/26 (96.2%) 2/12 (16.6%) - 
Genital tract viral load [RNA copies/ml; median (IQR)] 1389 (LDLc-20060) LDLc - 
Number of men with detectable HIV RNA in semen [N/Total (%)] 19/26 (73.1%) 2/12 (16.6%) - 
aN = 13; CD4 counts were not available for the remainder of the participants  
 bN = 9    
cLDL = lower than the detection level (70 HIV-1 RNA copies/ml) 
dTwo participants had plasma viral loads of 740 and 880 copies/ml; a different two participants had seminal viral loads of  414 and 60200 copies/ml 
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 Figure 3.1  Matched viral loads in plasma and semen of HIV-infected men.  Plasma viral 
loads (red) and seminal viral loads (blue) in HIV-infected ARV-naïve and ARV-treated men.  Bars 
represent the matched viral loads (log scale) in both compartments.  The dotted lines represent the lower 
limit of detection of the assay (70 HIV-1 RNA copies/ml). 
 
 
Table 3.2  T cell counts and CD4:CD8 ratios in semen  
 
 
T cell subset 
Yieldsa (IQR) p 
valueb HIV+ ARV-naïve  (n=26) 
HIV+ ARV-treated  
(n=12) 
HIV-uninfected  
(n=42) 
CD3 
 
12190 (3825–29929) 
 
10567 (5563–21391) 
 
14069 (7489–43443) 
 
ns 
 
CD4 
 
250 (69–1285) 
 
91 (53–365) 
 
330 (284–1120) 
 
0.039 
 
CD8 
 
1201 (333–7997) 
 
1146 (389–2129) 
 
799 (284–3050) 
 
ns 
 
CD4:CD8 ratio 
 
0.18 (0.12– 0.5) 
 
0.13 (0.05–0.43) 
 
0.71 (0.2–1.27) 
 
0.0011 
 
aMedian of yields with interquartile range (IQR), semen samples adjusted for dilution factor 
bKruskal-Wallis with Dunn’s post test 
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Figure 3.2  The association of viral loads in blood and semen of HIV-infected men.  (A) 
Data points represent plasma viral load (filled circles) and seminal viral load (unfilled circles) from 26 
HIV-infected untreated men.  Bars represent medians and the dotted line indicates the lower limit of 
detection of the assay (70 HIV-1 RNA copies/ml).  The Wilcoxon signed rank test was used to test for a 
significant difference between the groups. (B) Each data point represents the viral load of each 
participant in blood and semen.  Statistical analysis was performed using the Spearman Rank Test and p-
values ≤ 0.05 were considered significant.  Spearman r-value is shown on the plot. 
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Figure 3.3  The association between viral loads and CD4 counts.  (A) Each data point 
represents the matched seminal viral load and plasma CD4 count of 13 of the ARV-naïve men.  
Statistical analysis was performed using the Spearman Rank Test and p-values ≤ 0.05 were considered 
significant.  Spearman r-value is shown on the plot.  (B)  Bar-and-whisker plots represent the median 
viral load in blood (filled bars) and semen (unfilled bars) separated into CD4 counts > 350 and CD4 
counts ≤ 350.  The Mann-Whitney U test was performed and p-values ≤ 0.05 were considered 
significant. 
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It was of interest to determine whether there were any differences in seminal viral 
loads in those men in a relationship with a partner who was HIV-infected (concordant) 
or uninfected (discordant).  Within the group of 26 HIV-infected, untreated men that 
formed part of this study, 15 men were in concordant and 9 men were in discordant 
relationships. In the case of two men, the HIV-status of their partners was unknown, 
and they were thus excluded from this analysis.  As shown in Figure 3.4, there were no 
significant differences between plasma or semen viral loads in HIV concordant and 
discordant men. 
 
In summary, these results show that there were a positive correlation between viral 
loads in blood and semen, with median viral loads approximately one log higher in 
plasma compared to semen of HIV-infected, untreated men.  ARVs successfully 
suppressed viral replication in the genital tract of 10/12 men, and two viral shedders 
(17%) were identified, despite suppressed plasma viral replication.  Seminal viral load 
increased with decreasing blood absolute CD4 counts.  Finally, there was no 
significant difference in seminal or plasma viral load between men in HIV-concordant 
relationships or those in HIV-discordant relationships. 
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Figure 3.4  Viral loads in blood and semen of HIV-infected men in HIV-concordant and 
discordant relationships.  (A) Plasma viral loads and (B) seminal viral loads of HIV-concordant 
(unfilled circles) and HIV-discordant (filled circles) men.  The Mann-Whitney U test was performed and 
p-values < 0.05 were considered significant. 
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3.3.4 Frequencies of activated T cells are higher in semen than blood 
Four colour flow cytometry was used to determine the proportions of CCR5 and CD38 
expressing-CD4+ and CD8+ T cells in blood and semen of HIV-infected and uninfected 
men, as a measure of immune activation and to enumerate potential target cells for 
HIV-infection.  The gating strategy and representative flow plots are shown in Figure 
3.5.  Overall, the frequencies of activated T cells in semen were higher than those in 
blood (Figure 3.6).  In HIV-uninfected men (Figure 3.6A), there were significantly 
more CD8+ T cells expressing CCR5 (p<0.0001) and CD38 (p<0.0001) in semen 
compared to blood.  CD4+ T cells expressing CCR5 was also significantly increased in 
semen compared to blood (p<0.0001).  In HIV-infected men the same pattern was 
maintained (Figure 3.6B).  Both CCR5- (p=0.0001) and CD38-expressing CD8+ T 
cells (p=0.0002) were significantly higher in semen than in blood, with only CCR5-
expressing CD4+ T cells reflecting the same significant increases in semen (p=0.0003).  
In ARV-treated men (Figure 3.6C), the number of CD8+ T cells expressing CCR5 
(p=0.002) and CD38 (p=0.0029) were significantly higher in semen than in blood. 
 
These results indicate that semen contains greater numbers of activated CD4 and CD8 
T cells, and CD4+CCR5+-expressing T cells than blood, regardless of HIV infection or 
treatment. 
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Figure 3.5  Gating scheme used for enumeration of activated T cells in blood and semen.  Cells were first gated 
on lymphocytes, then CD3+ T cells, followed by CD4+/CD8+ gating.  Next CD4+ and CD8+ T cells expressing either CCR5 or 
CD38 were gated on. 
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Figure 3.6  Activated T cells in blood and semen I.  A comparison is shown between the frequencies of activated T cells in blood and semen of 
(A) HIV-uninfected, (B) HIV-infected and (C) ARV-treated men.  In (D) a comparison of the frequency of CCR5+ T cells between HIV-unexposed and 
HIV-exposed sero-negative men in blood and semen is shown.  Each box-and-whisker plot indicates the median, IQR and 5-95% range (error bars). * 
indicates p<0.05, ** indicates p<0.01 and *** indicates p<0.0001, using the Wilcoxon signed rank test (A – C) and Mann-Whitney U test (D). 
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3.3.5 Frequencies of activated T cells in HIV-infected and uninfected men 
To further characterise cellular activation, a comparison of frequencies of activated T 
cell subsets were performed between the three patient groups in this study: HIV-
uninfected, HIV-infected (ARV-naïve) and HIV-infected (ARV-treated) men.  The 
results are shown in Figure 3.7. 
 
With the exception of the CD4+CCR5+ T cell subset, the frequencies of activation of 
all other immune subsets in both blood and semen were highest in HIV-infected (ARV-
naïve) men, followed by HIV-infected (ARV-treated) men, and the lowest in HIV-
uninfected men (Figure 3.7A and B).  In blood, CD4+CD38+ T cell frequencies were 
significantly higher in HIV-infected (ARV-naïve) men than frequencies in HIV-
uninfected men (p=0.0003). In the blood of HIV-infected (ARV-naïve) men, both 
CCR5-expressing) and CD38-expressing CD8+ T cell frequencies were significantly 
higher than frequencies in HIV-uninfected men (p=0.033 and p<0.0001, respectively).  
In semen, CD8+CD38+ T cell frequencies in HIV-infected (ARV-naïve) men were 
significantly higher than frequencies in HIV-uninfected men (p=0.006).  In blood, 
median frequencies of CD4+CCR5+ T cells, the target cells for HIV infection, were 
higher (though not significantly so) in HIV-uninfected compared to HIV-infected 
(ARV-naïve) men, whereas in ARV-treated men they were the lowest.  Interestingly, 
the opposite was found in semen.  A median of 19% more CD4+CCR5+ T cells were 
found in HIV-infected (ARV-naïve) men compared to both ARV-treated and HIV-
uninfected men.  Furthermore, the frequencies of CD4+CCR5+ T cells in semen of 
ARV-treated men were comparable to those of HIV-uninfected men. 
 
To investigate the possible influence of HIV-infected partners on expression 
frequencies of CCR5 and CD38 on T cells in HIV-uninfected men, frequencies of 
immune subsets were compared between blood and semen in HIV-uninfected, exposed 
(n=21) and HIV-uninfected, unexposed men (n=21).  In semen, although not 
significant, there was a consistent decrease in CCR5 expression on both CD4+ and 
CD8+ T cells in HIV-exposed compared to HIV-unexposed men.  In blood, there were 
no differences between the expression frequencies of CCR5 in either CD4+ or CD8+ T 
cells (Figure 3.6D).  There were no significant differences observed in frequencies of 
CD38 expressing T cells in both semen and blood of the groups compared. 
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Thus, when comparing HIV-uninfected, HIV-infected (ARV-treated) and HIV-infected 
(ARV-naïve) men, the highest frequencies of immune activation in semen were found 
in untreated HIV-infected men, and this was mirrored in blood.  Frequencies of the 
target cells for HIV infection, CD4+CCR5+ T cells, were depleted from the blood of 
HIV-infected men; however, they were found in higher frequencies in the semen of 
these men, possibly indicating a greater influx of these cells due to factors such as 
inflammation or viral replication (or both), than destruction.  Finally, although ARV-
treatment effectively reduced T cell activation, it was not restored to levels found in the 
semen of HIV-uninfected men. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
84 
 
 
 
Figure 3.7  Activated T cells in blood and semen II.  Frequencies of activated T cells in (A) blood 
and (B) semen of HIV-uninfected, HIV-infected (ARV+) and HIV-infected (ARV-). Each box-and-
whisker plot indicates the median, IQR and 5-95% range (error bars). * indicates p<0.05, ** indicates 
p<0.01 and *** indicates p<0.0001, using the Kruskal-Wallis test with Dunn’s post test for the 
comparison of three or more unmatched groups. 
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3.3.6 The relationship between T cell activation in blood and semen 
To investigate whether there was a relationship between activation in blood and semen, 
correlations between activated immune subsets in HIV-uninfected, HIV-infected 
(ARV-naïve) and HIV-infected (ARV-treated) participants were compared for the two 
compartments.  As was to be expected, there was no correlation of CD8+CD38+ 
frequencies between blood and semen of HIV-uninfected men (Figure 3.8A). In 
contrast, there was a significant positive correlation between CD8+ CD38+ T cells 
between blood and semen of HIV-infected men (p=0.0077, r=0.44; Figure 3.8B).  This 
association held true even when the ARV-treated subset was removed from the 
analysis.  There were no significant associations of activated CD4+ T cells between 
compartments, likely due to their deletion as target cells for HIV. 
 
Next the relationship between CD4+ and CD8+ T cell activation, in blood and semen 
was examined. In blood, strong and significant associations between the frequencies of 
CD4+CD38+ and CD8+CD38+ T cells were found in HIV-uninfected (p=0.0003; 
r=0.53; Figure 3.9A), HIV-infected (ARV-treated) [p=0.0053; r=0.75; Figure 3.9B] 
and HIV-infected (ARV-naïve) men (p=0.0002; r=0.66; Figure 3.9C).  As observed 
previously, a striking difference between HIV-infected and uninfected men was that 
the majority of HIV-infected men, expressed CD38 on both immune subsets at a 
frequency of > 30%, compared to less than a third of HIV-uninfected men.  The strong 
positive association seen for CD38 expression in the two immune subsets in uninfected 
men was mirrored for CCR5 (Figure 3.9D), as well as HIV-infected (ARV-treated) 
men (Figure 3E).  This relationship was predictably disrupted in the case of HIV-
infected men (ARV-naïve), with the deletion of CD4+CCR5+ cells (Figure 3.9F).  In 
semen, CD38 expression followed the same general pattern as in blood.  Both HIV-
uninfected and infected men showed significant positive associations between the 
frequencies of CD4+CD38+ and CD8+CD38+ T cells (p<0.0001, r=0.68 and p=0.0089, 
r=0.53, respectively; Figure 3.10 A and C).  HIV-infected (ARV-treated) men followed 
a similar trend, however too few data points make this analysis unreliable (Figure 3.10 
B and E).  A strong and significant positive correlation between CD4+CCR5+ and 
CD8+CCR5+ T cells in semen was maintained in healthy men, similar to results from 
blood (p<0.0001, r=0.73; Figure 3.10D).  However, in contrast to results from blood, 
HIV-infected men also had a strong positive correlation between CD4+CCR5+ and 
CD8+CCR5+ T cells in semen (p=0.0026, r=0.68, Figure 3.10F). 
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These results show that the frequencies of activated CD8+ T cells correlate between 
semen and blood in HIV-infected men but not uninfected men. In agreement with 
blood, the frequencies of activated CD4+ T cells correlated with frequencies of 
activated CD8+ T cells in semen of both HIV-uninfected and infected men.  Somewhat 
surprisingly, contrary to what was found in blood, the frequencies of CCR5 expression 
in semen also correlated strongly between CD4 and CD8 T cell subsets in HIV-
infected men, once again indicating an additional driver of the influx of these cells into 
the genital tract.  
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Figure 3.8  Association of activated CD8+ T cells between blood and semen.  Shown are correlations of 
CD8+CD38+ T cells between compartments in (A) HIV-uninfected [blue circles] and (B) HIV-infected, ARV naïve [red 
circles] + HIV-infected, ARV-treated [green circles] men.  Each circle represents a matched CD8+ T cell frequency of a 
participant in blood and semen.  The Spearman rank test was used for statistical analysis and p-values ≤ 0.05 were considered 
significant.  
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Figure 3.9  Association of activated CD4+ T cells with activated CD8+ T cells in blood.  Shown are correlations of (A – C) CD4+CD38+ with CD8+CD38+ T 
cells and (D – F) CD4+CCR5+ with CD8+CCR5+ T cells of HIV-uninfected [blue circles], HIV-infected (ARV-treated) [green circles] and HIV-infected, ARV-naïve [red 
circles] men.  Each circle represents a matched CD4+ with CD8+ T cell frequency of a participant in blood.  Dashed lines indicate 30% frequency.  The Spearman rank test 
was used for statistical analysis and p-values ≤ 0.05 were considered significant.  
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Figure 3.10  Association of activated CD4+ T cells with activated CD8+ T cells in semen.  Shown are correlations of (A – C) CD4+CD38+ with CD8+CD38+ T 
cells and (D – F) CD4+CCR5+ with CD8+CCR5+ T cells of HIV-uninfected [blue circles], HIV-infected (ARV-treated) [green circles] and HIV-infected, ARV-naïve [red 
circles] men.  Each circle represents a matched CD4+ with CD8+ T cell frequency of a participant in semen.  Dashed lines indicate 30% frequency. The Spearman rank test 
was used for statistical analysis and p-values ≤ 0.05 were considered significant. 
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3.3.7 No association between semen viral load and T cell activation 
To investigate the relationship between viral loads and T cell activation, activated T 
cell subsets were correlated with viral loads in both blood and semen.  There were no 
significant correlations between activated CD4+ or CD8+ T cell subsets or CCR5-
expressing cells and seminal and plasma viral loads in either compartment examined 
(data not shown).   
 
To investigate the influence of viral loads on frequencies of activated T cells further, 
the viral loads of all HIV-infected men were divided into 3 groups, namely LDL (lower 
than the detection level), VL < 104 (viral load lower than 10 000 HIV-1 RNA 
copies/ml) and VL > 104 (viral load higher than 10 000 HIV-1 RNA copies/ml) [Figure 
3.11].  In blood, a significant elevation in the frequency of activated CD4+ T cells in 
men with viral loads > 10000 HIV-1 RNA copies/ml compared with men with viral 
loads < 10000 HIV-1 RNA copies/ml was found.  No such a difference, however, was 
seen in semen.  In fact, regardless of the concentration of viral load, neither the 
frequency of CD4+ or CD8+ T cells expressing CD38 differed significantly from each 
other.  In blood, a significant decrease in the median frequency of HIV-1 target cells, 
CD4+CCR5+ expression was found in men with viral loads > 104 HIV-1 RNA 
copies/ml compared with men with viral loads < 104 HIV-1 RNA copies/ml (p=0.032; 
Figure 3.11A).  In semen, the frequency of CCR5 expression did not follow the same 
pattern as was evident in blood.  In fact, frequencies of T cells expressing CCR5 were 
notably higher, regardless of the level of viral load, in comparison to frequencies in 
blood. 
 
In summary, although no significant associations were found between levels of 
activated T cells and viral loads in either compartment, elevated levels of activated 
CD4+ T cells in blood were found to be associated with viral loads higher than 10 000 
HIV-1 RNA copies/ml.  Conversely, a decrease in the frequency of CCR5 expressing 
CD4+ T cells were found to be associated with viral loads higher than 10 000 HIV-1 
RNA copies/ml.  Interestingly, no differences in activated cells were found in semen at 
different viral loads, likely indicating an influx of activated cells not linked to the level 
of virus. 
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Figure 3.11  Influence of high viral loads on activated T cells in blood and semen.  Graphs 
depict comparisons between men with plasma (A – D) and seminal (E – H) viral loads that are LDL 
(lower than detectable level), VL < 104 (viral load < 10 000 HIV-1 RNA copies/ml), VL > 104 (viral 
load > 10 000 HIV-1 RNA copies/ml) and (A & E) CD4+CD38+, (B & F) CD8+CD38+, (C & G) 
CD4+CCR5+, (D & H) CD8+CCR5+ T cells.  Wilcoxon signed rank tests were performed and p-values ≤ 
0.05 were considered significant. 
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3.3.8 T cell activation in exposed sero-negative (ESN) men 
Within the group of HIV-uninfected men that were included in this study, 21/42 
formed part of an established heterosexual discordant couples cohort.  To investigate 
the influence of HIV exposure on T cell activation in exposed sero-negative (ESN) 
men, the frequencies of activated T cells in blood and semen of HIV-unexposed and 
ESN men were compared (Figure 3.12).  There were no significant differences in either 
CCR5 or CD38 expression on CD4+ or CD8+ T cells in blood or semen between the 
two groups (Figure 3.12).  In semen, although not significant, there were lower median 
frequencies of CCR5+ CD4+ and CD8+ T cells in ESN men (Figure 3.12 C and D).   
 
To investigate the impact of viral loads in HIV-infected partners on the frequencies of 
activated T cells of ESN men, plasma viral loads of HIV-infected partners were 
correlated with activated T cell subsets in blood and semen (Figure 3.13).  In blood, 
there was a significant positive correlation between the plasma viral load of the 
infected partner and CCR5-expressing CD8+ T cells (p=0.028, r=063; Figure 3.13B).  
A weak significant inverse correlation was observed when comparing frequencies of 
CD38-expressing CD4+ T cells with plasma viral loads of the infected partners 
(p=0.041, r=-0.59; Figure 3.13C).  There were no significant correlations between 
plasma viral loads of the infected partners and CD4+CCR5+ and CD8+CD38+ T cells 
(Figure 3.13A & D).  When the same analysis was performed in semen, no significant 
correlations were evident (data not shown). 
 
Thus, in semen there was a trend toward lower frequencies of CCR5 expressing CD4+ 
and CD8+ T cells in ESN men.  Furthermore, in ESN men there was no relationship 
between plasma viral loads of the infected partners and activated T cells in semen.  
However, in the blood of ESN men, higher frequencies of CCR5-expressing CD8+ T 
cells were related to higher viral replication in the plasma of the infected partner. 
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Figure 3.12  T cell activation in blood and semen of HIV-uninfected and exposed sero-
negative men.  Shown are comparisons of frequencies of (A) CD4+CD38+, (B) CD8+CD38+, (C) 
CD4+CCR5+, (D) CD8+CCR5+ T cells in blood and semen of HIV-unexposed (HIV-; unfilled bar) and 
exposed sero-negative (ESN) men (filled bars).  Box-and-whisker plots show the median, IQR and 5-95% 
range (error bars). Mann-Whitney U tests were performed to detect significant differences between 
groups.   
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Figure 3.13  Impact of viral load on exposed sero-negative (ESN) men.  Shown are correlations 
between plasma viral load of the infected partner and frequencies of (A) CD4+CCR5+, (B) CD8+CCR5+, (C) 
CD4+CD38+, (D) CD8+CD38+ T cells.  Each circle represents a plasma viral load of the infected partner 
with the concomitant frequency of the relevant activated T cells in the ESN men.  Spearman test was used 
and p-values < 0.05 were considered significant.  Spearman Rho score is shown on each plot. 
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3.4 Discussion 
 
HIV infection weakens and ultimately destroys the immune system by CD4 T cell 
depletion, and hyperactivation of the immune system contributes to this, in part by 
providing a steady supply of target cells for the virus to infect.  In this study, immune 
activation and HIV replication were investigated in the male genital tract, using semen, 
and compared between HIV-uninfected and infected men, including a subset on ARV 
therapy.  The major findings were as follows:  (i) HIV replication was detected in the 
genital tract of the majority of HIV-infected (ARV-naïve) men studied. Although viral 
loads in semen were substantially lower than in plasma, there was a positive 
correlation between viral loads in the two compartments. ARVs successfully 
suppressed viral replication in the male genital tract in the majority of men on 
treatment; (ii) There was substantially greater immune activation in semen compared to 
blood, with semen containing greater numbers of activated CD4 and CD8 T cells, and 
CD4 CCR5-expressing T cells, regardless of HIV infection or treatment; (iii) The 
highest levels of immune activation in semen were found in HIV-infected (ARV-naïve) 
men, and this was mirrored in blood. Notably, although ARV-treatment reduced the 
numbers of activated T cells in semen, frequencies were not restored to those observed 
in HIV-uninfected men; (iv) Although frequencies of activated CD8+ T cells correlated 
between compartments in HIV-infected men, there were no associations between 
immune activation and viral loads; (v) Finally, HIV-uninfected men in partnerships 
with HIV-infected women had elevated frequencies of CD8+CCR5+ T cells in their 
blood, but no differences were seen in the genital tract. 
 
HIV was detected in the genital tract of 73% of infected (ARV-naïve) men in this 
study.  A significant positive association was found between viral loads in blood 
plasma and semen. Previously, a number of studies have confirmed a correlation 
between viral load in blood and semen (Coombs et al., 1998, Vernazza et al., 1997, 
Bourlet et al., 2001, Sheth et al., 2004).  These findings imply that there is movement 
of virus between blood and the genital tract.  It has been shown that the male genital 
tract is a source for distinct seminal viral populations from blood (Smith et al., 2007, 
Pillai et al., 2005, Diem et al., 2008), and a recent study by Anderson and colleagues 
suggested that these distinct viral populations are possibly supplemented by direct 
import of both infected CD4+ T cells as well as virus from blood (Anderson et al., 
2010).  It was also found that semen of HIV-infected (ARV-naïve) men contained 
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approximately 10-fold lower levels of detectable virus compared to plasma viral loads.  
This confirms the findings of a number of studies showing that HIV is less 
concentrated in semen than in blood plasma, with differences often exceeding 1 log 
(Dyer et al., 1998, Pilcher et al., 2007, Vernazza et al., 1997, Stekler et al., 2008). 
   
While successful suppression of HIV in semen was evident in the majority of men on 
ARV treatment, HIV replication was found in 2/12 men. Both of these individuals had 
successful viral suppression in blood, and one individual’s seminal viral load was 
60200 copies/ml, third highest among HIV-infected men.  Studies have shown that 
despite ARV-treatment, genital HIV shedding is evident in the genital tract of both 
men and women (Kaul et al., 2008, Sheth et al., 2009, Marcelin et al., 2008).  There 
are several factors that may contribute to suboptimal viral suppression in the genital 
tract.  These include drug potencies, absorption, drug penetration (Kashuba et al., 
1999, Eron et al., 2000) and non-adherence to drug regimens.  Effective drug 
penetrance into the genital compartment has largely been found to be dependent on the 
ARV regimen used.  In the female genital tract, studies have shown that nucleoside 
reverse transcriptase inhibitors (NRTIs) penetrate more efficiently than either non-
nucleoside reverse transcriptase inhibitors (nNRTIs) or protease inhibitors (PIs)[Kwara 
et al., 2008, Dumond et al., 2007].  In semen, the ineffective penetrance of certain 
nNRTIs, such as efavirenz (Taylor et al., 2001), highlights the necessity for drugs to 
achieve therapeutic concentrations within the male genital tract where they may 
potentially control local viral replication and thus subsequent transmission.  In South 
Africa, the recommended first-line treatment consists of the NRTIs lamivudine and 
stavudine in combination with the nNRTIs efavirenz or nevirapine (Fairall et al., 
2008).  If the two men that were shedding virus in semen were on first-line treatment 
that included efavirenz, it may explain the persistence of viral replication in the genital 
tracts of these men. 
 
In this study, higher levels of seminal HIV were significantly associated with lower 
plasma CD4 counts.  Although not significant, higher plasma HIV levels were 
associated with lower plasma CD4 counts as well.  Similar results were found by 
Pilcher et al., (Pilcher et al., 2007).  Recent studies have shown that ARVs are able to 
restore depleted CD4+ T cells in the semen of ARV-treated men as well as at the cervix 
of ARV-treated women (Politch et al, 2009, Mkhize et al., 2010).  In the present study, 
the number of CD4+ T cells in the semen of ARV-treated men was more than two-fold 
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lower than untreated men.  Since the time on ARV treatment was not known, the 
reason for poor CD4+ T cell recovery in semen remains speculative.  Poor recovery 
could have been due to insufficient duration on ARV-treatment.  This seems likely, 
since the median blood CD4 counts of the ARV-treated men at sampling (264 
cells/mm3) had not improved substantially over enrolment (212 cells/mm3).  The 
number of CD8+ T cells was 1.5-fold higher in HIV-infected men compared to 
uninfected men.  This may be due to an influx of CD8+ T cells or depletion of CD4+ T 
cells or a combination of both in the HIV-infected male genital tract.  This was not 
related to local levels of viral replication.  This observation was also made recently in 
the HIV-infected female genital tract (Nkwanyana et al., 2009). 
 
Previous studies have shown that HIV-infected individuals have significantly elevated 
levels of CD38 expression on both CD4+ and CD8+ T cells in blood (Hunt et al., 2003, 
Eggena et al., 2005, Benito et al., 2004, Almeida et al., 2007, Restrepo et al., 2010) 
and in the genital tract of HIV-infected women (Biasin et al., 2000).  CD4+ T cells 
expressing CCR5 are the main targets for HIV infection (Brenchley et al., 2004, 
Mehandru et al., 2004, Guadalupe et al., 2003).  Immune activation exacerbates the 
depletion of target cells in HIV infection by promoting surface expression of CCR5 
(Wu et al., 1997, Bleul et al., 1997).  Since the genital tract is an effector site, higher 
levels of CCR5-expressing T cells are to be expected, and CCR5-expressing cells have 
been shown to be present in high numbers in the genital tract of female SIV-infected 
macaques (Veazey et al, 2003) and in the genital mucosa of women (Hladik et al., 
1999).  Indeed, higher levels of CCR5+ CD4+ and CD8+ T cells in the genital tract of 
both HIV-infected and uninfected men were found, compared to numbers of these cells 
in blood.  There were also significantly higher frequencies of CD8+CD38+ T cells in 
the semen of HIV-infected compared to uninfected men.  CD38 up-regulation on CD8+ 
T cells was previously reported in the semen of HIV-infected men (Lo Caputo et al., 
2003).  Furthermore, frequencies of this subset of activated T cells were found to be 
correlated between blood and semen of HIV-infected men, suggesting that systemic 
immune activation may be used to predict levels in the genital tract.  Interestingly, 
whilst frequencies of activated CD8+ T cells in semen were significantly elevated in 
HIV-infection, frequencies of these cells, as well as CCR5-expressing CD4+ T and 
CD8+ T cells, were also significantly higher in the semen of HIV-uninfected men 
compared to blood. This implies a high degree of genital tract immune activation in 
HIV-uninfected men.  Men in this study were not screened at the time of sampling for 
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STIs other than HIV, and the possibility of concurrent sub-clinical STIs elevating 
activation levels in the genital tract may be quite likely.  This could lead to activation 
of resident genital T cells, as well as the recruitment of systemic T cells. 
 
In individuals on ARV treatment, a rapid reduction in T cell activation in blood has 
been demonstrated (Giorgi et al., 1998).  However, T cell activation may persist in a 
proportion of individuals at levels higher than in healthy individuals despite years of 
ARV treatment (Hunt et al., 2003).  In the present study, although the ARV-treated 
subset was small, a reduction in activation levels to those of uninfected individuals was 
not achieved in either semen or blood, supporting previous findings that ARV 
treatment does not necessarily reduce levels of T cell activation to baseline levels.  Yet, 
in the semen of the majority of men, ARV-treatment effectively suppressed viral 
replication.  Furthermore, in the present study, there were no associations found 
between seminal viral load and either activated T cells or CCR5-expressing T cells.  
Although several studies showed distinct associations between immune activation and 
viral loads (Eggena et al., 2005, Chun et al., 2004), these studies were conducted in 
plasma only.  Therefore, if viral replication does not necessarily drive immune 
activation in the male genital tract, what are the possible factors involved?  Hunt and 
colleagues speculated that elevated immune activation despite suppressive ARV 
treatment may be due to ongoing antigenic stimulation from either low-level HIV 
replication, the presence of other infections or due to persistence of immune damage, 
such as gut damage leading to microbial translocation and immune activation (Hunt et 
al., 2003).  Although that study was performed in blood, the same findings may be 
relevant to the present study.  In the semen of HIV-infected men, recurring STIs are 
even more likely to contribute or even drive immune activation, thereby masking the 
effects of local HIV replication, resulting in no discernable associations between 
immune activation and seminal viral loads.  Since the male genital tract is a mucosal 
site, lack of any correlations with seminal viral loads may be because of high 
‘background noise’ levels of CD38+ T cells and CCR5 expression due to effector site 
homing, obscuring any direct relationship with viral load. 
 
Recent findings from our laboratory have demonstrated a significant increase in plasma 
and cervical viral loads in HIV-concordant (HIV-infected couple) women when 
compared to HIV-discordant (HIV-uninfected partner) women was found (Jaumdally 
et al., unpublished data).  The present study showed that there were no significant 
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differences in viral loads between HIV-concordant and HIV-discordant men in either 
blood or semen.  In the HIV-uninfected group of men, half of them were in HIV-
discordant relationships, and were termed HIV-exposed seronegative (ESN) 
individuals.  Whilst the majority of studies on ESN have focused on blood, one study 
demonstrated that frequencies of activated CD8+ T cells in the semen of ESN men 
were significantly elevated above levels in the semen of healthy men (Lo Caputo et al., 
2003).  Frequencies of CCR5 expression in the genital tract of ESN women were 
significantly enhanced above levels of activated CD8+ T cells compared to healthy 
controls (Biasin et al., 2000).  A previous study also found significant correlations 
between activated CD4+ and CD8+ T cells in blood of ESN men and plasma viral loads 
in HIV-infected female partners were shown (Suy et al., 2007).  In the present study, 
no significant differences in seminal activation levels between ESN and unexposed 
men were found.  The presence of HIV-specific CD8+ T cells in ESN men has also 
been reported, and may be indicative of HIV exposure as a result of an unproductive 
infection leading to systemic specific immunity (Lo Caputo et al., 2003).  Although 
HIV-specific T cells were not enumerated in the present study, it was found that 
numbers of CCR5-expressing CD8+ T cells in the blood of ESN men were significantly 
positively correlated with viral loads of their infected female partners, implying that 
there may be some level of exposure affecting up-regulation of CCR5 expression on T 
cells in blood.  This finding is interesting and deserves further study in a larger, well-
characterised cohort.  A limitation of our study was that data on high risk exposures 
within discordant couples were not available for the men included in the study.  At 
baseline, in the cohort as a whole, 64% of men reported using condoms with their 
regular partners, however, no data was available on the frequency of this condom 
usage.  
 
This study had several limitations.  At the time of semen donation, no STI screening 
was performed on the participants.  The presence of undiagnosed STIs could have an 
enormous impact on immune activation and CCR5 expression on T cells in the genital 
tract, and indeed, high T cell activation in the semen of HIV-uninfected men provides 
evidence for this.  In the HIV-infected men, the time of infection was also unknown.  
This is important if levels of seminal viral loads are to be compared with other studies.  
Furthermore, within the ARV-treated subgroup, the duration of treatment was not 
known.  This study was a cross-sectional one, and longitudinal data would be ideal to 
assess the effects of ARV treatment on seminal levels of immune activation.  Also, 
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only in two of the ARV-treated men were ARV regimens known.  To properly assess 
the risk of HIV transmission from the male genital tract, the ARV regimen in seminal 
viral shedders would be useful to know.  On the technical front, only a single activation 
marker (CD38) and CCR5 expression was assayed, since this study was limited to 
performing four-colour flow cytometry.  Incorporation of additional markers such as 
Ki67 and HLA-DR may be useful in further characterising immune activation, using 
polychromatic flow cytometry.  In addition, despite applying an optimised method, the 
limited numbers of T cells obtained from semen could lead to possible inaccuracies in 
assessing CD38 and CCR5 frequencies expressed on T cells; the minimum event 
number cut-off established for this study led to the exclusion of up to 40% of the 
samples from analysis, depending on the subset and marker studied.  
 
In summary, this study identified a high degree of immune activation in semen, 
regardless of HIV infection.  CCR5-expressing CD4+ targets were abundant in HIV-
uninfected men, which have implications for HIV acquisition.  In addition, 3/4 of the 
HIV-infected untreated men in the cohort were shedding virus, which has implications 
for transmission.  No direct relationship between T cell activation in the genital tract of 
HIV-infected men and viral replication was observed.  This finding, together with the 
high degree of T cell activation in the semen of HIV-uninfected men implies that there 
may be ongoing inflammation due to other causes resulting in immune activation, 
which is investigated in the following chapter.  
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CHAPTER 4 
 
Characterisation of the cytokine and chemokine milieu in 
semen of HIV-infected and uninfected men 
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4.1 Introduction 
 
Cells of the innate and adaptive immune response, as well as other non-hematopoeitic 
cells, secrete cytokines and chemokines in response to infection (Hofmann et al., 
2002).  Cytokines mediate a host of immune functions, while chemokines are chiefly 
responsible for trafficking and recruitment of leukocytes to sites of inflammation 
(Glass et al, 2003).  Unsurprisingly, several studies have described differing levels of 
cytokines and chemokines in plasma of HIV-infected individuals compared to those 
uninfected.  Elevated plasma levels of pro-inflammatory cytokines such as TNFα, IL-
1β, IL-6 and IL-8 (Clouse et al., 1991; Herbein et al., 1995, Herbein et al., 1994, 
Karsten et al., 1996, Olivetta et al., 2003) as well as chemokines such as MIP-1α, MIP-
1β and RANTES have been demonstrated in HIV-infected individuals (Olivetta et al., 
2003, Canque et al., 1996, Muthumani et al., 2000, Cremer, Vieillard & De Maeyer 
2000, Kim et al., 1999).  Stacey and colleagues (Stacey et al., 2009) recently described 
a plasma cytokine ‘storm’ in acute HIV infection, which was strikingly more intense 
compared with that induced by HCV or HBV infection.  Early elevated levels of MCP-
1, TNFα, IL-8, IL-6, IL-18 and IFNγ described in this study may detrimentally affect 
disease outcome in HIV infection.  In a comprehensive study examining 30 cytokines, 
our group (Roberts et al., 2010) identified a range of plasma cytokines during acute 
HIV infection that were associated with higher viral set points or greater CD4 loss, 
namely IL-7, IL-15, IL-1α and eotaxin. 
 
In the genital tract of vaginally SIV-infected macaques, pro-inflammatory cytokines 
were induced early on in infection, positively correlating with viral replication likely 
due to the recruitment of target cells (Abel et al., 2005).  In the genital tract of women, 
previous studies have associated HIV infection with increased inflammation at the 
cervix (Gumbi et al., 2008, Belec et al., 1995, Thea et al., 1996, Zara et al., 2004).  
HIV-infected women had upregulated IL-6, IL-10, IL-12, IFNγ and TNFα in the cervix 
as well as in plasma (Biasin et al., 2000).  In addition, IL-1β, IL-8 and RANTES were 
elevated (Iqbal et al., 2005, Nkwanyana et al., 2009), while MIP-1α levels were 
significantly lower at the cervix of HIV-infected compared to uninfected women (Iqbal 
et al., 2005).  During acute HIV infection, our group found elevated levels of IL-6, IL-
8 and IL-12 in the female genital tract (Bebell et al., 2008).  Interestingly, this study  
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 103
suggested that greater mucosal inflammation resulted in higher CD4 loss. Whilst 
different studies have measured different cytokines using a range of technologies with 
differing sensitivities, it does appear from multiple studies that HIV induces higher 
levels of pro-inflammatory cytokines in the female genital tract. 
  
Fewer studies have comprehensively characterised the immune milieu of the male 
genital tract in the context of HIV infection.  In healthy, fertile men, examination of 23 
cytokines and other mediators of inflammation in semen indicated a broad array of 
cytokines, with TGFβ, IL-7, SDF-1α, MCP-1 and IL-8 present at high concentrations 
(Politch et al., 2007).  Using a comprehensive approach similar to what this chapter 
will describe, semen levels of IL-1β, IL-4, IL-6, IL-7, IL-8, GM-CSF and MCP-1 were 
all shown to be up-regulated in HIV-infection (Anderson et al., 2010).  A few studies 
have shown positive associations between seminal viral load and increased levels of 
IL-1β and RANTES (Storey et al., 1999, Berlier et al., 2006a).  These results imply 
that elevated levels of pro-inflammatory mediators in the male genital tract during HIV 
infection may be as a result of local viral replication, which in turn exacerbate the 
activation of potential target cells. 
 
This study describes a comprehensive investigation of the cytokines and chemokines 
present in the semen of HIV-infected and uninfected men, using multiplex technology.  
Cytokine/chemokine levels were compared to those in blood in order to identify 
differences between compartments. The influence of ARV treatment on 
cytokine/chemokine levels was also investigated.  Since many immune regulators act 
in networks, how HIV infection might influence or disrupt the relationships between 
cytokines was examined.  Using data described in Chapter 3, the relationship between 
levels of cytokines and chemokines and viral loads as well as cellular activation was 
assessed.  The relationship between viral replication, T cell activation and genital tract 
inflammation is discussed, as well as the implications of these findings for HIV 
transmission and acquisition. 
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4.2 Materials and Methods 
 
4.2.1 Study participants and sample collection 
The cohort of study participants used to generate the data in this chapter is the same as 
that described in Chapter 3.  Briefly, this consisted of 26 ARV-naïve and 12 ARV-
treated HIV-infected men, along with 28 HIV-uninfected men, from the Empilisweni 
Clinic in Athlone, Cape Town, South Africa.  Ejaculates were collected in sterile 
specimen jars following voluntary self masturbation, and blood was collected in ACD 
Vacutainer tubes.  After sample processing, seminal fluid and and blood plasma were 
stored at -80°C. 
 
4.2.2 Measurement of cytokines and chemokines 
Twenty-one cytokines and chemokines were measured in seminal and blood plasma 
from HIV-uninfected and HIV-infected men using High Sensitivity Human and 
Human Cytokine Milliplex® MAP kits (Millipore Corporation, St. Charles, Missouri, 
USA).  The following analytes were measured with the High Sensitivity Human 
Cytokine kit: Interleukin (IL)-1β, IL-2, IL-6, IL-7, IL-12p70, Granulocyte-macrophage 
(GM)-CSF, interferon (IFN)-γ and tumor necrosis factor (TNF)-α.  The sensitivity of 
this kit ranged between 0.05 and 0.46 pg/ml for each of the cytokines measured (Table 
S1).  The following analytes were measured with the Human Cytokine kit:  IL-1α, IL-
8, IL-12p40, IL-15, Eotaxin, Fractalkine, Granulocyte colony stimulating factor (G-
CSF), Monocyte chemotactic protein (MCP)-1, Macrophage inflammatory protein 
(MIP)-1α, MIP-1β and RANTES.  The sensitivity of this kit ranged between 0.2 and 
10.5 pg/ml for each of the cytokines measured (Table S1).  Samples were thawed and 
filtered by centrifugation using 0.2 μm cellulose acetate filters (Sigma, USA) prior to 
cytokine/chemokine measurements.  For each kit, two plates were used, with all 
seminal plasma samples (undiluted) assayed on a single plate, and matching blood 
plasma samples on a separate plate.  To monitor variation between plates, quality 
controls, included with each kit, were used.  To control for backgrounds, assay buffer 
alone was used and values subtracted from all readings.  Each assay was performed on 
separate days, while all quality controls and background values were within acceptable 
ranges.  Data were collected using a Bio-Plex Suspension Array Reader (Bio-Rad 
Laboratories Inc., Hercules, California, USA) in the laboratory of Prof Gerhard Walzl, 
University of Stellenbosch.  A 5 PL regression formula was used to calculate sample 
concentrations from the standard curves. Data was analysed using BIO-plex manager 
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software (version 4).  Cytokine concentrations below the lower limits of detection were 
reported as the midpoint between the lowest concentration and zero for each cytokine 
measured, as described previously (Bebell et al., 2008).  IL-1α was undetectable in 
blood plasma samples and was subsequently excluded from any comparative analysis 
between semen and blood. 
 
4.2.3 Statistical analysis 
Statistical analyses were performed using GraphPad Prism version 5 (GraphPad 
Software, San Diego, CA, USA) and STATATM version 10 (StataCorp, Texas, USA).  
Mann Whitney U test was used for unmatched comparisons.  Wilcoxon Signed Rank 
test was used to compare cytokine levels in men matched semen and blood.  Non-
parametric Spearman correlation was used for correlations.  Linear regression was used 
to evaluate the relationships between cytokine levels and viral load in blood and 
semen, and activated T cell subsets.  Multivariate regression was used to adjust for the 
use of ARVs and viral loads.  P-values ≤ 0.05 were considered significant.  For 
comparisons of frequencies of cytokines/chemokines between blood and semen, 
semen:blood ratios, HIV-uninfected, ARV naïve nd ARV-treated men, as well as all 
correlations of cytokines/chemokines between each other within each compartment, P-
values were adjusted using the False Discovery Rate (FDR) step-down procedure in 
order to reduce false positive results when multiple comparisons were made (Columb 
& Sagadai 2006). 
 
Principal component analysis (PCA) was used to determine whether all the variables 
(in this case the cytokines and chemokines) in three groups (categorized according to 
whether there was a detectable viral load or not) clustered in these groups.  It is a 
useful tool for reducing the number of observed variables to a smaller dataset that 
account for most of the variance in the larger dataset.  Hierarchical cluster heat maps 
were used to visualise the concentrations of the cytokines and chemokines within 
groups.  The analyte concentration level is generally indicated by red for high 
expression and green for low expression.  Relationships between analytes are 
represented by a tree whose branch lengths reflect the degree of similarity between 
them, as is assessed by a pairwise similarity function.  In supervised clustering, 
analytes are classified with respect to known reference vectors, whereas in 
unsupervised clustering, no predefined reference vectors are used (Eisen et al., 1998).  
In the present study, unsupervised clustering was performed. 
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4.3 Results 
 
4.3.1 Detection of cytokines and chemokines in semen and blood 
Twenty pro-inflammatory, regulatory and adaptive cytokines and chemokines were 
measured in paired blood and semen samples in 28 HIV-uninfected and 38 HIV-
infected men, of whom 12 of the latter were on ARV treatment.  Descriptive statistics 
are provided for cytokines and chemokines assayed in seminal plasma (Table 4.1) and 
blood plasma (Table 4.2), and the frequencies of detection and concentrations of the 20 
analytes are represented graphically in Figure 4.1A and B.  Of the 20 cytokines and 
chemokines investigated in the study, 14 were classified as pro-inflammatory (IL-1β, 
IL-6, Il-8, IL-12p40, IL-12p70, TNFα, Eotaxin, Fractalkine, G-CSF, GM-CSF, MCP-
1, MIP-1α, MIP-1β and RANTES).  IL-10 was classified as regulatory, whereas IFNγ, 
IL-2, IL-7 and IL-15 were classified as adaptive cytokines based on their function.  
Overall, for the set of cytokines and chemokines tested, concentrations were higher in 
semen than in blood for the majority of cytokines (15/20).  Analytes were also more 
frequently detected in semen compared to blood (96% vs 81% detectable 
observations).  On the whole, and somewhat surprisingly, median concentrations of 
cytokines and chemokines were generally comparable in semen between HIV-infected 
and uninfected groups, and the same was true for blood (Fig 4.1C and D).  This 
indicates a homogeneity within compartments that is relatively conserved, regardless 
of HIV infection. 
 
In seminal plasma, all 20 cytokines and chemokines assayed were detectable in 46% of 
samples, whereas 10 out of 20 cytokines were detectable in 93% of samples (Table 
4.1).  Six analytes were detected in all samples, namely MCP-1, RANTES, Fractalkine, 
G-CSF, IL-15 and TNF-. MCP-1 was present in the highest concentrations in the 
seminal plasma of all groups, at a median of 14 110 pg/ml in HIV-uninfected men, 
9805 pg/ml in HIV-infected men, and 17 720 pg/ml in HIV-infected ARV-treated men 
(Table 4.1 and Figure 4.1C).  In addition, one cytokine and three chemokines were 
detected in high concentrations in all three groups:  IL-8 (median 1141 pg/ml), 
Fractalkine (median 802 pg/ml), RANTES (median 370 pg/ml) and IL-7 (median 715 
pg/ml).  IL-1α, IL-6, Eotaxin, MIP-1β, G-CSF, IL-10 and IL-15 were detected in all 
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Table 4.1  Descriptive statistics of cytokines and chemokines in seminal plasma of HIV-uninfected, HIV-infected and ARV-treated men. 
Cytokines/chemokines HIV-uninfecteda HIV-infected, ARV-naïveb ARV-treatedc 
Pro-inflammatory % 
Positive Median (IQR) 
% 
Positive Median (IQR) 
% 
Positive Median (IQR) 
IL-1α 92 16.3 (5.5 – 32.9) 100 17.2 (5.3 – 79.3) 100 17.4 (6.5 – 82) 
IL-1β 86 0.25 (0.08 – 0.4) 81 0.17 (0.05 – 0.69) 75 0.32 (0.044 – 1) 
IL-6 96 32.5 (6.8 – 118.3) 100 22 (8.7 – 122) 92 33.4 (7.3 – 147.2) 
IL-8 95 1 486 (241 – 2 771) 100 1 110 (643 – 2 115) 100 1 141 (540.5 – 2 947) 
IL-12p40 7 2.8 (1.3 – 3.5) 19 1.9 (1.4 – 3.5) 50 3.1 (1.78 – 9.85) 
IL-12p70 43 0.05 (0.03 – 1.9) 35 0.036 (0.02 – 0.99) 58 1.2 (0.036 – 2.57) 
TNF-α 100 1.82 (0.79 – 4.5) 100 1.2 (0.57 – 3.95) 100 1.88 (0.27 – 5.9) 
Eotaxin 62 23 (4.4 – 38.9) 85 16.3 (8.6 – 37.9) 92 28.2 (23.3 – 41.3) 
Fractalkine 100 802.9 (333 – 1 636) 100 655.8 (251 – 1 489) 100 875.6 (250 – 1 019) 
MCP-1 100 14 110 (3 908 – 31 028) 100 9 805 (3 211 – 18 029) 100 17 720 (7 486 – 27 430) 
MIP-1α 22 3.15 (1.3 – 4.9) 54 7.5 (2.3 – 36) 75 15.7 (5.5 – 86.4) 
MIP-1β 90 78.1 (31.9 – 112.2) 100 53 (35.4 – 171.6) 100 83.4 (30.2 – 195.8) 
RANTES 100 370.9 (189.2 – 649.3) 100 266.5 (98.6 – 818.3) 100 419.5 (178.6 – 1 239) 
G-CSF 100 29.5 (12.2 – 60.5) 100 21.2 (7.5 – 84.3) 100 20 (12.9 – 58.1) 
GM-CSF 93 2.4 (0.65 – 7.35) 100 2.9 (1.6 – 6.2) 92 5.05 (2.1 – 14.7) 
Regulatory       
IL-10 86 27.1 (7.1 – 52.4) 77 10.9 (2.02 – 17.5) 67 7.7 (0.8 – 24.5) 
Adaptive       
IFN-γ 89 6.3 (2.7 – 21.9) 96 5.6 (1.9 – 10.2) 92 9.8 (0.78 – 40.5) 
IL-2 57 0.4 (0.03 – 2.56) 58 0.2 (0.026 – 1.22) 58 1.6 (0.022 – 3.52) 
IL-7 96 786.4 (395.9 – 1 930) 100 715.8 (347 – 1 865) 100 524.4 (414 – 2 011) 
IL-15 100 27.8 (8.8 – 45.4) 100 27.6 (10.1 – 64.8) 100 30.7 (27.6 – 39.5) 
aN = 28;  bN = 26;  cN = 12 
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Table 4.2  Descriptive statistics of cytokines and chemokines in blood plasma of HIV-uninfected, HIV-infected and ARV-treated men. 
Cytokines/chemokines HIV-uninfecteda HIV-infected, ARV-naïveb ARV-treatedc 
Pro-inflammatory % 
Positive Median (IQR) 
% 
Positive Median (IQR) 
% 
Positive Median (IQR) 
IL-1β 86 0.15 (0.04 – 0.33) 100 0.26 (0.012 – 0.59) 92 0.09 (0.012 – 0.35) 
IL-6 100 6.5 (4 – 12.3) 100 6.6 (4 – 14.1) 100 5.5 (3.2 – 9.2) 
IL-8 80 2.3 (0.27 – 4.7) 92 2.5 (1.07 – 3.7) 67 2.8 (0.04 – 9.2) 
IL-12p40 50 5.4 (0.47 – 44.7) 38 0.47 (0.47 – 46.1) 42 0.47 (0.47 – 3.07) 
IL-12p70 29 0.01 (0.01 – 0.17) 38 0.01 (0.01 – 1.16) 17 0.01 (0.01 – 0.01) 
TNF-α 100 5.9 (4.6 – 7) 100 10.1 (7.02 – 12.5) 100 7.6 (6.4 – 9.8) 
Eotaxin 100 89.1 (37.8 – 182.8) 100 89.2 (59 – 195.1) 100 49.8 (44.2 – 68.3) 
Fractalkine 75 42.6 (11.1 – 102.3) 81 42.6 (18.8 – 82.4) 42 0.59 (0.59 – 42.6) 
MCP-1 100 216.7 (174.1 – 301.1) 100 221.3 (168.4 – 364.7) 100 220.3 (155.2 – 303.8) 
MIP-1α 40 1.95 (1.95 – 9.52) 35 1.95 (1.95 – 7.24) 25 1.95 (1.95 – 5.9) 
MIP-1β 68 8.7 (1.5 – 12.7) 69 3.01 (1.5 – 12.7) 50 5.1 (1.5 – 16.1) 
RANTES 100 2 809 (1 997 – 3 156) 100 2 663 (2 080 – 3 207) 100 2 637 (2 483 – 3 332) 
G-CSF 100 25.8 (15.5 – 47.8) 100 40.02 (24.6 – 53.2) 100 23.3 (15.5 – 30.7) 
GM-CSF 43 0.01 (0.01 – 0.86) 62 0.26 (0.01 – 0.69) 50 0.02 (0.01 – 0.69) 
Regulatory       
IL-10 100 1.26 (0.88 – 2.02) 100 2.02 (1.26 – 2.8) 100 1.07 (0.88 – 1.5) 
Adaptive       
IFN-γ 82 0.86 (0.37 – 2.9) 85 2.4 (0.86 – 7.8) 83 1.21 (0.37 – 1.33) 
IL-2 54 0.1 (0.01 – 0.98) 81 0.47 (0.05 – 1.39) 50 0.08 (0.01 – 0.86) 
IL-7 86 3.12 (1.27 – 7.44) 100 3.13 (1.5 – 5.26) 100 1.91 (0.54 – 4.9) 
IL-15 50 0.37 (0.25 – 1.25) 42 0.25 (0.25 – 1.25) 17 0.25 (0.25 – 0.25) 
aN = 28;  bN = 26;  cN = 12 
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three groups assayed at concentrations < 100 pg/ml.  IL-12p40, TNFα, GM-CSF, MIP-
1α and IFNγ were present at < 10 pg/ml, whereas IL-1β, IL-12p70 and IL-2 were 
present in concentrations < 1 pg/ml in all three groups assayed. 
 
In blood plasma, all 20 cytokines and chemokines assayed were detectable in 41% of 
samples, whereas half the analytes were detectable in 81% of samples (Table 4.2).  
RANTES was present in the highest concentrations in the plasma of HIV-uninfected, 
infected and ARV-treated men (median of 2 809, 2 663 and 2 637 pg/ml, respectively; 
Figure 4.1D).  MCP-1 was detected in moderately high concentrations in all three 
groups (median 220 pg/ml), although this represented a 5-fold lower concentration 
than in semen.  Eotaxin, Fractalkine, and G-CSF were detected in all three groups at 
concentrations < 100 pg/ml.  IL-6, IL-7, IL-8, IL-10, TNFα, IFNγ, MIP-1α and MIP-1β 
were present at < 10 pg/ml, whereas IL-1α, IL-1β, IL-2, IL-12p40, IL-12p70, IL-15 
and GM-CSF were present in concentrations < 1 pg/ml in all three groups assayed, if at 
all. 
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Figure 4.1  Detection of cytokines and chemokines in semen and blood.  Frequency of 
detection of all analytes in (A) semen and (B) blood.  A 100% stacked bar graph of median concentrations 
(pg/ml) of cytokines/chemokines in semen (C) and blood (D) of HIV-uninfected, HIV-infected (ARV-naïve) 
and HIV-infected (ARV-treated) men. 
  
Eotaxin
3%
Fractalkine
1% G-CSF
1%
MCP-1
7%
RANTES
87%
IL-8
7%
Fractalkine
5%
MCP-1
81%
RANTES
2%
IL-7
4%
BA
HIV-uninfected ARV naïve ARV-treatedHIV-uninfected ARV naïve ARV-treated
IL-15
IL-7
IL-2
IFNγ
IL-10
RANTES
MIP-1β
MIP-1α
MCP-1
GM-CSF
G-CSF
Fractalkine
Eotaxin
TNFα
IL-12p70
IL-12p40
IL-8
IL-6
IL-1β
IL-1α
Pe
rc
en
ta
ge
 c
yt
ok
in
e/
ch
em
ok
in
e
0
10
20
30
40
50
60
70
80
90
100
0
10
20
30
40
50
60
70
80
90
100C D
Percentage cytokine/chem
okine
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 111
4.3.2 The cytokine and chemokine milieu in semen and blood differ substantially 
To assess whether the levels of cytokines and chemokines detected differed between 
semen and blood, matched comparisons were performed (Table 4.3).  In HIV-
uninfected men, 14 out of 19 (74%) cytokines/chemokines assayed differed 
significantly between semen and blood, whereas in HIV-infected men 10 out of 19 
(53%) and in ARV-treated men 8 out of 19 (42%) differed significantly between semen 
and blood.  Specifically, in the semen of HIV-uninfected men, concentrations of IL-
12p70 and IFNγ were significantly higher than in blood, whereas IL-12p40 
concentrations were significantly higher in blood compared to semen of HIV-
uninfected men (Table 4.3).  Eotaxin and RANTES levels were significantly higher in 
blood compared to semen of both HIV-uninfected and infected men (Table 4.3).  In the 
semen of HIV-uninfected, infected and ARV-treated men, levels of IL-6, IL-8, 
Fractalkine, MCP-1, MIP-1β, GM-CSF, IL-7 and IL-15 were significantly higher in 
semen compared to blood (Table 4.3). 
 
To assess whether seminal plasma has a distinct immunological profile relative to 
blood plasma, semen:blood ratios of analytes were calculated (Figure 4.2).  Ratios at 
concentrations 5-fold and higher were empirically considered meaningful.  A subset of 
cytokines and chemokines, IL-8, Fractalkine, GM-CSF, MCP-1, MIP-1β, IL-7 and IL-
15, were concentrated in the semen of all three groups (HIV-uninfected, HIV-infected 
and ARV-treated men), with median levels 5 to approximately 600 fold greater than in 
blood.  Conversely, the concentration of RANTES in all three groups was more than 5-
fold higher in blood than in semen.  Some differences were observed between HIV-
infected and uninfected men.  In the semen of HIV-uninfected men, IL-6 
concentrations were >5 times higher than in blood, while in blood Eotaxin 
concentrations were >5 times higher than in semen.  In the blood of HIV-infected men, 
TNFα and Eotaxin concentrations were >5 times higher than in semen, whereas in 
semen of ARV-treated men, IL-12p70 and IFNγ concentrations were >5 times higher 
than in blood.  Although there were several differences in levels of semen:blood ratios 
between the three groups investigated, controlling for multiple comparisons showed 
that only IL-10 semen:blood ratios remained significantly higher in HIV-uninfected 
compared to infected men (p=0.034; Figure 4.2). 
 
In summary, the levels of the majority of cytokines and chemokines in semen differed 
significantly from levels in blood.  Furthermore, the composition of the major 
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detectable cytokines and chemokines in semen were not substantially different between 
HIV-uninfected and infected men.   
 
 
 
 
 
Table 4.3  Comparison of cytokine/chemokines between blood and semen of HIV-infected 
and HIV-uninfected men. 
Cytokines/chemokines HIV-uninfected HIV-infected ARV-treated 
Pro-inflammatory: IL-1β nsa ns ns 
 IL-6 0.0038b 0.02 0.013 
 IL-8 <0.0019 <0.0019 0.0095 
 IL-12p40 0.027c ns ns 
 IL-12p70 0.032 ns ns 
 TNF-α 0.046 ns ns 
 Eotaxin <0.0019 <0.0019 ns 
 Fractalkine <0.0019 <0.0019 0.0095 
 MCP-1 <0.0019 <0.0019 0.0095 
 MIP-1α ns ns ns 
 MIP-1β <0.0019 <0.0019 0.0095 
 RANTES <0.0019 <0.0019 ns 
 G-CSF ns ns ns 
 GM-CSF 0.0032 <0.0019 0.023 
Regulatory: IL-10 ns ns ns 
Adaptive: IFN-γ 0.0043 ns ns 
 IL-2 ns ns ns 
 IL-7 <0.0019 <0.0019 0.0095 
 IL-15 <0.0019 <0.0019 0.0095 
Wilcoxon matched pair analyis, p-values adjusted for multiple comparisons by false discovery rate (FDR) step-down procedure 
ans:  non-significant 
bRed: cytokine/chemokine levels in semen higher than in blood 
cBlue: cytokine/chemokine levels in blood higher than in semen 
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Figure 4.2  Graphic representation of semen:blood ratios of 19 cytokines and chemokines in HIV-uninfected (blue circles) [n = 28], HIV-infected (ARV-naïve) (red 
squares) [n = 26] and ARV-teated (green triangles) [n = 12] men. The dashed line illustrates an equivalent semen:blood cytokine/chemokine ratio. Boxed 
cytokines/chemokines have median semen:blood ratios >5 in all three groups. Cytokine/chemokine labels in red are considered pro-inflammatory and those in blue are 
regulatory/adaptive.  Mann-Whitney t tests adjusted for multiple comparisons by false discovery rate (FDR) step-down procedure.  p-values ≤ 0.05 was considered significant. 
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4.3.3 Characterisation of cytokines and chemokines in semen and blood of HIV-
uninfected and infected men 
Next, differences in quantities of cytokines/chemokines in semen and blood between 
HIV-uninfected, HIV-infected (ARV-naïve) and HIV-infected (ARV-treated) men 
were investigated.  These data are presented graphically in Figure 4.3, with the 
indicated p values adjusted for multiple comparisons.  The results from univariate 
analyses are summarised in the Appendix, Table S2 and S3. 
 
Of note, there was a large degree of heterogeneity in the levels of the majority of 
cytokines and chemokines in semen compared to blood (Figure 4A and C compared to 
Figure 4B and D).  For example, median levels of IL-6 were between 1 and 100 pg/ml 
in both compartments (Figure 4A and B).  Variation in IL-6 levels in blood between 
individuals were within this range, however this was not the case in semen, where 
individual variation spanned five orders of magnitude, from less than 10-1 to almost 104 
pg/ml.  Univariate analysis revealed significantly lower levels of the chemokine MIP-
1α in the semen of HIV-uninfected men compared to HIV-infected ARV-naïve 
(p=0.045) and ARV-treated men (p=0.0076; Table S2).  In contrast, IL-10 levels were 
significantly higher in HIV-uninfected compared to HIV-infected (ARV-naïve) men.  
In blood, both TNFα (p=0.0001) and IL-10 levels (p=0.017) were significantly lower 
in HIV-uninfected compared to HIV-infected men, whereas Eotaxin (p=0.0087), 
Fractalkine (p=0.025), G-CSF (p=0.0077), IL-10 (p=0.025) and IFNγ levels (p=0.021) 
in blood were significantly higher in HIV-infected (ARV-naïve) men compared to 
those on treatment (Table S3).  After adjusting for multiple comparisons, there were no 
significant differences in levels of cytokines or chemokines in semen between the three 
groups investigated (Figure 4.3A and C).  In blood, however, TNFα and Eotaxin 
remained significantly higher in HIV-infected (ARV-naïve) compared to HIV-
uninfected men (p=0.0014 and p=0.04, respectively; Figure 4.3B).  Among regulatory 
and adaptive cytokines and chemokines, both IL-10 (p=0.042) and IFNγ levels 
(p=0.05) remained significantly higher in the blood of HIV-infected (ARV-naïve) 
compared to HIV-infected (ARV-treated) men.  
 
Thus, comparison of the concentrations of 19 cytokines and chemokines in the semen 
in HIV-uninfected, HIV-infected (ARV-naïve) and HIV-infected (ARV-treated) men 
failed to detect significant differences in any analytes between these groups, after 
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adjustment for multiple comparisons. The extensive intra-cytokine variation between 
individuals and the number of cytokines measured are likely causes of this observation. 
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Figure 4.3  Levels of pro-inflammatory mediators in (A) semen and (B) blood and levels of regulatory and adaptive cytokines and chemokines in 
(C) semen and (D) blood of HIV-uninfected, HIV-infected (ARV-naïve) and ARV-treated men.  Box-and-whisker plots reperesents the median, IQR 
and 5-95% range (error bars).  Mann-Whitney t-tests were adjusted for multiple comparisons by the false discovery rate (FDR) step-down procedure.  
p-values ≤ 0.05 were considered significant. 
C D
I
L
-
1
0

I
F
N
I
L
-
2
I
L
-
7
I
L
-
1
5
10 -2
10 -1
10 0
10 1
10 2
10 3
10 4
10 5
C
y
t
o
k
i
n
e
/
c
h
e
m
o
k
i
n
e
 
l
e
v
e
l
s
 
(
p
g
/
m
l
)
HIV-uninfected HIV-infected (ARV-naïve) ARV-treated
I
L
-
1
0

I
F
N
I
L
-
2
I
L
-
7
I
L
-
1
5
10 -3
10 -2
10 -1
10 0
10 1
10 2
10 3
10 4
10 5
p=0.042
p=0.05
C
y
t
o
k
i
n
e
/
c
h
e
m
o
k
i
n
e
 
l
e
v
e
l
s
 
(
p
g
/
m
l
)
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 119
4.3.4 HIV infection leads to dysregulation of pro-inflammatory and other 
mediators in the male genital tract 
Cytokines and chemokines within the body work in synergy to not only elicit immune 
responses, but to establish gradients at sites of infection attracting immune cells 
(Fivenson et al., 1997).  Participating cell types, together with the cytokines and 
chemokines they produce, may form a cytokine network that can be highly disease-
specific.  To illustrate this interaction between cytokines and chemokines in semen 
better, 17 cytokines and chemokines assayed in the semen of healthy men were used to 
design a network using Ingenuity Pathway Analysis software (Figure 4.4).  This 
analysis revealed an intricate network of relationships between the cytokines measured.  
In this network, NFκB upregulation is influenced by IL-6, IL-8, IL-12p40, IL-12p70, 
IFNγ and TNFα levels, while upregulation of NFκB in turn results in enhanced 
production of these pro-inflammatory mediators.  Interestingly, both IL-10 and TNFα 
have an effect on HLA-DR and IL-10, IL-6 and IFNγ influences MHC Class II 
expression. 
 
To determine whether HIV infection had any impact on relationships in the cytokine 
network, correlations between cytokines and chemokines in the semen of HIV-
uninfected men (Table 4.4) were compared to the same correlations in HIV-infected 
men (Table 4.5).  After adjustment for multiple comparisons correlations of all 
cytokines and chemokines within the semen of HIV-uninfected men showed that 
114/190 (60%) were significantly positively correlated with each other,.  The four 
correlations that showed the strongest correlations were IL-8 versus RANTES, IL-2 
versus Fractalkine, IL-2 versus IL-1β and IL-7 versus IFNγ (all: p=0.0095; r=0.66).  
The cytokines and chemokines that showed the highest number of significant positive 
correlations with other cytokines and chemokines were fractalkine (16 other 
cytokines), IL-6, IL-10, IL-15 and MIP-1β (15 other cytokines).  In stark contrast to 
HIV-uninfected men, in semen from HIV infected men only 56/190 (29.5%) 
relationships between cytokine/ chemokine pairs remained significant (Table 4.5). In 
contrast to semen, substantially fewer correlations (~10%) are evident in the blood of 
HIV uninfected men, however in HIV-infected men the frequency of correlations 
decrease to ~4% (data not shown) reflecting the situation in semen. These analyses 
reveal a highly dysregulated cytokine network in semen as a result of HIV infection. 
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IL-10 is a key immunoregulatory cytokine primarily involved in an anti-inflammatory 
capacity.  To investigate the relationship between IL-10 and key Th1 cytokines IFNγ 
and TNFα, ratios of these cytokines were compared between HIV-uninfected, HIV-
infected (ARV-naïve) and HIV-infected (ARV-treated) men (Figure 4.5).  In blood 
both IL-10:IFNγ and IL-10:TNFα ratios did not differ significantly between HIV-
uninfected, infected or ARV-treated men (Figure 4.5A).  In semen, there was a trend 
towards higher IL-10:IFNγ ratios in HIV-uninfected than both HIV-infected (ARV-
naïve) and HIV-infected (ARV-treated) men.  IL-10:TNFα ratios were significantly 
higher in HIV-uninfected compared to HIV-infected men (p=0.0012; Figure 4.5B).  
These data further demonstrate the dysregulated nature of cytokine networks in semen 
in HIV infection. 
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Figure 4.4  Schematic representation of relationships between cytokines and chemokines in 
semen.  Shown here is a network based on 17 cytokines and chemokines in semen assayed in this study in relation to 
cellular and extra-cellular location.  CCL2 = MCP-1; CCL3 = MIP-1α; CCL4 = MIP-1β; CCL5 = RANTES; CCL11 = 
Eotaxin and IL12B = IL12p40.  Also shown is the NFκβ-complex in the nucleus, membrane bound MHC Class II 
complex, TCR, CD3 and HLA-DR.  Dotted lines represent one-way and solid lines represent reciprocal 
relationships/effects between cytokines and chemokines.  The intensity of the red icons is proportional to the rise in 
concentration while the intensity of green icons is proportional to the fall in concentration of cytokines and chemokines. 
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Table 4.4  Correlations of cytokines and chemokines in semen of HIV-uninfected men.  Cytokines and chemokines in red are pro-inflammatory while blue are 
regulatory and adaptive.  CCL11 = Eotaxin, CX3CL1 = Fractalkine, CCL2 = MCP-1, CCL3 = MIP-1α, CCL4 = MIP-1β and CCL5 = RANTES. Spearman Rank 
test was used and resulting p-values were adjusted for multiple comparisons using false discovery rate (FDR) step-down procedure.  Significant p-values ≤ 0.01 are 
in yellow cells and p-values ≤ 0.05 are in lavender cells. 
HIV- IL-1α IL-1β IL-2 IL-6 IL-7 IL-8 IL-10 IL-12p40 
IL-
12p70 IL-15 IFNγ TNFα 
GM-
CSF 
CCL1
1 
CX3C
L1 
G-
CSF CCL2 CCL3 CCL4 CCL5 
IL-1α -                    
IL-1β ns -                 
IL-2 ns p=0.0095 r=0.66 -                  
IL-6 ns p=0.017r=0.6 
p=0.013
r=0.64 -           p ≤ 0.05     
IL-7 ns p=0.03, r=0.52 
p=0.016
r=0.61 ns -          p ≤ 0.01     
IL-8 ns ns ns p=0.015r=0.62 ns -               
IL-10 ns p<0.019r=0.74 
p<0.019
r=0.86 
p<0.019
r=0.8 
p=0.014
r=0.64 ns -              
IL-
12p40 ns ns ns ns 
p=0.03, 
r=0.51 ns 
p=0.036
r=0.49 -             
IL-
12p70 ns ns ns ns ns ns ns 
p=0.049
r=0.46 -            
IL-15 ns ns p=0.025r=0.56 
p=0.016
r=0.61 
p<0.019
r=0.67 
p=0.03, 
r=0.52 
p=0.023
r=0.57 
p<0.019
r=0.71 
p=0.034
r=0.5 -           
IFNγ ns p<0.019r=0.71 p<0.019r=0.8 p<0.019r=0.76 p=0.0095r=0.66 ns p<0.019r=0.89 ns ns p=0.037r=0.48 -          
TNFα ns p<0.019r=0.75 p<0.019r=0.69 p<0.019r=0.76 ns ns p<0.019r=0.85 ns ns ns p<0.019r=0.73 -         
GM-
CSF ns 
p=0.033
r=0.51 
p=0.027
r=0.53 
p=0.016
r=0.62 
p=0.017
r=0.6 ns 
p=0.013
r=0.64 ns 
p=0.024
r=0.55 
p=0.033
r=0.5 
p=0.013
r=0.64 
p=0.03, 
r=0.52 -        
CCL1
1 ns ns 
p=0.031
r=0.51 
p=0.017
r=0.6 ns ns 
p=0.023
r=0.57 
p=0.014
r=0.63 ns 
p<0.019
r=0.73 
p=0.023
r=0.57 ns 
p=0.017
r=0.6 -       
CX3C
L1 ns ns 
p=0.0095
r=0.66 
p=0.016
r=0.61 
p<0.019
r=0.74 ns 
p<0.019
r=0.67 
p=0.023
r=0.57 
p=0.023
r=0.55 
p<0.019
r=0.78 
p<0.019
r=0.75 
p=0.034
r=0.5 
p=0.002
r=0.58 
p<0.019
r=0.68 -      
G-
CSF ns 
p=0.023
r=0.57 
p=0.025
r=0.56 
p=0.023
r=0.54 
p=0.033
r=0.5 ns 
p<0.019
r=0.76 ns ns ns 
p<0.019
r=0.67 
p<0.019
r=0.73 ns 
p=0.034
r=0.5 
p=0.024
r=0.55 -     
CCL2 ns ns ns p=0.025r=0.55 ns 
p=0.024
r=0.55 ns 
p=0.024
r=0.55 
p=0.034
r=0.5 
p<0.019
r=0.72 ns ns 
p=0.024
r=0.55 
p<0.019
r=0.8 
p=0.015
r=0.63 ns -    
CCL3 p=0.027r=0.52 ns 
p=0.023
r=0.54 
p=0.034 
r=0.5 ns ns 
p=0.013
r=0.66 
p=0.025
r=0.56 ns 
p=0.036
r=0.49 ns 
p=0.023
r=0.54 
p=0.027
r=0.39 
p=0.024
r=0.56 
p=0.023
r=0.41 
p=0.023
r=0.57 ns -   
CCL4 ns ns p=0.015r=0.62 
p<0.019
r=0.72 
p=0.04, 
r=0.47 
p=0.046
r=0.47 
p<0.019
r=0.74 
p=0.037
r=0.49 ns 
p=0.019
r=0.59 
p=0.017
r=0.6 
p=0.025
r=0.56 
p=0.024
r=0.55 
p=0.037
r=0.48 
p=0.04, 
r=0.47 
p=0.015
r=0.63 ns 
p=0.013
r=0.65 -  
CCL5 ns ns p=0.023r=0.54 
p=0.016
r=0.61 
p<0.019
r=0.78 
p=0.0095
r=0.66 
p=0.023
r=0.54 
p=0.024
r=0.56 
p=0.027
r=0.53 
p<0.019
r=0.83 
p=0.024
r=0.56 ns 
p=0.016
r=0.62 
p=0.015
r=0.62 
p<0.019
r=0.83 ns 
p=0.013
r=0.65 ns 
p=0.033
r=0.5 - 
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Table 4.5  Correlations of cytokines and chemokines in semen of HIV-infected men.  Cytokines and chemokines in red are pro-inflammatory while blue are 
regulatory and adaptive.  CCL11 = Eotaxin, CX3CL1 = Fractalkine, CCL2 = MCP-1, CCL3 = MIP-1α, CCL4 = MIP-1β and CCL5 = RANTES. Spearman Rank test  
was used and resulting p-values were adjusted for multiple comparisons using false discovery rate (FDR) step-down procedure.  Significant p-values ≤ 0.01 are in 
yellow cells and p-values ≤ 0.05 are in lavender cells. 
HIV+ IL-1α IL-1β IL-2 IL-6 IL-7 IL-8 IL-10 IL-12p40 
IL-
12p70 IL-15 IFNγ TNFα 
GM-
CSF 
CCL1
1 
CX3C
L1 
G-
CSF CCL2 CCL3 CCL4 CCL5 
IL-1α -                    
IL-1β p<0.019 r=0.59 -                 
IL-2 ns p<0.019r=0.6 -                  
IL-6 ns ns p=0.019r=0.45 -           p ≤ 0.05     
IL-7 ns ns p=0.035r=0.49 ns -          p ≤ 0.01     
IL-8 ns ns ns p<0.019r=0.77 ns -               
IL-10 ns p=0.021r=0.52 ns 
p<0.019
r=0.63 ns ns -              
IL-
12p40 ns ns ns ns ns ns ns -             
IL-
12p70 ns 
p=0.019
r=0.52 
p<0.019
r=0.57 ns ns ns ns ns -            
IL-15 ns ns ns ns p<0.019r=0.79 
p=0.019
r=0.57 ns ns ns -           
IFNγ ns ns p<0.019r=0.64 p=0.019r=0.54 ns ns p<0.019r=0.65 ns p=0.019r=0.58 ns -          
TNFα p=0.019r=0.53 p<0.019 r=0.76 p=0.038r=0.48 p<0.019r=0.83 ns p=0.019r=0.53 p<0.019r=0.69 ns ns ns p<0.019r=0.6 -         
GM-
CSF ns 
p=0.05, 
r=0.45 
p=0.019
r=0.53 
p=0.048
r=0.46 ns ns ns ns 
p=0.019
r=0.53 ns 
p=0.019
r=0.58 ns -        
CCL1
1 ns ns ns ns ns 
p=0.047
r=0.46 ns ns 
p=0.019
r=0.55 
p=0.019
r=0.55 ns ns ns -       
CX3C
L1 ns ns ns ns 
p<0.019
r=0.68 ns ns ns ns 
p<0.019
r=0.81 ns ns ns 
p<0.019
r=0.63 -      
G-
CSF 
p=0.035
r=0.49 
p=0.019
r=0.54 ns ns ns ns ns ns ns ns ns 
p<0.019
r=0.64 ns ns ns -     
CCL2 ns ns ns p=0.03, r=0.5 ns 
p<0.019
r=0.75 ns ns ns 
p=0.019
r=0.56 ns ns ns 
p=0.021
r=0.51 ns ns -    
CCL3 p=0.019r=0.54 
p<0.019
r=0.64 ns 
p=0.045
r=0.47 ns ns ns ns ns ns ns 
p<0.019
r=0.6 ns ns ns 
p=0.021
r=0.51 ns -   
CCL4 ns p<0.019r=0.6 ns 
p<0.019
r=0.79 ns 
p<0.019
r=0.71 ns ns ns ns ns 
p<0.019
r=0.72 ns ns ns 
p=0.019
r=0.58 
p=0.019
r=0.52 
p=0.019
r=0.56 -  
CCL5 ns ns ns ns p<0.019r=0.74 ns ns ns ns 
p<0.019
r=0.74 ns ns ns ns 
p<0.019
r=0.76 ns ns ns ns - 
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Figure 4.5  Relationship between regulatory and pro-inflammatory cytokines.  Ratios 
between regulatory cytokine, IL-10 and IFNγ or TNFα in (A) blood and (B) semen of HIV-uninfected, 
HIV-infected (ARV-naïve) and ARV-treated men.  Box-and-whisker plots reperesents the median, IQR 
and 5-95% range (error bars).  Mann-Whitney t tests were used to compare ratios.  A p-value of < 0.05 
was considered significant. 
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4.3.5 The relationship between cytokines/chemokines and viral loads 
To investigate whether there was an association between viral loads and cytokine and 
chemokine levels in blood and semen, the first approach was to perform univariate 
analysis by correlating cytokine and chemokine concentrations with matched viral load 
levels in blood and semen, respectively. This analysis is shown in Table 4.6, and 
significant correlations are depicted in Figure 4.6.  TNFα in both blood and semen 
were significantly positively correlated with both plasma viral load (r=0.53, p=0.0054) 
and seminal viral load (r=0.55, p=0.013). Furthermore, seminal viral load was 
significantly positively correlated with G-CSF (r=0.61, p=0.0057), IL-10 (r=0.61, 
p=0.006) and IFNγ (r=0.57, p=0.01).  No association with viral load was detected for 
the remainder of the analytes measured in blood or semen.  After adjusting for multiple 
comparisons, however, none of these associations remained significant. 
 
To investigate the influence of seminal viral load on cytokine and chemokine levels in 
seminal plasma, a univariate logistic regression analysis was performed between levels 
of cytokines and chemokines and seminal viral load.  Resulting regression coefficients 
were adjusted for the effect of plasma viral load (Table 4.7).  In semen, after adjusting 
for the influence of plasma viral load there were significant associations between viral 
load and both IL-10 and IFNγ.  For every log increase in seminal viral load, IL-10 and 
IFNγ levels increased by 0.96 and 0.97 pg/ml respectively (Table 4.7). 
 
In the analysis above, a number of cytokines/chemokines in semen were significantly 
positively correlated with seminal viral load.  Thus, it was hypothesised that men 
shedding virus in semen may have differing levels of cytokines/chemokines compared 
to non-shedders.  To investigate whether men would cluster according to viral loads, 
participants were divided into three groups, namely HIV-uninfected men, HIV-infected 
men who had detectable viral loads in semen, and HIV-infected men who have no 
detectable viral loads in semen.  The same analysis was performed in blood. An 
unsupervised clustering was performed using principle component analysis (PCA).  
PCA analysis showed no group-specific clustering for any of the analytes measured 
(Figure 4.7).  Secondly, to visualise the levels of cytokines and chemokines in the 
blood and semen of each participant graphically, hierarchical clustering was used to 
create heat maps, in order to detect linkage of individuals with detectable viral loads to 
levels of cytokines and chemokines assayed.  None of the groups demonstrated any 
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Fig 4.6  Association between seminal viral load and cytokines/chemokines in semen.  
Shown are correlations for (A) IL-10, (B) G-CSF, (D) IFNγ and TNFα with viral loads of HIV-infected men with 
detectable seminal viral load (n=19).  Each circle represents a viral load (copies/ml) with corresponding 
cytokine/chemokine concentration (pg/ml).  The Spearman Rank test was used and p-values ≤ 0.05 were 
considered significant.  Spearman rho values are indicated.  
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Table 4.6  Correlations between viral loads and cytokines/chemokines in semen and blood of 
HIV-infected (ARV-naïve) men. 
Cytokines/chemokines 
Plasma viral load Seminal viral load 
Rho  p-value Rho  p-value 
Pro-inflammatory: IL-1α - - -0.012 0.96 
 IL-1β 0.26 0.2 0.38 0.1 
 IL-6 0.14 0.49 0.27 0.26 
 IL-8 -0.32 0.11 0.01 0.96 
 IL-12p40 -0.068 0.74 0.11 0.63 
 IL-12p70 0.17 0.39 0.28 0.23 
 TNF-α 0.53 0.0054 0.55 0.013 
 Eotaxin 0.21 0.31 0.38 0.099 
 Fractalkine 0.11 0.58 0.17 0.48 
 MCP-1 -0.035 0.86 -0.41 0.079 
 MIP-1α -0.071 0.73 0.32 0.17 
 MIP-1β -0.21 0.29 0.25 0.31 
 RANTES -0.15 0.47 0.037 0.88 
 G-CSF -0.19 0.36 0.61 0.0057 
 GM-CSF -0.054 0.79 -0.04 0.87 
Regulatory: IL-10 0.12 0.56 0.61 0.006 
Adaptive: IFN-γ 0.31 0.13 0.57 0.01 
 IL-2 0.22 0.29 0.065 0.78 
 IL-7 0.046 0.82 -0.0035 0.98 
 IL-15 -0.079 0.69 0.068 0.78 
aIL-1α cytokine data in blood not used  
Univariate analysis using Spearman Rank test, with p-values considered significant ≤ 0.05 are shown in bold.   
Multivariate analysisusing the False discovery rate (FDR) step-down procedure showed no surviving significant p-values. 
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Table 4.7  Multivariate analysis of association between seminal cytokines/chemokines and seminal viral 
load adjusted for plasma viral load. 
Cytokines/chemokines β-coefficient (95% CI) Adj. β-coefficient (95% CI) 
Pro-inflammatory: IL-1α 0.07 (-0.57 – 0.72) 0.33 (-0.50 – 1.18) 
 IL-1β -0.01 (-0.66 – 0.63) 0.37 (-0.54 – 1.28) 
 IL-6 0.11 (-0.53 – 0.76) 0.59 (-0.34 – 1.53) 
 IL-8 0.05 (-0.59 – 0.70) 0.58 (-0.30 – 1.47) 
 IL-12p40 0.22 (-0.44 – 0.89) 0.63 (-0.32 – 1.58) 
 IL-12p70 -0.45 (-1.12 – 0.21) -0.02 (-0.88 – 0.83) 
 TNF-α 0.30 (-0.37 – 0.97) 0.90 (-0.07 – 1.88) 
 Eotaxin -0.16 (-0.82 – 0.48) 0.47 (-0.40 – 1.35) 
 Fractalkine 0.26 (-0.41 – 0.94) 0.50 (-0.41 – 1.42) 
 MCP-1 -0.14 (-0.81 – 0.51) 0.44 (-0.44 – 1.34) 
 MIP-1α -0.03 (-0.68 – 0.60) 0.50 (-0.39 – 1.39) 
 MIP-1β 0.10 (-0.54 – 0.75) 0.90 (-0.14 – 1.94) 
 RANTES -0.04 (-0.69 – 0.59) 0.24 (-0.54 – 1.04) 
 G-CSF -0.06 (-0.71 – 0.57) 0.80 (-0.15 – 1.76) 
 GM-CSF 0.09 (-0.55 – 0.74) 0.33 (-0.56 – 1.22) 
Regulatory: IL-10 0.25 (-0.44 – 0.95) 0.96 (0.01 – 1.91) 
Adaptive: IFN-γ 0.58 (-0.15 – 1.32) 0.97 (0.001 – 1.94) 
 IL-2 0.17 (-0.47 – 0.83) 0.93 (-0.11 – 1.98) 
 IL-7 0.32 (-0.37 – 1.01) 0.70 (-0.14 – 1.56) 
 IL-15 0.34 (-0.32 – 1.01) 0.86 (-0.16 – 1.90) 
aβ-coefficient: logistic regression between plasma cytokines/chemokines and seminal viral load 
bAdj. β-coefficient: logistic regression adjusted for presence of ARVs 
cNumbers in bold represent statistically significant associations 
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clustering in either blood (Figure S1) or semen (Figure S2), with HIV-infected men 
with detectable viral loads in blood or semen spread throughout the uninfected and 
HIV-infected undetectable viral load groups. 
 
In summary, using multiple methods to investigate the relationship between semen 
cytokines/chemokines and viral loads, little evidence of any particular cytokine 
associating with viral shedding in semen was apparent.  Although TNFα was 
significantly positively correlated with plasma viral load, and in semen, TNFα, G-CSF, 
IL-10 and IFNγ were significantly positively correlated with seminal viral load, these 
associations were lost after adjusting for multiple comparisons.  In semen, controlling 
for the influence of plasma viral load, IL-10 and IFNγ were significantly positively 
associated with increases in seminal viral load when regression analysis was applied.  
Lastly, cluster analyses revealed that cytokines and chemokines did not group into 
clusters according to the presence or absence of viral replication in semen in HIV-
infected men. 
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Figure 4.7  Schematic representation of principal component analysis (PCA).  Shown are plots of all study participants  that are HIV-
uninfected (blue), have no detectable viral loads (green) and have detectable viral loads (red) in (A) blood and (B) semen.  PCA plots were used to visualize 
results from unsupervised variance filtration used to test clustering of cytokines and chemokines in abovementioned three groups. 
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4.3.6 The relationship between cytokines/chemokines and cellular activation 
As can be seen from data presented in Chapter 3 and here in Chapter 4, levels of both 
immune activation and inflammation in the male genital tract were high compared to 
blood.  This was evidenced by higher frequencies of activated T cells and higher 
concentrations of inflammatory cytokines/chemokines in semen.  Although immune 
activation may be either directly or indirectly linked to viral replication (Appay & 
Sauce 2008), the contribution and effect of inflammation on immune activation, 
especially in the genital tract, needs further examination.  Thus, the relationship 
between local genital tract inflammation, T cell activation and viral load was 
investigated.  
 
A range of analyses were conducted to explore these relationships.  To investigate the 
relationship between inflammatory cytokines and chemokines and levels of activated T 
cells in semen, univariate correlations were performed.  All p-values and Spearman rho 
values can be found in Table S4 (for semen) and Table S5 (for blood).  In the semen of 
HIV-uninfected men, frequencies of CD8+CD38+ T cells were significantly positively 
correlated with both MCP-1 (p=0.0044, r=0.45; Figure 4.8A) and Eotaxin (p=0.0002, 
r=0.56; Figure 4.8B), whereas in the semen of HIV-infected men (ARV-naïve), 
although weak, both CD4+ and CD8+ CCR5+ T cell frequencies were significantly 
inversely correlated with IL-2 (p=0.046, r=-0.49) and IL-7 (p=0.045, r=-0.43), 
respectively.  In the semen of HIV-infected (ARV-treated) men (n=12), frequencies of 
CD4+CD38+ T cells were significantly negatively correlated with IL-1α (p=0.024, r=-
0.73), IL-1β (p=0.035, r=-0.7), G-CSF (p=0.035, r=-0.7) and MIP-1β (p=0.049, r=-
0.67).  Also in the semen of HIV-infected (ARV-treated) men, frequencies of 
CD8+CCR5+ T cells were significantly positively correlated with IL-1β (p=0.021, 
r=0.71).  In contrast, in blood, the strongest positive correlation was found between IL-
10 levels and frequencies of CD8+CD38+ T cells in HIV-infected (ARV-treated) men 
(p=0.0027, r=0.78; Figure 4.8D), whereas a strong negative correlation existed 
between MIP-1β levels and frequencies of CD8+CCR5+ T cells in HIV-infected (ARV-
naïve) men (p=0.0021, r=-0.58; Figure 4.8C).  After adjusting for multiple 
comparisons, only Eotaxin levels in semen of HIV-uninfected men remained positively 
associated with activated CD38+ CD8 T cells (p=0.044, r=0.56 data not shown).  None 
of the correlations in blood remained significant after adjusting for multiple 
comparisons. 
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Immune activation in the genital tract may be as a direct result of viral replication.  
However, activated immune cells and other local cells produce pro-inflammatory 
cytokines and chemokines that may also attract more immune cells to sites of infection 
(Appay & Sauce 2008).  To investigate the influence of seminal viral loads on the 
association between cellular activation and cytokines and chemokines in semen, a 
univariate regression analysis was performed between levels of cytokines and 
chemokines and frequencies of activated T cells.  Resulting regression coefficients 
were adjusted for the influence of seminal viral load in a multivariate analysis (Table 
4.8).  In univariate analysis, high levels of G-CSF were significantly associated with 
high frequencies of CD8+CCR5+ T cells.  After adjusting for the effect of seminal viral 
load, this association remained significant (Table 4.8).  This indicated that for a log 
increase in the frequency of CD8+CCR5+ T cells, the concentration of G-CSF would 
increase by 0.36 pg/ml after controlling for the influence of seminal viral load.  By 
comparison, the same analysis was performed in the systemic compartment.  Here it 
was found that even after adjusting for the influence of plasma viral load, there was a 
significant positive association between frequencies of CD4+CD38+ T cells and levels 
of RANTES as well as CD8+CD38+ T cells and levels of IL-2 (Table 4.9).  There was a 
significant positive association between frequencies of CD8+CD38+ T cells and levels 
of IL-7, however, after controlling for the influence of plasma viral load, this 
association was lost. 
  
Thus, in the semen of HIV-infected men, an increase in immune activation was 
associated with an increase in G-CSF even after accounting for the effect of seminal 
viral load. In comparison, correlative analysis revealed a significant positive 
association between activated T cells and Eotaxin in the semen of HIV-uninfected men 
alone.  When comparing compartments, there were no shared associations of any of the 
analytes investigated.  In blood, levels of RANTES and IL-2 remained positively 
associated with increases in frequencies of activated CD8+ T cells after controlling for 
the influence of plasma viral load.  
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Figure 4.8  Association between activated T cells and cytokines and 
chemokines.  Shown are the two correlations with the highest significant p-values in semen 
between CD8+CD38+ T cells and MCP-1 levels (A) and Eotaxin levels (B) in HIV-uninfected men 
[blue] as well as the two correlations with the highest significant p-values in blood between (C) 
CD8+CCR5+ T cells and MIP-1β levels in HIV-infected (ARV naïve) men [red] and between 
CD8+CD38+ T cells and (D) IL-10 levels in HIV-infected (ARV-treated) men [cyan].  Each circle 
represents a cytokine/chemokine concentration (pg/ml) with a corresponding frequency of an 
activated T cell subset.  Spearman Rank test were used and p-values ≤ 0.05 were considered 
significant.  Spearman rho values are indicated. 
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Table 4.8  Multivariate analysis of association between levels of cytokines/chemokines and T cell activation subsets in semen of HIV-infected men adjusted 
for seminal viral load. 
Cytokines/ 
chemokines CD4
+ T cells CD8+ T cells 
Pro-
inflammatory 
CCR5 CD38 CCR5 CD38 
β-coeff.  
(95% CI) 
Adj. β-coeff.  
(95% CI) 
β-coeff.  
(95% CI) 
Adj. β-coeff.  
(95% CI) 
β-coeff.  
(95% CI) 
Adj. β-coeff.  
(95% CI) 
β-coeff.  
(95% CI) 
Adj. β-coeff.  
(95% CI) 
IL-1α 0.21 (-0.2 – 0.62) 0.22 (-0.19 – 0.63) -0.14 (-0.5 – 0.22) -0.14 (-0.5 – 0.23) 0.16 (-0.2 – 0.52) 0.15 (-0.21 – 0.52) 0.027 (-0.31 – 0.37) 0.024 (-0.32 – 0.37) 
IL-1β 0.18 (-0.21 – 0.57) 0.15 (-0.28 – 0.58) -0.22 (-0.58 – 0.14) -0.24 (-0.61 – 0.12) 0.17 (-0.18 – 0.53) 0.16 (-0.2 – 0.52) 0.087 (-0.25 – 0.43) 0.072 (-0.27 – 0.42) 
IL-6 0.026 (-0.37 – 0.42) -0.02 (-0.44 – 0.4) -0.26 (-0.6 – 0.08) -0.27 (-0.61 – 0.08) 0.057 (-0.3 – 0.42) 0.035 (-0.34 – 0.41) -0.2 (-0.53 – 0.13) -0.22 (-0.56 – 0.12) 
IL-8 0.005 (-0.45 – 0.46) -0.019 (-0.48 – 0.45) 0.2 (-0.19 – 0.6) 0.19 (-0.22 – 0.6) 0.003 (-0.39 – 0.4) -0.012 (-0.42 – 0.39) -0.22 (-0.55 – 0.11) -0.22 (-0.55 – 0.11) 
IL-12p40 0.12 (-0.32 – 0.56) 0.088 (-0.37 – 0.55) -0.099 (-0.45 – 0.25) -0.13 (-0.5 – 0.24) 0.029 (-0.33 – 0.39) 0.005 (-0.36 – 0.38) -0.037 (-0.38 – 0.31) -0.066 (-0.42 – 0.29) 
IL-12p70 0.31 (-0.16 – 0.78) 0.29 (-0.2 – 0.78) -0.22 (-0.6 – 0.15) -0.21 (-0.59 – 0.18) 0.25 (-0.096 – 0.61) 0.28 (-0.084 – 0.64) -0.016 (-0.36 – 0.33) -0.001 (-0.35 – 0.35) 
TNF-α 0.14 (-0.25 – 0.53) 0.1 (-0.35 – 0.55) -0.2 (-0.58 – 0.17) -0.24 (-0.63 – 0.14) 0.13 (-0.22 – 0.48) 0.1 (-0.27 – 0.48) -0.024 (-0.36 – 0.32) -0.07 (-0.43 – 0.29) 
Eotaxin -0.026 (-0.49 – 0.44) -0.056 (-0.53 – 0.42) 0.12 (-0.24 – 0.48) 0.11 (-0.26 – 0.48) 0.26 (-0.11 – 0.62) 0.25 (-0.13 – 0.62) 0.095 (-0.24 – 0.43) 0.085 (-0.26 – 0.43) 
Fractalkine 0.081 (-0.33 – 0.49) 0.048 (-0.39 – 0.48) 0.015 (-0.33 – 0.36) -0.003 (-0.36 – 0.35) 0.14 (-0.21 – 0.5) 0.12 (-0.25 – 0.5) -0.033 (-0.37 – 0.3) -0.055 (-0.4 – 0.29) 
MCP-1 -0.2 (-0.62 – 0.21) -0.18 (-0.61 – 0.24) -0.1 (-0.45 – 0.24) -0.084 (-0.44 – 0.27) -0.17 (-0.53 – 0.2) -0.16 (-0.53 – 0.21) -0.13 (-0.47 – 0.2) -0.12 (-0.46 – 0.22) 
MIP-1α 0.09 (-0.35 – 0.53) 0.06 (-0.4 – 0.52) -0.2 (-0.58 – 0.17) -0.21 (-0.59 – 0.17) 0.058 (-0.3 – 0.42) 0.043 (-0.33 – 0.41) -0.056 (-0.4 – 0.29) -0.068 (-0.42 – 0.28) 
MIP-1β 0.069 (-0.32 – 0.46) 0.058 (-0.34 – 0.46) -0.22 (-0.58 – 0.13) -0.22 (-0.58 – 0.14) 0.072 (-0.28 – 0.42) 0.063 (-0.29 – 0.42) -0.12 (-0.46 – 0.22) -0.13 (-0.47 – 0.21) 
RANTES 0.094 (-0.43 – 0.62) 0.06 (-0.49 – 0.61) -0.15 (-0.51 – 0.21) -0.15 (-0.51 – 0.21) -0.026 (-0.4 – 0.34) -0.033 (-0.41 – 0.34) 0.077 (-0.26 – 0.41) 0.073 (-0.27 – 0.42) 
G-CSF 0.23 (-0.14 – 0.62) 0.22 (-0.17 – 0.61) -0.094 (-0.49 – 0.3) -0.1 (-0.5 – 0.3) 0.37 (0.036 – 0.7) 0.36 (0.017 – 0.71) 0.029 (-0.31 – 0.37) 0.0098 (-0.34 – 0.36) 
GM-CSF 0.062 (-0.36 – 0.49) 0.028 (-0.42 – 0.47) -0.059 (-0.4 – 0.29) -0.066 (-0.42 – 0.28) 0.036(-0.35 – 0.42) 0.024 (-0.36 – 0.41) 0.075 (-0.26 – 0.41) 0.071 (-0.27 – 0.41) 
Regulatory        
IL-10 0.27 (-0.099 – 0.64) 0.25 (-0.14 – 0.65) -0.31 (-0.69 – 0.072) -0.33 (-0.71 – 0.059) 0.18 (-0.16 – 0.52) 0.16 (-0.19 – 0.52) -0.24 (-0.57 – 0.089) -0.27 (-0.61 – 0.061) 
Adaptive        
IFN-γ 0.26 (-0.1 – 0.63) 0.27 (-0.19 – 0.74) -0.27 (-0.6 – 0.066) -0.34 (-0.69 – 0.014) 0.24 (-0.1 – 0.58) 0.23 (-0.14 – 0.61) -0.21 (-0.54 – 0.12) -0.27 (-0.62 – 0.078) 
IL-2 0.074 (-0.36 – 0.51) 0.046 (-0.41 – 0.5) -0.23 (-0.6 – 0.13) -0.24 (-0.61 – 0.13) 0.014 (-0.35 – 0.37) 0.01 (-0.35 – 0.38) 0.053 (-0.29 – 0.4) 0.049 (-0.3 – 0.39) 
IL-7 -0.005 (-0.4 – 0.39) -0.007 (-0.41 – 0.39) -0.036 (-0.39 – 0.32) -0.04 (-0.4 – 0.32) -0.18 (-0.52 – 0.16) -0.19 (-0.54 – 0.16) -0.067 (-0.4 – 0.27) -0.07 (-0.41 – 0.27) 
IL-15 0.075 (-0.38 – 0.53) 0.039 (-0.44 – 0.52) 0.038 (-0.31 – 0.39) 0.017 (-0.34 – 0.38) -0.027 (-0.41 – 0.36) -0.066 (-0.47 – 0.34) -0.16 (-0.5 – 0.18) -0.19 (-0.53 – 0.15) 
aβ-coefficient (95% confidence interval) linear regression analysis of T cell activation subsets and cytokines/chemokines;   
bAdjusted β-coefficient (95% confidence interval) for ARV treatment 
Red-shaded cells represent significant associations 
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Table 4.9  Multivariate analysis of association between levels of cytokines/chemokines and T cell activation subsets in blood of HIV-infected men 
adjusted for plasma viral load. 
Cytokines/ 
chemokines CD4
+ T cells CD8+ T cells 
Pro-
inflammatory 
CCR5 CD38 CCR5 CD38 
aβ-coeff.       (95% 
CI) 
bAdj. β-coeff.  
(95% CI) 
aβ-coeff.         
(95% CI) 
bAdj. β-coeff.  
(95% CI) 
aβ-coeff.         
(95% CI) 
bAdj. β-coeff.  
(95% CI) 
aβ-coeff.         
(95% CI) 
bAdj. β-coeff.  
(95% CI) 
IL-1β 0.07 (-0.25 - 0.41)    0.05 (-0.32 - 0 .42)  0.005 (-0.33 - 0.34) -0.16 (-0.51 - 0.18) 0.022 (-0.31 - 0.36) -0.07(-0.43 - 0.29) 0.22 (-0.09 - 0.55) 0.10 (-0.24 - 0.45) 
IL-6 -0.08 (-0.42 - 0.24) -0.11 (-0.46 - 0.23) 0.04 (-0.29 - 0.37) -0.039 (-0.10 - 0.53) -0.10 (-0.44 - 0.22) -0.16(-0.50 - 0.17) 0.065 (-0.27 - 0.40) -0.012 (-0.34 - 0.31) 
IL-8 0.034 (-0.30 - 0.37) 0.028 (-0.31 - 0.37) -0.073 (-0.41 - 0.26) -0.099 (-0.42 - 0.22) -0.12 (-0.45 - 0.21) -0.13(-0.46 - 0.19) 0.13 (-0.19 - 0.47) 0.11 (-0.20 - 0.43) 
IL-12p40 0.28 (-0.04 - 0.60) 0.27 (-0.058 - 0.60) -0.051 (-0.38 - 0.28) -0.10 (-0.42 - 0.21) 0.086 (-0.25 - 0.42) 0.057(-0.28 - 0.39) 0.10 (-0.23 - 0.43) 0.051 (-0.27 - 0.37) 
IL-12p70 0.12 (-0.21 - 0.45) 0.10 (-0.24 - 0.45) -0.005 (-0.33  - 0.34) -0.085 (-0.41 -  0.24) 0.029 (-0.30 - 0.36) -0.021(-0.36 - 0.32) 0.11 (-0.22 - 0.44) 0.026 (-0.30 - 0.35) 
TNF-α -0.14 (-0.48 - 0.18) -0.23 (-0.61 - 0.13) 0.12 (-0.21 - 0.45) -0.047 (-0.40 -  0.31) -0.028 (-0.36 -  0.30) -0.15 (-0.52 - 0.22) 0.14 (-0.18 - 0.48) -0.015 (-0.37 - 0.34) 
Eotaxin 0.18 (-0.14 - 0.51) 0.17 (-0.18 - 0.52) 0.14 (-0.19 - 0.47) 0.090 (-0.26 - 0.44) -0.074 (-0.41 - 0.26) -0.20 (-0.53 - 0.12) 0.14 (-0.19 - 0.47) 0.036 (-0.30 - 0.37) 
Fractalkine -0.067 (-0.40 - 0.26) -0.10 (-0.46 - 0.25) 0.26 (-0.05 - 0.59) 0.17 (-0.15 - 0.51) -0.14 (-0.47 - 0.19) -0.22(-0.57 - 0.11) 0.28 (-0.038 - 0.60) 0.19 (-0.13 - 0.52) 
MCP-1 0.071 (-0.26 - 0.40) 0.069 (-0.27 - 0.41) -0.21 (-0.54  - 0.11) -0.22 (-0.53 - 0.08) -0.10 (-0.43 - 0.23) -0.10(-0.43 - 0.22) -0.22 (-0.55 - 0.10) -0.23 (-0.54 - 0.081) 
MIP-1α -0.064 (-0.40  - 0.27) -0.058 (-0.40  - 0.28) 0.072 (-0.26  -  0.40) 0.098 (-0.22 - 0.41) -0.17 (-0.50 - 0.15) -0.16(-0.49 - 0.17) 0.096 (-0.24 - 0.43) 0.12 (-0.19 - 0.44) 
MIP-1β -0.22 (-0.55 - 0.10) -0.22 (-0.55 - 0.11) -0.30 (-0.62 - 0.01) -0.25(-0.56 -  0.05) -0.30(-0.62 - 0.013) -0.28(-0.60 - 0.044) -0.051 (-0.38 - 0.28) 0.006 (-0.32 - 0.33) 
RANTES -0.016 (-0.35  - 0.32) -0.017 (-0.35  - 0.32) 0.41 (0.10 - 0.72) 0.41 (0.12 - 0.70) 0.047 (-0.29 - 0.38) 0.043(-0.29 - 0.37) 0.35 (0.034 - 0.66) 0.34 (0.046 - 0.64) 
G-CSF -0.070 (-0.40 - 0.26) -0.086 (-0.43  - 0.25) 0.23 (-0.08 - 0.56) 0.18 (-0.13 - 0.50) -0.098 (-0.43 - 0.23) -0.13(-0.47 - 0.20) 0.21 (-0.11 - 0.54) 0.16 (-0.15 - 0.48) 
GM-CSF 0.11 (-0.22 - 0.44) 0.11 (-0.22 - 0.45) -0.069 (-0.40 - 0.26) -0.081 (-0.40 - 0.23) -0.021 (-0.35 - 0.31) -0.028(-0.36 - 0.30) 0.10 (-0.23 - 0.44) 0.092 (-0.22 - 0.41) 
Regulatory        
IL-10 0.086 (-0.25 - 0.42) 0.068 (-0.28 - 0.42) -0.051 (-0.38 - 0.28) -0.15 (-0.48 - 0.17) 0.054 (-0.28 - 0.39) 0.001(-0.34 - 0.35) 0.11 (-0.22 - 0.44) 0.021 (-0.31 - 0.35) 
Adaptive        
IFN-γ 0.014 (-0.32 - 0.35) -0.032 (-0.41 - 0.35) 0.13 (-0.39 - 0.27) -0.28 (-0.63 - 0.06) 0.001 (-0.33 - 0.33) -0.11(-0.49 - 0.26) 0.10 (-0.22 - 0.44) -0.067 (-0.43 - 0.29) 
IL-2 -0.077 (-0.41  - 0.25) -0.12 (-0.49 - 0.23) 0.26 (-0.06 - 0.58) 0.15 (-0.18 - 0.49) -0.017 (-0.35 - 0.32) -0.10(-0.46 - 0.25) 0.46 (0.16 - 0.76) 0.38 (0.069 - 0.70) 
IL-7 -0.22 (-0.55 - 0.10) -0.25 (-0.58 - 0.084) -0.31 (-0.71 - 0.086) -0.31 (-0.71 - 0.094) -0.18 (-0.51 - 0.14) -0.22(-0.56 - 0.10) 0.35 (0.041 - 0.67) 0.30 (-0.007 - 0.61) 
IL-15 -0.016 (-0.35  - 0.32) -0.035 (-0.38  - 0.31) -0.068 (-0.40 - 0.26) -0.14 (-0.47 - 0.17) -0.048 (-0.38 - 0.28) -0.094(-0.43 - 0.24) 0.18 (-0.14 - 0.51) 0.11 (-0.21 - 0.44) 
aβ-coefficient (95% confidence interval) linear regression analysis of T cell activation subsets and cytokines/chemokines;   
bAdjusted β-coefficient (95% confidence interval) for ARV treatment 
Red-shaded cells represent significant associations 
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4.4 Discussion 
 
This study investigated the concentrations of cytokines and chemokines in the male 
genital tract, using semen samples, in order to describe the immune milieu of this 
compartment in the context of HIV infection.  Analyte levels were compared between 
blood plasma and semen, and between HIV-infected and uninfected men.  The main 
findings of this study were that (i) semen and blood differed substantially with respect 
to the cytokine milieu, with the majority of cytokines and chemokines found at higher 
concentrations in semen than blood, both in HIV-infected and uninfected men;  (ii) 
there were no significant differences between any cytokines/chemokines in the semen 
of HIV-infected vs uninfected men after rigorous statistical analysis; (iii) although 
specific differences at the individual cytokine level were not evident between HIV-
infected and uninfected men, HIV-infection caused a dysregulation of the network of 
cytokine/chemokine associations in semen; (iv) no significant associations were found 
between levels of cytokines/chemokines and seminal viral load after rigorous 
statistical analyses; and (v) investigating relationships between T cell activation and 
cytokine levels revealed that higher levels of G-CSF in semen of HIV-infected men 
were associated with higher levels of CCR5+CD8+ T cells in semen.  
 
Why would the cytokine milieu differ so substantially between blood and the genital 
tract?  Being a mucosal surface, exposed to the outside environment, the genital tract 
is likely to differ intrinsically from the systemic compartment.  It is a mucosal effector 
site to which immune cells from the periphery traffic for immune defence, in response 
to chemokine gradients, and therefore contains a range of immune molecules involved 
in recruitment, maturation, and signalling of different immune cells (Kutteh et al, 
2005).  The differences may also be due to the reproductive functions associated with 
the male genital tract.  Semen is a reproductive fluid and contains substances involved 
in immune regulation, such as those inducing immune tolerance to spermatozoa 
within the male genital tract itself, or dampening inflammatory responses to seminal 
components after semen deposition in the vagina (Kutteh et al, 2005).  Particular 
immune proteins such as TGF-β, present in very high levels, have been shown to have 
a role in reproduction (Robertson et al., 2002, Robertson 2005). 
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Of all the cytokines and chemokines assayed in this study, monocyte chemoattractant 
protein-1 (MCP-1/CCL2) was found in the highest concentrations in semen, 
regardless of HIV infection status.  The concentration of MCP-1 was approximately 
60 times higher in semen than in blood plasma.  MCP-1 is a chemokine for 
monocytes, T cells, and dendritic cells, produced by various cell types, including 
monocytes themselves, as well as non-haematopoeitic cells such as endothelial and 
epithelial cells, fibroblasts and smooth muscle cells (Cushing et al., 1990, Standiford 
et al., 1991).  MCP-1 regulates the infiltration of monocytes, memory T cells, 
dendritic cells and NK cells (Deshmane et al., 2009).  In HIV-1 infection, plasma 
MCP-1 levels have previously been correlated with viral load (Weiss et al., 1997).  
This study did not show any association with viral load.  In fact high MCP-1 levels 
were present in those with viral suppression on ART, and in HIV-uninfected 
participants. This may reflect the existing high levels of inflammation in the male 
genital tract, possibly due to continuous exposure of this mucosal surface to sexually-
transmitted pathogens. Recruitment of the additional producers of MCP-1, monocytes 
and macrophages (Cinque et al., 1998), likely only serves to enhance the levels of this 
chemokine in semen.  An alternative explanation may be that this chemokine is found 
at high concentrations in semen naturally.  Highly concentrated levels of MCP-1 were 
also found in semen in two other studies (Politch et al., 2007, Anderson et al., 2010).  
In the Politch study, healthy men expressed high levels of MCP-1 in semen; thus, the 
levels that we have detected in this study may represent constitutively high expression 
levels of MCP-1, and not necessarily elevation due to concurrent infections or 
conditions.   
 
What may be the consequences for HIV acquisition?  It has been shown that memory 
CD4+ T cells express CCR2 at high levels and therefore MCP-1 recruitment can 
facilitate HIV-1 infection of these cells (Matsushima et al., 1989).  High MCP-1 
levels may therefore recruit potential target cells, thereby facilitating the replication 
and spread of HIV.  If this is the case, this opens up potential avenues for modulating 
leukocyte infiltration in the genital tract; doxycycline and leukotriene receptor 
antagonists (LTRAs) can downregulate MCP-1 or block chemotaxis via MCP-1 
(Deshmane et al., 2009).  However, these approaches must always take into account 
the potential for pleiotropic effects and the beneficial role of MCP-1 in protective 
immune responses or normal functioning in the male genital tract.  Endogenous MCP-
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1 in the female genital tract has been shown to be up-regulated by exposure to seminal 
plasma in a dose-dependent manner (Sharkey et al., 2007), indicating that MCP-1 
may also play a role in recruiting immune cells to the vaginal mucosa in the female 
genital tract subsequent to ejaculation, which may have a role in HIV transmission.   
 
Although not as dramatically elevated as MCP-1, levels of IL-8, Fractalkine, GM-
CSF, IL-7 and IL-15 were more than 5-fold higher in semen than in blood regardless 
of HIV status.  Fractalkine, produced by endothelial venule cells as well as dendritic 
cells, can recruit monocytes, CD8+ T cells and NK cells to sites of inflammation 
(Fong et al., 1998). GM-CSF, produced by T cells, macrophages and endothelial cells 
are mainly responsible for the maturation of progenitors into dendritic cells and 
monocytes (Abbas & Lichtman 2007).  IL-15 is produced mainly by monocytes to 
stimulate the proliferation of NK cells and also functions as a T cell growth factor 
(Mueller & Katsikis 2010).  These findings confirm those of Politch et al. (2009) and 
Anderson et al. (2010), who also found higher levels of IL-7 and IL-8 in semen 
regardless of HIV infection.  IL-7 plays a role in T and B cell development and is 
secreted by stromal cells in many tissues (Chahroudi & Silvestri 2010).  Specifically, 
IL-7 plays a role in supporting CD4+ and CD8+ T cells, binding to CD127 (the IL-7 
receptor) to enhance T cell survival.  In semen, high levels of IL-7 are likely to play a 
similar role.  IL-8 is a chemokine that attracts neutrophils to sites of inflammation 
upon production by mast cells, endothelial cells and monocytes (Sheridan et al.,1997, 
Male 2006).  IL-8 has been associated with the enhancement of HIV-1 replication 
(Lane et al., 2001).  In HIV-infected individuals these authors also found high levels 
of TGFβ, SDF1α, IL-5 and monokine induced by IFNγ (MIG) in semen, which was 
not tested for in the present study.  In the present study higher levels of RANTES 
were found in blood compared to semen, reflecting the same finding as Anderson et 
al. (2010).  Thus, the male genital tract contains high levels of immune mediators 
involved in the recruitment, maturation and survival of immune cells at this site. 
 
Differences in the cytokine and chemokine levels in the semen of HIV-uninfected, 
infected and antiretroviral-treated men were investigated. Surprisingly, there were no 
significant differences between the levels of cytokines and chemokines in semen of 
the three groups investigated. One explanation is that pre-existing levels of 
inflammation in the seminal compartment may have masked any significant 
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differences between cytokine and chemokine levels in HIV-uninfected and infected 
men.  There was, however, evidence of dysregulation of cytokine networks in HIV-
infected men compared to uninfected men.  Regulation of cytokines and chemokines 
is complex.  The dysregulation of proinflammatory cytokines and chemokines in HIV 
infection has been reported previously (reviewed in Decrion et al., 2005).  In the 
present study the associations and interactions between cytokines and chemokines in 
semen of HIV-uninfected men highlights the complexity of their regulation, and how 
HIV may disrupt this.   
 
Previous studies have described an association between seminal viral loads and levels 
of IL-1β, IL-6, IL-12, IFNγ and RANTES (Sheth et al., 2005, Storey et al., 1999, 
Berlier et al., 2006a).  In the present study, plasma levels of TNFα and IFNγ levels 
were positively associated with plasma viral load.  In semen, however, there were no 
significant relationships evident between seminal viral load and the cytokines and 
chemokines measured.  The present study differed from previous smaller studies in 
several aspects; here a larger number of cytokines were assayed (20); statistical 
analyses were rigorous, adjusting for multiple comparisons for all tests.  An additional 
explanation could be that other genital tract co-infections (discussed below) may have 
created a high background inflammatory ‘noise’ which precluded the ability to link 
HIV replication with any particular immune mediators. 
  
HIV-induced immune activation can lead to enhanced HIV replication, promoting 
further cellular activation.  This cycle is further exacerbated by pro-inflammatory 
cytokines, such as IL-1β, IL-6 and TNFα working synergistically to elevate levels of 
activation (Appay & Sauce 2008, Decrion et al., 2005).  In the present study, the 
influence of levels of inflammatory, regulatory and adaptive cytokines and 
chemokines on cellular activation was assessed.  In semen, enhanced levels of 
granulocyte colony stimulating factor (G-CSF) were found to be associated with 
higher levels of CD8+CCR5+ T cells in HIV-infected men, independent of seminal 
viral load.  G-CSF is a pro-inflammatory cytokine produced by macrophages and 
endothelial cells at sites of infection and attracts and promotes the survival of 
neutrophils (Abbas & Lichtman 2007).  G-CSF may function in the same way in the 
male genital tract, where the presence of high levels of neutrophils is important in 
innate immune protection against pathogenic bacteria.  In fact, in this study (Chapter 
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2), high levels of neutrophils were found in semen.  The association of CD8+CCR5+ 
with G-CSF may thus be indirect, related to underlying bacterial co-infections in HIV-
infected men, rather than with HIV replication. 
 
The present study had a number of limitations.  The possible (and likely) presence of 
sexually-transmitted infections (STIs) that could have contributed to genital tract 
inflammation was not assessed.  A high incidence of HSV-2 seroprevalence (17%), 
chlamydia (12.4%), syphilis (8.1%) and gonorrhoea (3.3%) infection have been 
demonstrated among men, many going untreated, leading to some describing a 
“hidden epidemic of STIs” in South Africa (reviewed in Johnson et al., 2005).  
Ongoing genital tract inflammation due to concurrent STIs may have masked any 
effects that HIV replication alone may have had on inflammation and cellular 
activation in this compartment.  A further limitation was that only 12 men among the 
HIV-infected cohort were on ART, weakening statistical power in this group. 
Furthermore, we limited the study to detecting the 20 cytokines in the Milliplex MAP 
kits.  The presence of other cytokines and chemokines in seminal plasma, which may 
be important in the context of HIV-infection and inflammation, needs further 
investigation. These include MIP-3α, shown to be important in the female genital tract 
for recruitment of target cells during initial HIV acquisition (Haase 2010), and 
upregulated by semen in the vagina (Berlier et al., 2006b); and TGF-β, previously 
described to be at high levels in semen (Politch et al., 2007).  TGF-β is known to play 
a role in reproduction, as well as a central role in TH17 cell differentiation.  These 
cells produce IL-17, which has an important role in neutrophil mobilisation and the 
expression of antimicrobial factors (Campillo-Gimenez et al., 2010) and has not been 
characterised in semen.  TH2 cytokines such as IL-4, IL-5 and IL-13 could provide 
further insight into the critical balance between pro- and anti-inflammatory cytokines 
during HIV infection.  A future study could include measuring these analytes by high 
sensitivity ELISA or an extended multiplex panel. 
 
Taken together, the data in this chapter demonstrate that the immune milieu of the 
genital tract differs substantially from blood, with the majority of cytokines and 
chemokines tested elevated in semen.  However, unexpectedly, there were no striking 
differences in the levels of cytokines and chemokines in the semen of HIV-infected 
and uninfected men, or HIV-infected men on suppressive ART.  Thus, even in the 
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absence of HIV infection, the male genital tract appears to maintain a state of 
inflammation in the participant population that was studied, which may have been the 
result of undetected and untreated co-infections.  This inflammation may have masked 
any additional effect of HIV replication. However, comparisons of relationships 
between cytokines in the seminal compartment of HIV-uninfected and infected men, 
indicated that a disruption of interrelated associations may be due to dysregulation of 
cytokine and chemokine levels as a result of HIV infection.  No associations between 
any cytokines and HIV replication levels in semen were evident after adjustment for 
multiple comparisons. When investigating the impact of inflammation in the male 
genital tract on cellular immune activation, only G-CSF was linked to increases in 
CCR5-expressing CD8+ T cells. This illustrates that the relationship between 
inflammation, cellular activation and viral replication is unlikely to be simplistic. 
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CHAPTER	5	
	
	Discussion	
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The largest HIV-1 epidemic in the world is in sub-Saharan Africa, where the majority 
of HIV transmission occurs through sexual contact (UNAIDS 2010).  A prophylactic 
vaccine to prevent new HIV infections or effectively halt disease progression and 
transmission is urgently needed.  In Chapter 2, functional T cells and other immune 
subsets were characterised in semen after developing optimal protocols to isolate 
these cells from semen.  These protocols could be applied to assessing immunological 
responses in clinical trials of candidate HIV vaccines.  Current efforts to develop an 
HIV vaccine acknowledge that both robust cellular immune responses and strong 
humoral immune responses may be needed for effective protection.  These responses 
may need to be elicitied in the genital tract, where most infection takes place.  Only a 
handful of studies have characterised HIV-specific cellular immune responses in the 
male genital tract, and this has been in the context of HIV infection and not vaccine 
trials.  HIV-1 Env-, Gag- and Pol-specific CD8+ T cells have been identified in semen 
(Quayle et al., 1998).  Sheth and colleagues found that CD8+ T cell responses in 
semen did not correlate with levels of virus in semen, and concluded that these cells 
were not effectively controlling HIV replication locally (Sheth et al., 2005).  This is 
similar to findings in blood, where the overall frequency of responses may be a poor 
measure of effective HIV-specific responses, and that it is rather the functional nature 
or specificity for particular parts of the virus that dictate efficacy of T cell responses 
(Betts et al., 2006; Ferre et al., 2009; Kiepiela et al., 2007).  Although our study 
established optimised protocols for T and other immune cell isolation from semen, the 
yield of cells obtained is still too low to perform many or detailed immunological 
assessments.  Establishing additional protocols to supplement these methodologies, 
such as expanding seminal T cells in culture, are warranted. 
 
With regard to humoral immunity required to protect against HIV infection, this 
translates into the presence of local broadly neutralising HIV-specific antibodies in 
the genital tract.  In Chapter 2 of the present study, B cells were found in far greater 
numbers in semen than T cells.  Previous studies have shown that the major antibody 
isotype in seminal plasma was IgG (Moldoveanu et al., 2005), although 
characterisation of penile washes suggested a preponderance of IgA (Anderson et al., 
2011).  Very little is known about HIV-specific B-cell responses in the male genital 
tract and whether HIV-specific neutralising antibodies are found within the male 
genital tract and its secretions in infected men.  Clearly, there are still major gaps in 
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our knowledge concerning HIV infection and the immunology of the male genital 
tract that are important areas for future study. 
 
During sexual transmission, semen remains the major carrier of HIV and contains 
cell-free and cell-associated HIV (Doncel et al., 2011).  There is strong evidence 
indicating that the main factor that influences transmission is the viral load in semen, 
which peaks during acute and again during late stages of infection in untreated disease 
(Tachet et al., 1999; Pilcher et al., 2007).  During early HIV infection, seminal viral 
load can reach a peak level of 4.5 log10 copies/ml (Pilcher et al., 2007).  In sero-
discordant couples where the uninfected partners became infected, 80% of the 
infecting partners had plasma viral loads of >10 000 HIV RNA copies/ml, whereas no 
transmissions were found when the infected partner’s viral load was <1500 HIV RNA 
copies/ml (Quinn et al., 2000).  In the present study, 13/26 ARV-naïve men (50%) 
had plasma viral loads of >10 000 HIV RNA copies/ml, whereas 6/26 (23%) men had 
<1500 HIV RNA copies/ml.  In semen, 50% of ARV-naïve men had viral loads 
>1500 HIV RNA copies/ml.  Highly active antiretroviral treatment (HAART) is 
successful in lowering viral load systemically and in semen (Vernazza et al., 2000), 
although genital HIV shedding was evident in 2 out of 12 men on ARV treatment in 
the present study.  This illustrates the substantial risk of HIV transmission to 
unprotected partners posed by genital HIV shedding both without and even with ARV 
treatment. 
 
An unexpected finding from this study was the large degree of immune activation in 
semen, even in the absence of HIV infection. Levels of immune activation were 
highest in semen of untreated HIV-infected men and levels of seminal immune 
activation were substantially higher in semen than blood regardless of HIV status.  
Genital tract inflammation was assessed by studying various pro-inflammatory and 
other immune mediators, and consistent with the T cell activation findings, levels of 
seminal inflammation were higher than systemic levels regardless of whether men 
were HIV infected or not.  In the genital tract, one of the major factors causing 
inflammation is sexually transmitted co-infections (Johnson et al., 2009).  In South 
Africa, syndromic management of STIs has reduced STI prevalence among both sexes 
(Johnson et al., 2011); however, it appears clear from this study that there are either a 
large amount of untreated STIs, or asymptomatic STIs in this study population, giving 
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rise to persistent inflammation and T cell activation.  This may enhance recruitment of 
HIV target cells to the genital tract or act locally in activating resident T cells, 
elevating the risk of HIV acquisition in the male genital tract.  In HIV-infected men, 
this may give rise to greater shedding of HIV.  For example, co-infection with HSV-2 
increases seminal HIV viral load (Lingappa et al., 2010), and sub-clinical 
asymptomatic HSV-2 replication may attract HIV target cells to the genital tract (Zhu 
et al., 2009). 
 
Levels of genital tract immune activation in healthy women in sub-Saharan Africa 
have been shown to be elevated compared to levels of immune activation in their 
counterparts in the United States (Cohen et al., 2010), even after taking the effect of 
common STIs into account. This is an intriguing finding and warrants further study.  
Although the present study did not control for the effects of common STIs or compare 
levels of immune activation between local and non-local participants, this observation 
may account for the unexpectedly high levels of immune activation and CCR5-
expressing target cells in the semen of HIV-uninfected men, and may provide a partial 
explanation for the higher incidence of HIV infection among men in sub-Saharan 
Africa. 
 
Although the immune cells within semen may be important for HIV infection, there 
are limitations to studying semen as a representative of the entire male genital tract.  
Other tissues of the male genital tract may be very important in HIV acquisition, such 
as the foreskin and penile urethra.  Only three studies have investigated HIV infection 
using in vitro models of the male genital tract.  Patterson et al. (2002) showed that 
HIV preferentially infects Langerhans cells and CCR5-expressing CD4+ T cells of the 
inner foreskin.  Fischetti et al. (2009) introduced HIV to foreskin, glans, meatus and 
urethral tissue, and found that R5-tropic HIV strains infected all these tissues equally 
well.  Ganor and colleagues (2010) developed in vitro models using inner and outer 
foreskin tissue as well as layered foreskin epithelia and exposed these to free HIV 
virions or HIV-infected cells.  The inner foreskin was preferentially infected by HIV-
infected cells through the formation of synapses with keratinocytes, and virions that 
budded from these synapses were internalised by Langerhans cells, that then migrated 
to the dermal layer where HIV was transferred to T cells.  These studies not only 
emphasize the need for modeling penile infection in men to elucidate the early events 
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of HIV infection in the male genital tract, but also highlight the fact that activated 
CD4+ T cells and other cell types such as Langerhans cells in these ‘frontline’ tissues 
may be more important in the susceptibility to infection than activated T cells 
elsewhere in the male genital tract, that were measured in semen in the present study.  
On the other hand, amplification of initial foci of HIV infection in the male genital 
tract may be due to the pool of activated CD4+ T cells and other cell types locally, that 
then migrate to the rest of the body and establish infection.  In addition, although 
removal of the foreskin may reduce HIV target cells and therefore decrease infection 
in up to 60% of men, activated CD4+ T cells and other cell types in uncircumcised 
men in other tissues may then contribute to establishing productive infection.  To date, 
animal models characterising early transmission events have been limited to SIV 
infection of the female macaque genital tract, and early events in male genital tissue 
are largely unknown.  Recently, two groups described the development of macaque 
models of penile HIV transmission, and these promise to yield important new insights 
into early events following HIV infection of the penis (Keele 2011; Yeh 2011). 
 
A controversial question in HIV transmission remains the issue of to what extent cell-
associated HIV transmission, in addition to infection by cell-free viral particles, is 
responsible for establishing a productive infection. HIV-infected cells may be 
important vectors in transmission of HIV-1 (reviewed in Anderson et al., 2010), and a 
recent macaque model of cell-associated infection was developed, and demonstrates 
evidence of cell-associated HIV transmission may indeed occur (Salle et al., 2010).  
In contrast, another recent study in men who have sex with men (MSM), provided 
evidence that the cell-free HIV component of semen, and not the cell-associated 
fraction, was responsible for productive HIV infection (Butler et al., 2010).  If indeed 
cell-associated transmission of HIV occurs, one of the major questions is what are the 
events that lead to this type of HIV transmission, and how can HIV prevention 
strategies target these (Anderson et al., 2010).  Thus, more research is needed to clear 
up this controversy. 
 
In conclusion, this study has contributed to research on the male genital tract by 
optimising methodologies for the isolation of immune cells from semen that may be 
applied to vaccine trials, and the identification of a range of immune cell types in 
semen, opening up areas of future research on innate and humoral immunity in the 
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male genital tract.  Furthermore, characterisation of immune activation and levels of 
CCR5-expressing potential CD4+ target cells in semen provides novel insights into 
immune activation within the male genital tract of HIV-uninfected and infected men.  
Finally, a comprehensive, multivariate analysis of levels of inflammatory markers and 
other immune mediators in semen highlights major differences with the systemic 
compartment, and illustrates their relationship with HIV replication. 
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Table S1  Assay sensitivities.  The minimum detectable concentration for the 
two assayed  used are listed. 
Kit Cytokines/ chemokines MinDCa 
High Sensitivity: IL-1β 0.06 
 IL-2 0.16 
 IL-6 0.10 
 IL-7 0.12 
 IL-12p70 0.11 
 IL-10 0.15 
 TNFα 0.05 
 IFNγ 0.29 
 GM-CSF 0.46 
Normal Sensitivity: IL-1α 3.50 
 sIL-2Rα 4.40 
 IL-8 0.20 
 IL-12p40 10.5 
 IL-15 0.40 
 Eotaxin 1.20 
 Fractalkine 6.00 
 G-CSF 0.50 
 MCP-1 0.90 
 MIP-1α 3.50 
 MIP-1β 4.50 
 RANTES 1.00 
aMinimum detectable concentration, pg/ml 
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Table S2  Comparisons between levels of cytokines and chemokines in the semen of HIV-uninfected, HIV-infected (ARV naïve) and HIV-
infected (ARV-treated) men. 
Cytokines/chemokines HIV-uninfecteda ARV naïvea ARV-treateda p-valueb p-valuec p-valued 
Pro-inflammatory: IL-1α 16.3 (5.5 – 32.9) 17.2 (5.3 – 79.3) 17.4 (6.5 – 82) 0.26 0.45 0.98 
 IL-1β 0.25 (0.08 – 0.4) 0.17 (0.05 – 0.69) 0.32 (0.044 – 1) 0.60 0.69 0.71 
 IL-6 32.5 (6.8 – 118.3) 22 (8.7 – 122) 33.4 (7.3 – 147.2) 0.92 0.92 0.86 
 IL-8 1 486 (241 – 2 771) 1 110 (643 – 2 115) 1 141 (540.5 – 2 947) 0.59 0.99 0.77 
 IL-12p40 2.8 (1.3 – 3.5) 1.9 (1.4 – 3.5) 3.1 (1.78 – 9.85) 0.75 0.088 0.13 
 IL-12p70 0.05 (0.03 – 1.9) 0.036 (0.02 – 0.99) 1.2 (0.036 – 2.57) 0.25 0.33 0.12 
 TNF-α 1.82 (0.79 – 4.5) 1.2 (0.57 – 3.95) 1.88 (0.27 – 5.9) 0.67 0.73 0.86 
 Eotaxin 23 (4.4 – 38.9) 16.3 (8.6 – 37.9) 28.2 (23.3 – 41.3) 0.76 0.19 0.11 
 Fractalkine 802.9 (333 – 1 636) 655.8 (251 – 1 489) 875.6 (250 – 1 019) 0.42 0.55 0.94 
 MCP-1 14 110 (3 908 – 31 028) 
9 805 (3 211 – 18 
029) 
17 720 (7 486 – 27 
430) 
0.097 0.92 0.16 
 MIP-1α 3.15 (1.3 – 4.9) 7.5 (2.3 – 36) 15.7 (5.5 – 86.4) 0.045 0.0076 0.35 
 MIP-1β 78.1 (31.9 – 112.2) 53 (35.4 – 171.6) 83.4 (30.2 – 195.8) 0.85 0.72 0.78 
 RANTES 370.9 (189.2 – 649.3) 266.5 (98.6 – 818.3) 419.5 (178.6 – 1 239) 0.59 0.67 0.2 
 G-CSF 29.5 (12.2 – 60.5) 21.2 (7.5 – 84.3) 20 (12.9 – 58.1) 0.23 0.65 0.73 
 GM-CSF 2.4 (0.65 – 7.35) 2.9 (1.6 – 6.2) 5.05 (2.1 – 14.7) 0.51 0.26 0.25 
Regulatory: IL-10 27.1 (7.1 – 52.4) 10.9 (2.02 – 17.5) 7.7 (0.8 – 24.5) 0.022 0.053 0.85 
Adaptive: IFN-γ 6.3 (2.7 – 21.9) 5.6 (1.9 – 10.2) 9.8 (0.78 – 40.5) 0.57 0.73 0.55 
 IL-2 0.4 (0.03 – 2.56) 0.2 (0.026 – 1.22) 1.6 (0.022 – 3.52) 0.52 0.88 0.47 
 IL-7 786.4 (395.9 – 1 930) 715.8 (347 – 1 865) 524.4 (414 – 2 011) 0.72 0.47 0.86 
 IL-15 27.8 (8.8 – 45.4) 27.6 (10.1 – 64.8) 30.7 (27.6 – 39.5) 0.56 0.54 0.84 
aMedian (IQR); Mann-Whitney t test for comparison of unmatched groups, p-values ≤ 0.05 were considered significant and are in bold 
bComparison between HIV-uninfected and ARV naïve 
cComparison between HIV-uninfected and ARV-treated 
dComparaison between ARV naïve and ARV-treated 
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Table S3  Comparisons between levels of cytokines and chemokines in the blood of HIV-uninfected, HIV-infected (ARV naïve) and HIV-infected 
(ARV-treated) men. 
Cytokines/chemokines HIV-uninfecteda ARV naïvea ARV-treateda p-valueb p-valuec p-valued 
Pro-inflammatory: IL-1β 0.15 (0.04 – 0.33) 0.26 (0.012 – 0.59) 0.09 (0.012 – 0.35) 0.15 0.44 0.087 
 IL-6 6.5 (4 – 12.3) 6.6 (4 – 14.1) 5.5 (3.2 – 9.2) 0.89 0.43 0.43 
 IL-8 2.3 (0.27 – 4.7) 2.5 (1.07 – 3.7) 2.8 (0.04 – 9.2) 0.76 0.84 0.73 
 IL-12p40 5.4 (0.47 – 44.7) 0.47 (0.47 – 46.1) 0.47 (0.47 – 3.07) 0.62 0.12 0.49 
 IL-12p70 0.01 (0.01 – 0.17) 0.01 (0.01 – 1.16) 0.01 (0.01 – 0.01) 0.37 0.51 0.22 
 TNF-α 5.9 (4.6 – 7) 10.1 (7.02 – 12.5) 7.6 (6.4 – 9.8) 0.0001 0.019 0.18 
 Eotaxin 89.1 (37.8 – 182.8) 89.2 (59 – 195.1) 49.8 (44.2 – 68.3) 0.42 0.24 0.0087 
 Fractalkine 42.6 (11.1 – 102.3) 42.6 (18.8 – 82.4) 0.59 (0.59 – 42.6) 0.66 0.013 0.025 
 MCP-1 216.7 (174.1 – 301.1) 221.3 (168.4 – 364.7) 220.3 (155.2 – 303.8) 0.49 0.82 0.54 
 MIP-1α 1.95 (1.95 – 9.52) 1.95 (1.95 – 7.24) 1.95 (1.95 – 5.9) 0.49 0.5 0.79 
 MIP-1β 8.7 (1.5 – 12.7) 3.01 (1.5 – 12.7) 5.1 (1.5 – 16.1) 0.86 0.69 0.77 
 RANTES 2 809 (1 997 – 3 156) 2 663 (2 080 – 3 207) 2 637 (2 483 – 3 332) 0.99 0.79 0.96 
 G-CSF 25.8 (15.5 – 47.8) 40.02 (24.6 – 53.2) 23.3 (15.5 – 30.7) 0.084 0.35 0.0077 
 GM-CSF 0.01 (0.01 – 0.86) 0.26 (0.01 – 0.69) 0.02 (0.01 – 0.69) 0.48 0.97 0.67 
Regulatory: IL-10 1.26 (0.88 – 2.02) 2.02 (1.26 – 2.8) 1.07 (0.88 – 1.5) 0.017 0.83 0.025 
Adaptive: IFN-γ 0.86 (0.37 – 2.9) 2.4 (0.86 – 7.8) 1.21 (0.37 – 1.33) 0.052 0.56 0.021 
 IL-2 0.1 (0.01 – 0.98) 0.47 (0.05 – 1.39) 0.08 (0.01 – 0.86) 0.20 0.74 0.13 
 IL-7 3.12 (1.27 – 7.44) 3.13 (1.5 – 5.26) 1.91 (0.54 – 4.9) 0.81 0.24 0.26 
 IL-15 0.37 (0.25 – 1.25) 0.25 (0.25 – 1.25) 0.25 (0.25 – 0.25) 0.62 0.033 0.11 
aMedian (IQR); Mann-Whitney t test for comparison of unmatched groups, p-values ≤ 0.05 were considered significant and are in bold 
bComparison between HIV-uninfected and ARV naïve 
cComparison between HIV-uninfected and ARV-treated 
dComparaison between ARV naïve and ARV-treated 
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Figure S1  Heat map of cytokine and chemokines assayed in semen.  Shown are the cytokine and chemokine responses in the semen of all participants 
ordered by hierarchical clustering (Spearman correlation with average linkage) creating a condition tree.  Coloured squares at the top of each profile indicate HIV-uninfected 
(blue), HIV-infected men with detectable viral loads (red) and HIV-infected men with undetectable viral loads (green).
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Figure S2  Heat map of cytokine and chemokines assayed in blood.  Shown are the cytokine and chemokine responses in the blood of all participants ordered 
by hierarchical clustering (Spearman correlation with average linkage) creating a condition tree.  Coloured squares at the top of each profile indicate HIV-uninfected (blue), 
HIV-infected men with detectable viral loads (red) and HIV-infected men with undetectable viral loads (green). 
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Table S4  Correlations between activated T cell subsets and cytokines/chemokines in semen of HIV-uninfected, HIV-infected (ARV-naïve) and 
HIV-infected (ARV-treated) men. 
Semen HIV-uninfecteda HIV-infected, ARV-naïveb ARV-treatedc 
Cytokines/ 
chemokines CD4 CD8 CD4 CD8 CD4 CD8 
Pro-
inflammatory 
CD38 CCR5 CD38 CCR5 CD38 CCR5 CD38 CCR5 CD38 CCR5d CD38 CCR5 
Rho, p-value Rho, p-value Rho, p-value Rho, p-value Rho, p-value Rho, p-value Rho, p-value Rho, p-value Rho, p-value Rho, p-value Rho, p-value Rho, p-value 
IL-1α 0.046,  0.79 0.12,  0.57 0.2,  0.21 0.21,  0.27 0.051,  0.82 -0.047,  0.86 0.13,  0.51 -0.047,  0.86 -0.73,  0.024 - -0.41,  0.21 0.35,  0.33 
IL-1β -0.26,  0.22 -0.15,  0.59 -0.079,  0.69 0.027,  0.91 0.014,  0.95 -0.33,  0.19 0.34,  0.093 -0.077,  0.73 -0.7,  0.035 - 0.009,  0.98 0.71,  0.021 
IL-6 0.067,  0.75 0.15,  0.59 0.28,  0.16 0.16,  0.48 -0.088,  0.69 -0.31,  0.23 0.06,  0.77 -0.1,  0.64 -0.53,  0.14 - -0.38,  0.25 0.15,  0.68 
IL-8 -0.026,  0.88 0.042,  0.84 0.29,  0.073 0.094,  0.61 0.28,  0.19 0.14,  0.59 -0.25,  0.22 0.14,  0.59 -0.48,  0.18 - -0.3,  0.37 0.25,  0.49 
IL-12p40 -0.003,  0.99 0.053,  0.79 0.14,  0.4 0.087,  0.64 0.25,  0.25 0.035,  0.89 0.22,  0.28 0.035,  0.89 -0.48,  0.19 - -0.12,  0.73 0.14,  0.7 
IL-12p70 -0.0002, 0.99 0.2,  0.47 0.13,  0.52 -0.067,  0.77 0.17,  0.43 0.11,  0.67 0.36,  0.067 0.039,  0.86 -0.52,  0.15 - -0.036,  0.92 0.59,  0.074 
TNF-α -0.18,  0.4 -0.047,  0.86 0.01,  0.96 0.23,  0.32 0.047,  0.83 -0.33,  0.2 0.2,  0.32 0.099,  0.66 -0.67,  0.049 - -0.28,  0.4 0.45,  0.19 
Eotaxin 0.28,  0.098 0.29,  0.15 0.56,  0.0002 0.39,  0.032 0.28,  0.18 0.078,  0.76 0.32,  0.11 0.078,  0.76 0.017,  0.97 - 0.24,  0.48 0.43,  0.21 
Fractalkine 0.058,  0.74 0.1,  0.61 0.21,  0.2 0.21,  0.26 0.12,  0.56 -0.071,  0.79 -0.18,  0.38 -0.071,  0.79 -0.1,  0.8 - -0.018,  0.96 0.39,  0.26 
MCP-1 0.2,  0.24 0.29,  0.14 0.45,  0.0044 0.31,  0.087 0.15,  0.5 0.024,  0.93 -0.25,  0.22 0.025,  0.93 0.033,  0.93 - -0.14,  0.69 0.006,  0.99 
MIP-1α 0.05,  0.77 0.09,  0.66 0.26,  0.11 0.27,  0.14 0.24,  0.27 0.33,  0.2 0.039,  0.85 0.33,  0.2 -0.56,  0.13 - -0.22,  0.51 0.2,  0.58 
MIP-1β 0.042,  0.81 0.16,  0.45 0.047,  0.77 0.15,  0.41 0.26,  0.23 0.21,  0.42 -0.037,  0.86 0.21,  0.42 -0.67,  0.049 - -0.064,  0.85 0.3,  0.4 
RANTES -0.014,  0.93 0.33,  0.099 0.14,  0.38 0.28,  0.12 0.14,  0.53 0.15,  0.57 -0.18,  0.39 0.15,  0.57 -0.033,  0.93 - -0.31,  0.35 0.48,  0.16 
G-CSF 0.049,  0.78 0.096,  0.64 0.12,  0.47 0.3,  0.11 0.14,  0.53 0.027,  0.92 -0.15,  0.45 0.027,  0.92 -0.7,  0.035 - -0.054,  0.87 0.39,  0.26 
GM-CSF -0.12,  0.58 0.044,  0.87 0.091,  0.64 -0.09,  0.7 0.071,  0.75 -0.074,  0.78 0.26,  0.2 -0.094,  0.68 -0.18,  0.64 - -0.25,  0.45 0.24,  0.51 
Regulatory          -   
IL-10 -0.27,  0.19 0.1,  0.7 0.028,  0.88 0.33,  0.15 -0.21,  0.33 -0.24,  0.35 0.054,  0.79 0.23,  0.31 -0.53,  0.14 - -0.25,  0.47 0.27,  0.45 
Adaptive          -   
IFN-γ -0.11,  0.61 0.12,  0.66 0.15,  0.43 0.17,  0.45 -0.21,  0.34 -0.022,  0.93 0.022,  0.91 0.09,  0.69 -0.43,  0.24 - -0.25,  0.47 0.49,  0.15 
IL-2 -0.27,  0.19 0.12,  0.66 -0.21,  0.29 0.25,  0.27 -0.27,  0.21 -0.49,  0.046 0.091,  0.66 -0.31,  0.15 -0.57,  0.11 - -0.045,  0.89 0.55,  0.098 
IL-7 -0.26,  0.21 0.24,  0.36 0.25,  0.36 0.079,  0.73 -0.098,  0.66 -0.17,  0.52 -0.13,  0.54 -0.43,  0.045 -0.1,  0.8 - 0.054,  0.87 0.39,  0.26 
IL-15 0.077,  0.66 0.22,  0.27 0.22,  0.17 0.27,  0.14 0.069,  0.75 0.17,  0.51 -0.039,  0.85 0.17,  0.51 -0.033,  0.93 - 0.09,  0.79 0.38,  0.28 
aN = 42;   bN = 26;   cN = 12;   dCorrelations not performed – only 4/12 ARV-treated men with CD4+CCR5+ T cell yields; Spearman Rank test withp-values ≤ 0.05 considered significant;  Red 
shaded cells show significant p-values 
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Table S5  Correlations between activated T cell subsets and cytokines/chemokines in blood of  HIV-uninfected, HIV-infected (ARV-naïve) and HIV-infected 
(ARV-treated) men. 
Blood HIV-uninfecteda HIV-infected, ARV-naïveb ARV-treatedc 
Cytokines/ 
chemokines CD4 CD8 CD4 CD8 CD4 CD8 
Pro-
inflammatory 
CD38 CCR5 CD38 CCR5 CD38 CCR5 CD38 CCR5 CD38 CCR5 CD38 CCR5 
Rho, p-value Rho, p-value Rho, p-value Rho, p-value Rho, p-value Rho, p-value Rho, p-value Rho, p-value Rho, p-value Rho, p-value Rho, p-value Rho, p-value 
IL-1β -0.34,   0.079 0.19,  0.32 0.067,  0.73 0.2,  0.3 -0.018,  0.38 -0.052,  0.8 -0.066,  0.75 -0.27,  0.17 -0.021,  0.95 0.039,  0.9 0.35,  0.26 0.23,  0.47 
IL-6 -0.15,   0.44 0.14,  0.47 -0.32,  0.098 0.22,  0.27 -0.048,  0.81 -0.087,  0.67 -0.13,  0.53 -0.26,  0.2 -0.12,  0.72 -0.028,  0.93 -0.1,  0.74 -0.07,  0.83 
IL-8 -0.27,  0.095 0.16,  0.33 -0.11,  0.51 -0.11,  0.5 -0.049,  0.81 -0.18,  0.37 0.097,  0.64 -0.3,  0.13 -0.066,  0.84 0.5,  0.096 0.021,  0.94 0.021,  0.95 
IL-12p40 -0.12,  0.45 0.13,  0.41 -0.29,  0.065 -0.085,  0.6 -0.13,  0.52 0.43,  0.029 -0.023,  0.91 0.012,  0.95 -0.083,  0.8 -0.031,  0.92 0.26,  0.41 -0.016,  0.96 
IL-12p70 -0.038,  0.85 0.2,  0.31 -0.079, 0.69 0.21,  0.27 -0.29,  0.15 0.09,  0.66 -0.19,  0.35 -0.22,  0.28 0.64,  0.024 -0.11,  0.73 0.65,  0.022 -0.005,  0.99 
TNF-α 0.01,  0.96 0.016,  0.94 -0.0008, 0.99 0.065,  0.74 0.17,  0.39 -0.31,  0.12 -0.042,  0.84 -0.34,  0.088 -0.063,  0.85 -0.13,  0.69 0.31,  0.33 0.14,  0.66 
Eotaxin -0.013,  0.94 0.054,  0.74 0.2,  0.21 -0.002,  0.99 -0.1,  0.62 0.13,  0.52 0.093,  0.65 -0.039,  0.85 -0.56,  0.06 0.34,  0.29 -0.52,  0.08 0.3,  0.34 
Fractalkine -0.11,  0.48 0.077,  0.64 0.057,  0.73 -0.045,  0.78 -0.21,  0.31 -0.095,  0.64 -0.044,  0.83 -0.35,  0.08 0.64,  0.024 - 0.23,  0.46 -0.19,  0.55 
MCP-1 0.18,  0.24 0.048,  0.77 0.2,  0.23 -0.1,  0.53 -0.24,  0.24 0.33,  0.097 -0.21,  0.29 -0.12,  0.57 -0.33,  0.3 -0.39,  0.21 -0.36,  0.24 -0.48,  0.11 
MIP-1α 0.056,  0.73 -0.27,  0.094 0.35,  0.025 -0.25,  0.12 -0.007,  0.97 -0.1,  0.62 0.19,  0.36 -0.046,  0.82 0.29,  0.36 0.37,  0.24 -0.064,  0.84 0.046,  0.89 
MIP-1β -0.17,  0.29 0.26,  0.11 0.25,  0.12 0.11,  0.49 0.26,  0.19 -0.12,  0.57 -0.19,  0.36 -0.58, 0.0021 -0.14,  0.67 -0.17,  0.6 0.041,  0.89 -0.064,  0.84 
RANTES -0.27,  0.46 0.26,  0.11 0.034,  0.83 0.034,  0.83 0.26,  0.2 0.14,  0.5 0.34,  0.87 0.26,  0.21 0.56,  0.058 0.42,  0.89 0.36,  0.25 0.36,  0.25 
G-CSF 0.0054,  0.97 0.23,  0.15 -0.058,  0.72 0.049,  0.77 0.059,  0.77 0.084,  0.68 -0.11,  0.59 -0.28,  0.16 0.3,  0.33 -0.097,  0.77 0.49,  0.1 -0.068,  0.83 
GM-CSF -0.11,  0.59 0.15,  0.43 0.31,  0.11 0.25,  0.2 -0.15,  0.48 0.053,  0.8 -0.074,  0.72 -0.05,  0.81 -0.045,  0.89 0.22,  0.5 0.13,  0.68 0.24,  0.46 
Regulatory             
IL-10 0.07,  0.81 -0.028, 0.89 -0.062,  0.75 0.22,  0.35 -0.08,  0.7 -0.15,  0.47 -0.23,  0.27 -0.19,  0.36 0.36,  0.25 -0.15,  0.64 0.78,  0.0027 0.12,  0.71 
Adaptive             
IFN-γ -0.077,  0.69 -0.026  0.89 0.021,  0.92 0.029,  0.88 -0.06,  0.77 -0.025,  0.9 -0.022,  0.91 -0.12,  0.54 -0.1,  0.75 0.018,  0.96 0.21,  0.51 0.18,  0.58 
IL-2 -0.029,  0.88 0.096,  0.63 -0.023,  0.91 0.25,  0.2 0.15,  0.46 -0.12,  0.56 0.28,  0.17 -0.089,  0.66 0.17,  0.6 -0.022,  0.95 0.62,  0.031 0.13,  0.69 
IL-7 -0.036,  0.86 0.083,  0.67 -0.044,  0.82 0.22,  0.25 -0.04,  0.85 -0.2,  0.33 -0.01,  0.96 -0.22,  0.29 0.58,  0.048 -0.26,  0.41 0.68,  0.015 -0.27,  0.39 
IL-15 -0.3,  0.058 0.27,  0.097 -0.11,  0.5 0.062,  0.7 -0.047,  0.82 0.014,  0.95 0.13,  0.52 0.093,  0.65 0.21,  0.52 0.39,  0.21 -0.12,  0.7 0.37,  0.24 
aN = 42;   bN = 26;   cN = 12;  Spearman Rank test withp-values ≤ 0.05 considered significant; red shaded cells show significant p-values	
